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Brain tumors such as gliomas have poor prognosis despite advanced surgical 
intervention and adjuvant chemo- and radiotherapies. The highly infiltrative 
and recurrent nature of this disease has often been attributed to stem-like 
cells with extensive self-renewal potential. These cells, termed “glioma-
propagating cells” (GPCs), can be isolated from clinical material, and we now 
have a way to cryopreserve them, with maintenance of essential primary 
tumor hallmarks such as karyotype and transcriptomic profile. Our 
foundational work established that histologically similar glioblastoma (GBM, 
grade IV) tumors yield GPCs with very distinct transcriptomic profiles, 
suggesting molecular heterogeneity and possibly accounting for the 
frequently observed inter-patient variability to treatment response. 
Importantly, we were able to show in the major glioma variants, 
oligodendroglial tumors and GBM, that GPCs contain signaling pathways, 
manifested as transcriptomic programs which dictate primary tumor behavior, 
disease progression and patient survival outcome. These findings emphasize 
that GPCs are clinically relevant and can serve as a valuable cellular platform 
for further studies. We explored one of these transcriptomic programs, Wnt, in 
detail. We showed pharmacologically and genetically that Wnt activation 
promotes GPC growth and tumorigenicity, mediated through the MITF 
transcription factor. GPCs (oligodendroglial and GBM) with high MITF 
expression were more sensitive to pathway inhibition, highlighting the 
limitation of relying solely on histology to diagnose and subsequently treat 
patients. Our study provides evidence that tumor growth can be mitigated by 
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CHAPTER 1 – INTRODUCTION 
Preamble 
This thesis explores the molecular characteristics of glioma-propagating cells 
(GPCs) and shows that GPC core activation pathways contribute to primary 
tumor behavior, glioma disease progression and patient survival outcome. In 
addition, we explore the Wnt signaling pathway in GPC maintenance, and 
show that glioma growth can be abrogated by targeting these long-term, self-
renewing cells. The “Introduction” chapter is divided into the following 
sections which form the basis of our exploration: 
i. Molecular classification of glioma. 
ii. Glioma-propagating cells (GPCs). 
iii. Mouse models relevant for glioma studies. 
iv. Targeting GPCs for an effective cure – signaling mechanisms. 
v. The Wnt signaling pathway. 
1.1 Classification of Gliomas 
 Gliomas are the most common primary brain tumors of the central 
nervous system with heterogeneous morphology and variable prognosis. 
Variants such as glioblastoma multiforme (GBM) portend poor prognosis with 
a mean survival period of 15 months despite advanced surgical intervention, 
accompanied by adjuvant radio- and chemotherapies (Louis et al, 2007) . The 
most widely used current classification of human gliomas is that of the World 
Health Organization (WHO) system (Louis et al, 2007).  The WHO system 
divides diffuse gliomas into astrocytic tumors, oligodendrogliomas, and 
oligoastrocytomas. These are then graded into histological degrees of 
malignancy. Two major subtypes are recognized, namely the astrocytic and 
the oligodendrocytic tumors. Astrocytic tumors are further subdivided into 
grades I (pilocytic astrocytomas, PA), II (low grade), III (anaplastic), and IV 
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(glioblastoma multiforme, GBM) (Table 1.1). Oligodendrocytic tumors are 
separated into grades II (low grade) and III (anaplastic). GBM, a WHO grade 
IV tumor, is characterized by rapid, highly invasive growth, extensive 
neovascularization and high mortality. The key reason for unsuccessful 
therapy is the infiltration of tumor cells into the surrounding brain parenchyma 
cells, preventing complete glioblastoma resection. Furthermore, glioma cells 
are notoriously resistant to chemotherapies. 
 
 
 Gliomas of better prognosis include the oligodendroglial tumors. 
These tumors possess genetic indicators such as the 1p/19q co-deletion 
status which renders the tumors highly sensitive to chemotherapy (Cairncross 
et al, 1998). Patient survival, time to progression and response to therapy are 
all associated with subtype and grade of the tumor (Louis et al, 2007). The 
current WHO classification of glioma, combined with the patient’s prognostic 
features (e.g. age and Karnofsky Performance Score, KPS), guides treatment 
decisions. Traditional anatomic and pathologic classification of tumors has 
Table 1.1. WHO classification of glial tumors based on histology. WHO 
grading of glial tumors into grades I-IV is based on the presence or absence 
of four criteria: (1) nuclear atypical, (2) mitoses, (3) endothelial cell 




very limited ability to stratify patients into meaningful subgroups for prognosis 
and intervention. Differences between histological subtypes are very subtle, 
and classifying gliomas is subjected to large inter-observer variability (Murphy 
et al, 2002). Consequently, this can result in misdiagnosis. Since treatment 
protocols often depend on the diagnosed histological subtype, accuracy in 
diagnosis is very important for patients to get optimal treatment (Murphy et al, 
2002). Therefore, more accurate methods to diagnose gliomas are urgently 
required.  
1.2 Molecular Classification of Gliomas  
 There have been extensive studies on the molecular characteristics of 
gliomas over the years in order to provide more objective and accurate 
methods of identifying distinct molecular tumor subgroups, and to identify 
specific molecular tumor markers that can assist diagnosis, and consequently 
impacting on treatment decisions. In 2006, the National Cancer Institute, 
USA, initiated a multi-consortial effort to deep profile, as one of the first 
cancers, glioblastoma multiforme (GBM), because of its dismal prognosis 
(Louis et al, 2007). This effort is predicated on the belief that histologically 
similar tumors can be molecularly heterogeneous, and that distinct pathways 
drive the biological phenotype. The first publication arising from The Cancer 
Genome Atlas (TCGA) effort showed that patients with GBM sustain 
mutations that can be grouped into 3 major signaling networks: Receptor 
tyrosine kinases (RTKs), p53 and Retinoblastoma (Rb) tumor suppressor 
pathways (Atlas, 2008). Importantly, GBM tumors are molecularly 
heterogeneous, further highlighting the limitations of relying solely on 
morphology-based histological methods to diagnose and subsequently treat 
patients. There have been several attempts to molecularly classify GBM 
(Table 1.2). At a transcriptomic level, Philips et al. described 3 subclasses of 
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GBM tumors; Proneural, Proliferative, and Mesenchymal that correspond to 
different stages of neurogenesis (Phillips et al, 2006a). Notably, proneural 
GBM comprises of patients with primary diagnosis, younger age, and better 
prognosis. In contrast, older age patients and patients with tumor relapses 
more often associate with Mesenchymal GBM (Lee et al, 2008; Phillips et al, 
2006a). A follow-up study at a genomic level then showed that GBM tumors 
can be further molecularly classified into four subgroups; Proneural, Classical, 
Mesenchymal and Neural, with each subgroup exhibiting unique gene 
expression, genomic aberrations and clinical profile (Verhaak et al, 2010). To 
complement the initial molecular sub-classification of GBM by proteomic 
analysis, Brennan et al. identified active platelet-derived growth factor (PDGF) 
signaling and loss of neurofibromatosis (NF1) tumor suppressor gene 
expression as characteristic features of proneural and mesenchymal GBM 
respectively (Brennan et al, 2009). Using an integrative subtype analysis to 
characterize subtypes with coordinated genomic, epigenomic, and 
transcriptomic alterations, Shen et al. applied the iCluster algorithm on a 
subset of 55 GBM samples and showed the existence of three distinct 
integrated tumor subtypes: (1) iCluster1, a subtype that is enriched for the G-
CIMP phenotype and displays a proneural expression profile; (2) iCluster2, a 
subtype that is characterized by near complete association with EGFR 
amplification, overrepresentation of promoter methylation of homeobox and 
G-protein signaling genes, and a classical expression profile; (3) iCluster3 is 
characterized by NF1 and Pten alterations and exhibits a mesenchymal-like 
expression profile (Shen et al, 2012). With the strength of an integrative 
clustering analysis, the authors were able to discover and visualize 
coordinated patterns of genomic alterations, providing a biologically 





 A major inference from these studies is that GBM patients can now 
potentially be treated according to their molecular subclasses and pathway 
activation. Indeed, Wiedemeyer et al. recently showed via pharmacological 
targeting in a panel of GBM cell lines that co-deletion of CDKN2A and 
CDKN2C served as a strong predictor of sensitivity to a selective inhibitor of 
CDK4/6 (Wiedemeyer et al, 2010). This mapped to similar patterns of 
CDKN2A and CDKN2C mutations in TCGA patients, leading to 
hyperactivated CDK4/6. The Wiedemeyer study thus demonstrates that the 
integration of genomic, functional and pharmacologic data can be exploited to 
inform the development of targeted therapy directed against specific cancer 
pathways. Importantly, the TCGA effort emphasizes that gene expression 
drives GBM disease progression and clinical outcome.   
1.3 Glioma-propagating Cells (GPCs) 
 The understanding of the normal development of the nervous system 
has dramatically increased in recent decades. The nervous system has a 
complex cellular hierarchy ranging from a neural stem cell (NSC) that can 
give rise to all of the major lineages in the brain parenchyma (neurons, 
astrocytes, and oligodendrocytes) to lineage-committed progenitors that have 
a more restricted differentiation potential to terminally differentiated cells 
(Rietze et al, 2001; Uchida et al, 2000). The expression of nestin, a common 
Table 1.2. Molecular classification of GBM tumors. Overview of the 
molecular subtypes of GBM at genomic, transcriptional, proteomic and 
integrated levels. Clustering methodology is shown on the left column. 
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marker of neural stem-progenitor cells was subsequently demonstrated in a 
variety of neuroepithelial brain tumors (Dahlstrand et al, 1992; Tohyama et al, 
1992). The interest in applying normal developmental biology to the field of 
cancers is perhaps fueled by work of John Dick and colleagues on the 
identification of cancer-initiating cells in leukemia (Bonnet & Dick, 1997). 
Subsequently, similar identifications of cancer-initiating populations have 
been found in multiple systemic cancer types including the breast, colon, 
pancreatic, prostate and brain (Al-Hajj et al, 2003; Collins et al, 2005; Li et al, 
2007; O'Brien et al, 2007; Singh et al, 2003).  
 Conceptually, cancer stem cells (CSCs) define a small, biologically 
unique subset of cells with the capability to self-renew and generate the 
diverse cell types that constitute the whole tumor (Reya et al, 2001). These 
cells are termed cancer stem cells because of their “stem-like” properties 
shared commonly with normal tissue stem cells. These properties include 
extensive self-renewal ability (symmetrical and asymmetrical) and 
differentiation capacity. The latter, however, is not a mandatory feature of 
CSCs. Nevertheless, the concept of CSC is of considerable importance as it 
highlights the need to eradicate the CSC populations to achieve an effective 
cure. In recent years, the several terminologies such as cancer/ tumor-
initiating cells (CICs or TICs) and cancer/ tumor-propagating cells (CPCs or 
TPCs) have emerged in part due to the operational detection of cells with 
CSC properties in different contexts. CICs or TICs are more accurately 
referred to the original cells from which the malignancy first arose as shown 
elegantly by several lineage tracing mouse models (described in Section 1.5) 
(Alcantara Llaguno et al, 2009; Jacques et al, 2010; Zheng et al, 2008). CPCs 
or TPCs, on the other hand, refer to cancer cells that can perpetuate and 
sustain tumor growth, at least in a serial xenotransplantation model, with the 
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ability to maintain key karyotypic hallmarks, stemness expression and 
multipotentiality. As such, in the context of our studies in gliomas, we termed 
glioma-propagating cells (GPCs) as patient-derived cancer cells from gliomas 
with the ability to serially transplant and perpetuate tumors that recapitulate 
the original patient pathophysiology in a xenograft model. 
1.3.1 Markers to identify GPCs 
 The seminal work by Singh et al. demonstrated that the expression of 
a putative neural stem cell marker, CD133, in malignant tumor cells derived 
from gliomas and medulloblastomas, was sufficient and necessary to initiate 
and recapitulate the tumor upon transplantation into immunodeficient mice 
(Singh et al, 2003). Since these initial observations, numerous groups have 
joined the effort in elucidating the role of cancer stem cells in brain tumors. 
Recent studies have suggested that several additional but not overlapping 
markers represent the tumor-propagating cells in brain tumors. These include 
stage-specific embryonic antigen 1 (SSEA-1) or CD15 (Son et al, 2009), 
nestin (Bar et al, 2007b), aldehyde dehydrogenase (Bar et al, 2007b), Sox2 
(Gangemi et al, 2009), CD44 (Anido et al, 2010), integrin-α6 (Lathia et al, 
2010), Bmi-1 (Abdouh et al, 2009) and the side population (Bleau et al, 2009; 
Chua et al, 2008). Since many of these markers are also expressed on 
normal cellular counterparts, they do not present the best targeting 
candidates in any therapeutic strategy. In addition, the initial finding that only 
CD133-positive cells are the tumor-initiating population has been disputed as 
tumors have been demonstrated to also arise from CD133-negative cells in a 
subset of GBM tumors (Beier et al, 2007; Sakariassen et al, 2006). 
Importantly, CD133 expression has been shown to change with surface 
sialylation according to disease state and progression, further complicating its 
definition as a marker of bona fide tumor-initiating capacity (Kemper et al, 
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2010; Zhou et al, 2010). Henceforth, the field of cancer stem cell biology is 
moving away from heavy reliance on surface marker identification of tumor-
initiating cells, to complementing findings that measure the functional 
activities of tumor stem cells (Figure 1.1). 
1.3.2 Functional assays to identify GPCs 
 The GPC is defined functionally and there are assays to measure this. 
One such frequently used assay is the neurosphere assay (Reynolds et al, 
1992). The neurosphere assay is often used to approximate neural stem cell 
frequency in the normal neural stem and progenitor cells of the adult central 
nervous system (CNS). Neurospheres are heterogeneous and comprise of 
bona fide long-term, self-renewing neural stem cells, as well as lineage-
committed short-term, transit-amplifying progenitors (Singec et al, 2006). 
Therefore, sphere-forming frequency defined by sphere number is typically 
scored over three to four generations to measure the activity of bona fide 
neural stem cells, compared to transit-amplifying progenitors which loses 
sphere-forming ability typically after one or two generations (Reynolds & 
Rietze, 2005). Importantly, this sphere forming frequency has been 
demonstrated to translate to in vivo animal survival outcome (Anido et al, 
2010; Clement et al, 2007). In addition, the readout of individual neurosphere 
size, which approximates proliferation, is important as it distinguishes 
proliferation arising from the bona fide stem cell population which would 
otherwise be masked if general short-term viability assays (e.g. MTT assay) 
are carried out that also measure the proliferation of progenitor cells.  
 The central theme of the cancer stem cell hypothesis is the ability of a 
subpopulation of cells at the apex of the hierarchy to propagate tumors and 
promote tumor progression in an orthotopic xenograft transplantation model 
as compared to the non-tumorigenic cells within the tumor bulk (Figure 1.1). 
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The gold standard to identify GPCs functionally is the ability for the GPCs to 
reform a phenotypic copy of the original tumor in an orthotopic transplantation 
model, usually performed as a limiting dilution assay. Non-GPCs, by 
definition, lack this ability and fail in the transplant model. It is important to 
note that the hierarchy model of the CSC hypothesis may not be ubiquitous 
for all cancers or be represented in certain experimental cancer models. For 
instance, Quintana et al. challenged the CSC hypothesis by demonstrating 
that CSC frequency could be altered based on several parameters: (1) 
addition of extracellular matrix in the form of matrigel; (2) extending the 
duration for tumor formation; (3) varying the severity of immune-compromised 
mice depending on strains used. This study demonstrated that the tumor-
initiating capacity, at least in melanoma, is an artifactual consequence of the 
conditions employed in the xenografts model. Despite the lack of ability of in 
vitro cultured stem-like GPCs to reflect the actual transformational cell in 
tumorigenesis, the use of GPCs remains important for several reasons. First, 
GPCs have been shown to retain their transcriptomic and karyotypic features 
commonly found in the primary tumor in contrast to the commercially 
procured serum-grown glioma cell lines that often contain additional genomic 
aberrations (Lee et al, 2006; Li et al, 2008). Second, only GPCs establish 
xenografts tumors that recapitulate the patient’s original histopathology (Lee 
et al, 2006). Finally, transcriptomic analyses suggest that the stemness 
properties of GPCs and other cancer stem cells are enriched in high grade, 
malignant tumors, and contributes to disease progression and survival 
outcome (Shats et al, 2011). These reasons underscore the importance of 
GPCs as a more reliable and physiologically relevant cellular system to study 
disease mechanism.  
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 Our work here describes the isolation and characterization of patient-
derived GPCs (Chong et al, 2009). We demonstrate that histologically similar 
GBM tumors yield GPCs with very different transcriptomic profiles, suggesting 
that these underlying differences may account for the frequently observed 
inter-patient variability to treatment response. In addition, Shats et al. has 
shown that a stemness signature derived from embryonic stem cells could 
predict the breast cancer patient cohort sensitive to small molecules linked to 
this signature using the Connectivity Map (Lamb et al, 2006; Shats et al, 
2011), highlighting the clinical contribution of cancer-initiating cells to patient 
outcome. As with many studies involving the prospective isolation of tumor-
initiating cells, only limited amounts of clinical material are available, and this 
limitation is compounded by the lack of methods to preserve such cells at 
convenient time points. Although in vivo serial passage of GPCs can provide 
a reliable means to maintain such primary cells, however in practice it is not 
always possible to have access to immune-compromised animals of suitable 
ages to continuously maintain these cells. In addition, serial propagation of 
GPCs in animals has been shown to result in a genetic drift towards highly 
proliferating genes as evident by the over-representation of the proliferative 
expression signature (Hodgson et al, 2009; Phillips et al, 2006a). Eventually, 
the original features and characteristics of these lines will be lost.  
 Using our novel modified cryopreservation technique, we essentially 
resolved the bottleneck in maintaining these cells. That is, we now have a 
reliable repository of different primary patients’ lines that can be thawed upon 
experimental needs, and since these lines are characterized, we now 
understand how each patient’s phenotypic and transcriptomic profiles looks 
like. This will greatly enhance any projects that deal with larger patient 







1.3.3 GPCs contribute to primary tumor phenotype 
 
In assessing the contribution of stem-like GPCs to the primary tumor 
phenotype, several studies have focused on analyzing common GPC marker 
expression in tissue paraffin sections, often with ambiguous data. This may 
be reconciled by the fact that GPC properties that sustain the tumor 
phenotype may reside in more than just specific marker profiles (Bar et al, 
2007b; Beier et al, 2007; Sakariassen et al, 2006; Singh et al, 2004; Son et al, 
2009). Consequently, pathway activation resembling those functioning in 
stem-like cells, represented by a set of genes, is more likely to correctly 
Figure 1.1. Cancer stem cells are defined by a set of functional 
characteristics. Some of the required functional characteristics that define 
cancer stem cells include sustained self-renewal, persistent proliferation, and 
the ability of tumor initiation and propagation. Other characteristics that are 
often, but not necessarily, associated with cancer stem cells include rarity 




interrogate the clinical contribution of GPCs. An elegant study was carried out 
by Visvader et al. in BRCA1 mutation-associated breast tumors (Lim et al, 
2009). The authors derived differentially regulated genes in subsets of 
epithelial cells and found that luminal progenitors were highly represented in 
BRCA1 mutation-associated breast tumors, even more than the commonly 
anticipated stem cell population. This suggests that luminal progenitors are 
more likely the cells-of-origin for BRCA1 mutation-associated breast cancers, 
later confirmed in a transgenic mouse model study (Molyneux et al, 2010). 
Such studies underscore the predictive capability of gene expression 
mapping of pathway activation, instead of focusing on a specific marker 
identity. In another separate study, John Dick and colleagues recently 
demonstrated that serial tumor-initiating (and not marker-defined) acute 
myeloid leukemia stem cells contribute to disease progression and patient 
survival outcome (Eppert et al, 2011), highlighting the importance of 
functionally defining the cancer stem cell.  
 Two other relevant studies demonstrated that GPCs contribute to 
GBM patient survival outcome, with preferential activation of core stem cell 
programs (hematopoietic, neural and embryonic stem cells) (Shats et al, 
2011; Yan et al, 2011). Yan et al. performed a transcriptomic profiling of 
CD133+ and CD133- from human GBM and established a CD133 gene 
expression signature composed of 214 differentially expressed genes. The 
authors subsequently compared their gene signature with a compendium of 
published gene expression profiles and found that the CD133 gene signature 
transcriptomically resembles the human embryonic stem (ES) cells. Most 
importantly, the CD133 gene signature identifies an aggressive subtype of 
GBM seen in younger patients with shorter survival who bear excessive 
genomic mutations as surveyed through TCGA GBM mutation spectrum. 
Hence, the study by Yan et al. provides molecular and genetic support for the 
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stem-like nature of cells and an objective means for evaluating cancer 
aggressiveness. In support, Shats et al. has shown that a stemness signature 
derived from embryonic stem cells could predict the breast cancer patient 
cohort sensitive to small molecules linked to this signature using the 
Connectivity Map (Lamb et al, 2006), demonstrating the clinical contribution of 
cancer stem cells to patient outcome. 
 The key message from these studies is that cancer stem cells 
perpetuate tumors not merely in terms of their cell numbers or surface marker 
expression, but more accurately reflected by their pathway activation. 
Consequently, the primary tumor phenotype is a manifest of cancer stem cell 
behavior and signaling. 
1.4 Mouse models of glioma 
 Gliomas are heterogeneous, both at the molecular and cellular levels. 
The complex biology of these tumors makes understanding glioma 
pathogenesis and the development of novel effective therapies extremely 
challenging. Unlike in vitro culture system using established glioma cell lines 
or primary cells, tumor development in mice is accompanied by other complex 
processes such as invasion, angiogenesis and metastasis, similar to those in 
human cancer. More importantly, mouse models provide a temporally and 
genetically controlled environment for studying the tumorigenic mechanisms 
and treatment response. Of note, mouse models of molecularly characterized 
GBM provide opportunities to determine whether activation of certain 
pathways can lead to a specific GBM subtype and to generate histologically 
and genetically accurate mimics of the human disease. Some of the 
genetically engineered mouse models (GEMMs) that are driven by the genes 
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known to be key drivers for each clinically distinct glioma subtype are 
discussed below. 
1.4.1 Xenograft Mouse Models 
 
 Xenografts are created by implanting tumor cells derived from clinical 
material or immortalized glioma cell lines into immunocompromised mice. 
There are two models of xenografts: (1) orthotopic (tumor cells implanted into 
the original site of occurrence) and (2) heterotypic (non-autochthonous site). 
The traditional glioma xenograft models uses glioma cell lines (commercially 
procured and immortalized, usually grown in serum-containing medium) that 
have been passaged and maintained in tissue culture for long periods of time. 
Gliomas that are generated from these cell lines do not recapitulate the 
classical glioma pathophysiology of human gliomas (Lee et al, 2006). In 
addition, they have not been predictive for response in preclinical trials.  
 The use of patient-derived tumor cells for orthotopic xenograft 
transplantation has yielded valuable information on important aspects of GBM 
histology. In particular, tumor cells derived from freshly isolated human glioma 
tumors, when cultured in serum-free conditions optimized for tumor stem cell 
growth and injected orthotopically in animals, more closely mirror the 
phenotype and genotype of the primary tumor than when cultured in serum-
containing medium (Lee et al, 2006). These tumors typically recapitulate the 
diffuse invasion of glioma cells into the normal brain structures. Moreover, 
serial passage of these cells in mice can lead to changes in tumor phenotype, 
suggesting that the progression from lower grade tumor to higher grade GBM 
may be modeled in such systems (Wang et al, 2009). Furthermore, the 
importance of recreating the tumor in an anatomically correct site is 
emphasized in Galli et al. where only orthotopic but not subcutaneous tumors 
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recapitulated the original patient tumor histopathology (Galli et al, 2004). 
Several groups are currently using these modern xenograft models in 
preclinical testing. The advantage to such systems is that they are derived 
from human gliomas. These orthotopic models have also allowed for 
experiments aimed at studying the biology of glioma-propagating cells 
(GPCs) and have recently been utilized to recreate the microenvironment and 
cellular heterogeneity seen in human tumors. Importantly, efforts from TCGA 
have shown that glioma xenografts established from clinical but not 
commercially procured material/cells recapitulate the 4 molecular subclasses, 
each with distinct gene expression, genetic aberrations and clinical profile 
(Verhaak et al, 2010). 
1.4.2 Genetically Engineered Mouse Models (GEMMs) 
 A second popular cancer model in animals is to use genetically 
engineered mouse models (GEMMs) with close genetic resemblance to 
human disease. The advantages of this model includes: (1) the ability to 
provide appropriate material for comparative onco-genomic studies, which are 
directed at identifying additional genes that are altered in the development of 
tumor; (2) tumors derived from these GEMMs can be used to validate the 
functionality of specific genes in tumorigenesis; (3) GEMMs can also be used 
to analyze network of genes with specific genetic mutations, hence allowing 
the assignment of genetic lesions into defined pathways and the testing of 
drugs targeting these activities. Taken together, GEMMs address the 
molecular causation of tumor initiation, progression, therapeutic response and 
histology, contributing to the understanding of the molecular pathways 
implicated.  
 Using germline genetic modification techniques, it was demonstrated 
that GEMMs with activation of receptor tyrosine kinase (RTK) pathways in the 
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brain along with simultaneous loss of cell cycle-related genes, develop 
gliomas with high penetrance. This was confirmed by TCGA project which 
showed that the core signaling pathways are crucial for gliomagenesis. With 
additional loss of the tumor suppressor phosphatase and tensin homolog 
(Pten), a higher grade malignancy and reduced survival in mouse glioma 
models occurred, recapitulating the clinical profile (Kwon et al, 2008).  
 Mouse modeling that enforces PDGFRB expression produces tumors 
that ranges from the low-grade oligodendroglioma or oligoastrocytoma to the 
high-grade GBM with oligodendroglial features (Shih et al, 2004; Uhrbom et 
al, 2002). The grade of these tumors is regulated by several factors such as 
the expression levels of PDGF, loss of p53 and Ink4a/arf, and Pten (Dai et al, 
2001; Fomchenko et al, 2011; Shih et al, 2004; Uhrbom et al, 2002). 
Expression profiling of these tumors shows a parallel expression pattern to 
the human proneural molecular subgroup, which is predominated by PDGF 
signaling (Lei et al, 2011). In addition, amplification and activating mutation of 
EGFR is the canonical genomic alteration in the classical molecular subgroup 
of GBM (Brennan et al, 2009; Verhaak et al, 2010). The mouse model of 
EGFR-driven gliomagenesis, with germline constitutive active variant of 
EGFR, in conjunction with deletion of Ink4a/arf and Pten, develops high 
penetrance GBM that histologically resembles the classical GBM in humans 
(Zhu et al, 2009). Creation of GBM in mice by deletion of NF1 and p53 tumor 
suppressors shed light on our understanding that NF1 loss is the canonical 
alteration in the mesenchymal subgroup of GBM (Atlas, 2008; Reilly et al, 
2000; Zhu et al, 2005). Furthermore, tumors with NF1 loss often exhibit loss 
of p53, Ink4a/arf, and Pten (Verhaak et al, 2010).  
 Recently, variations in genetic mouse models have been used to 
investigate one of the most important gaps in the knowledge of glioma biology 
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– the origin of glioma progression and development. With the availability of 
inducible Cre recombinase transgenes that allow both temporal and spatial 
induction of Cre recombinase, thereby effecting gene expression or knockout 
in cell type-specific compartments with a Rosa reporter to trace evolving 
progeny, the cells of origin alongside with its differentiated progeny, have 
been elegantly demonstrated in intestinal cancers (Barker et al, 2009; Barker 
et al, 2007). Recent works have highlighted the importance of neural stem 
cells as the cells-of-origin with mutations in NF1/Pten/p53, or p53/Pten, as 
opposed to arising from the more mature progeny such as astrocytes, in 
contributing to GBM formation (Alcantara Llaguno et al, 2009; Jacques et al, 
2010). GEMMS are useful as they offer a window into the events governing 
the tumorigenic process.  
1.5 Cell-of-origin of glioma 
 One of the major contributing factors to glioma heterogeneity is the 
tumor cell-of-origin. Cells-of-origin are the normal cells in which tumorigenic 
mutations first occur and accumulate to form a full-blown malignancy. Cancer 
stem cells (CSCs), on the other hand, are defined as cells that maintain an 
already formed tumor. Therefore, the term “tumor-initiating cells” is more in 
line with the “cells-of-origin”, whereas CSCs would be more accurately be 
referred to as “tumor-propagating cells” (Visvader, 2011).  
 There are several theories on the identity of the origin of gliomas. 
Before the discovery of adult neural stem cells (NSCs), the astrocytes, the 
only known replication-competent population, were thought to be the cells-of-
origin of gliomas. The theory of dedifferentiation of astrocytes to malignant 
forms is supported by recent findings that reprogramming a panel of 
transcription factors can turn terminally differentiated cells back to the 
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pluripotent state (Takahashi & Yamanaka, 2006). Moreover, Verma and 
colleagues most recently demonstrated that ectopic lentiviral knockdown of 
key tumor suppressor genes in astrocytes and neurons initiated glioma 
formation, which later dedifferentiated (Friedmann-Morvinski et al, 2012). 
However, to-date, definitive evidence supporting that astrocytes are the cells-
of-origin are lacking due to the lack of good astrocyte marker. Glial fibrillary 
acidic protein, GFAP, a widely used marker for astrocytes is also expressed 
in NSCs (Doetsch et al, 1999).  
 As NSCs have been shown to be the self-renewing population in 
postnatal mammalian brains, they were subsequently suspected to be the 
glioma cell of origin (Zhao et al, 2008). The long-term self-renewal capacity of 
NSCs offers an advantage to allow accumulation of oncogenic mutations or 
hits. Recent evidences have supported the NSCs as cells-of-origin. Alcantara 
et al. demonstrated that deleting the tumor suppressors p53, NF1, and Pten 
specifically in postnatal murine neural stem or progenitor cells resulted in 
glioma formation with 100% penetrance (Alcantara Llaguno et al, 2009). On 
the other hand, ablation of these genes in non-neurogenic adult murine brain 
regions did not produce any tumors. Similarly, Jacques et al. showed that 
ablation of p53, Pten, and/or Rb in stem cells of the subventricular zone 
(SVZ), but not in the peripheral astrocytes, generated gliomas (Jacques et al, 
2010). However, these studies were not able to distinguish between the more 
quiescent, long-term self-renewing NSCs from the more rapidly dividing 
progenitor cells. More recently, using mosaic analysis with double markers 
(MADM), Liu et al. demonstrated that the early expanding tumor cells in the 
Nf1;p53-based mouse oligoastrocytoma model are cells that express 
oligodendrocyte precursor cell (OPC) markers (Liu et al, 2011a).  
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 An ideal model to study the cell-of-origin should address: (1) whether 
the cells in question are capable of transformation after harboring a set of 
oncogenic events; and (2) the kinds of mutations that accumulate in these 
transformed cells. The development and identification of cell-specific markers 
and other technologies that enhance precise temporal and spatial somatic 
gene manipulation would greatly facilitate the study of cell-of-origin.  
1.6 Selected signaling pathways regulating GPCs 
 Key signaling pathways that are crucial for normal neural stem cells, 
such as Notch, Hedgehog, and the PI3K-Akt axis, have been a focus of 
increasing interest in cancer therapy as these pathways may underlie GBM 
therapeutic response and targeting of these pathways may preferentially 
deplete GPCs. Indeed, our lab’s earlier work with Eli Lilly pharmaceutical 
company utilizing a small molecule screen of several inhibitors against key 
oncogenic pathways showed that GPCs can be targeted via PI3K/Akt, 
GSK3β, mTOR, CDK9, PLK1 and TAK1 (Foong et al, 2011; Foong et al, 
2012). Certainly, there is much literature supporting our observations that 
these regulatory pathways promote GPC growth and survival (Bao et al, 
2006; Eyler et al, 2008; Kotliarova et al, 2008; Lee et al, 2012). Although the 
role of these pathways in glioma is not new, their effectiveness against 
specifically GPCs, the long-term self-renewing population, is of interest in 
designing a therapy with effective cure, abrogating the infiltrative and 
recurrent nature of the disease. The targeting of the slowly-dividing population 
also calls into place the appropriate endpoints for measuring drug 
effectiveness, since most conventional cancer assays detect short-term and 
mainly anti-proliferative effects. This would imply that the drugs selected 
could have been prioritized, paradoxically, against the eventually terminal 
progenitor population instead of targeting the actual tumor-sustaining fraction. 
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The cancer stem cell hypothesis thus forces a re-evaluation of endpoints for 
efficacious drug development. 
1.6.1 EGFR/PI3K/AKT axis in GPC regulation 
 The presence of autocrine and paracrine growth factor loops are 
common in malignant gliomas and these pathways regulate numerous pro-
tumorigenic cellular functions including cellular proliferation, apoptotic 
resistance, invasion and angiogenesis. Epidermal growth factor (EGF), 
routinely used in culturing EGF-responsive neural precursors, is a key growth 
factor used in the maintenance of GPCs (Lee et al, 2006). GBMs frequently 
display EGFR amplification, with expression of the constitutively active variant 
EGFRvIII, mediated through PI3K-Akt and Ras/mitogen-activated protein 
kinase (MAPK) downstream signaling in GBMs and is associated with 
enhanced tumorigenic potential and more aggressive phenotypes, such as 
invasiveness and therapeutic resistance (Brandes et al, 2008). Shinojima et 
al. evaluated 87 primary GBM patients and found EGFR amplification to be 
an independent, unfavorable predictor for overall survival (Shinojima et al, 
2003). In this cohort, EGFRvIII overexpression in the presence of EGFR 
amplification is the strongest indicator of a poor survival prognosis.  
 
 Intratumoral heterogeneity plays a major role in contributing to GBM 
resistance to EGFR targeted therapy due either to pre-existing resistant 
clones within the tumor or the interaction of non-resistant clones with the 
tumor cells or the tumor niche. Mazzoleni et al. showed that despite both the 
molecularly and functionally distinct EGFRpos and EGFRneg GPCs being able 
to form tumors on their own that phenocopy the original tumor sample, only 
EGFRpos  GPCs had elevated tumorigenic proliferation and highly invasive 
characteristic (Mazzoleni et al, 2010). Hence, the presence of distinct 
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subpopulations within the same tumor might contribute to GBM resistance 
and EGFR targeted therapies since EGFRneg GPCs are insusceptible to 
treatment and will survive to reform the tumor mass. Inda et al. demonstrated 
that EGFRvIII cells secrete IL-6 and LIF, which in turn promote the growth 
and proliferation of wild-type EGFR cells that form the tumor bulk. This small 
subset of EGFRvIII cells, driven in a paracrine manner to recruit wild type 
EGFR cells into accelerated proliferation, enhances the tumorigenic potential 
of the bulk tumor and actively maintains a heterogeneous expression of both 
the wild type and the mutant form (Inda et al, 2010). Mice orthotopic tumors 
overexpressing EGFRvIII are refractory to radiation therapy, with sustained 
repopulation and nondescript effect on overall survival. The efficacy of EGFR 
kinase inhibitors have been disappointing so far  as silencing of EGFRvIII 
compels GBM cells to undergo selective pressure in vivo to employ 
alternative compensatory pathways such as upregulating receptor tyrosine 
kinases (PDGFR, IGF1-R and c-Met) to maintain aggressiveness. These 
findings suggest that tumor cells are adept at bypassing single EGFR 
targeted therapies, reforming the tumor after an initial period of stasis, and 
inhibition of EGFR alone will not be adequate for translation into a beneficial 
clinical response in GBM patients. An effective therapeutic strategy should 
take into account the role of residual EGFRneg GPCs or that of the secreted 
factors in the tumor niche, and the development of a tailored combinatorial 
therapy targeted at both the aggressive EGFRpos GPCs and the less 
malignant EGFRneg GPCs or the microenvironment will be imperative to 
improve the clinical response of GBM patients.  
 One of the main molecular changes accompanying progression of 
gliomas to high grade, with simultaneous elevated stem cell expression and 
resistance to chemotherapy, is the loss of phosphatase and tensin homolog 
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(PTEN) and consequent elevation of Akt pathway activities (Hu et al, 2005). 
Deficiency in PTEN modulates Chk1 localization, initiating genetic instability 
and thereby conferring chemo-radioresistance in GBMs. A number of 
intracellular signaling cascades are activated upon EGFR stimulation, but the 
PI3K-Akt module has been predominantly linked to GPC biology and 
contribution to the resistant phenotype (Dreesen & Brivanlou, 2007; Eyler et 
al, 2008). Various studies have shown that hyperactivation of the PI3K/Akt 
and Ras/MAPK signaling pathways in cancer cells promotes tumorigenesis, 
increases tumor cell survival, proliferation, invasion and is significantly 
associated with radiotherapy resistance, either through the modulation of cell 
survival signaling or, by direct regulation of the DNA repair machinery. In 
human gliomas, there is evidence at genomic, mRNA and protein levels 
showing that aberrant Akt signaling prognosticates poorer survival (Phillips et 
al, 2006a). Indeed, chemoresistance in hepatocarcinoma stem cells may be 
conferred by activation of Akt (Ma et al, 2008), and Akt signaling promotes 
survival of stem-like tumor cells in the perivascular niche of mouse 
medulloblastoma models (Hambardzumyan et al, 2008). It has been recently 
demonstrated that GPCs are more dependent on Akt signaling than their 
matched non-stem counterparts (Eyler et al, 2008). Chakravati et al. observed 
that GBMs expressed significantly higher levels of phospho-PI3K and 
phospho-p70s6k, but not of phospho-Akt, compared to their non-GBM 
counterparts, implying that GBMs display dependency on these pathways 
possibly for their survival, proliferation and therapeutic resistance (Chakravarti 
et al, 2004). In addition, inverse correlation between phospho-PI3K, phospho-
Akt, and phospho-p70s6k levels with cleaved caspase 3 implicates the likely 
mechanisms employed by the members of the PI3K family in the inhibition of 
apoptosis and promotion of  radioresistance in GBMs (Chakravarti et al, 
2004). Functional inhibition of Akt with the pharmacologic inhibitors 
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preferentially disrupts GPC neurosphere formation, reduces motility and 
invasion, induces apoptosis in vitro, and significantly prevents intracranial 
tumor formation of GPCs (Bleau et al, 2009; Eyler et al, 2008). Although in 
vitro targeting of the EGFR-PI3K-Akt signaling cascade may have specific 
effects on GPC self-renewal and tumorigenic progression, clinical trials of 
EGFR inhibitors, such as Imatinib, have not resulted in significant survival, 
suggesting that EGFR inhibition solely is an insufficient therapeutic paradigm, 
prompting greater focus on PI3K inhibitors.  
 EGFR/EGFRvIII’s cross-interaction with the oncogenic transcription 
factor STAT3 and receptor tyrosine kinases (c-Met and PDGFR) mediates 
GPC resistance to anti-EGFR therapy. JAK-STAT3 pathway is constitutively 
activated in the majority of GBMs and the dynamic interactions between 
STAT3 and EGFR underlie resistance of GBM cells to Iressa (Lo et al, 2008). 
Combinatorial inhibition of JAK and EGFR/EGFRvIII abolishes STAT3 
activation and synergistically suppresses the GPC proliferation. JSI-124 acts 
as a highly selective inhibitor of the JAK/ STAT3 signaling pathway 
(Blaskovich et al, 2003) and has been shown to sensitize malignant glioma 
and medulloblastoma cells to TMZ, 1,3-bis(2-chloroethyl)-1-nitrosourea, and 
cisplatin (Lo et al, 2008).  In addition, the direct role of EGFR in the regulation 
of DNA repair was demonstrated by Bandyopadhyay et al. where they 
showed direct physical interaction of EGFR and DNA-dependent protein 
kinase (DNA-PK), a key component of the nonhomologous end-joining 
(NHEJ) machinery (Bandyopadhyay et al, 1998). Furthermore, a follow-up 
observation by Dittmann et al. showed that ionizing radiation (IR) and the use 
of a radiomimetic drug, cisplatin induces the translocation of EGFR into the 




 Taken together, these findings discussed here suggest that EGFR 
signaling, either directly through the interaction with the DNA repair 
machinery or indirectly through the activation of key oncogenic PI3K/ Akt and 
JAK/STAT signaling pathways, modulates sensitivity to radiation. Therefore, 
elucidation of the dynamic interactive EGFR networks will enable us to 
identify mechanisms that circumvent therapeutic resistance in GPCs and 
improve the modest efficacy of current EGFR-targeted therapy in GBM 
patients. Given the central role of the EGFR signaling pathway in conferring 
the aggressive phenotype in tumors, treatment resistance, and poor 
prognosis, considerable effort has been invested in the development of 
imaging strategies to non-invasively ascertain EGFR status and therapeutic 
response to EGFR targeting agents. Such approaches would enable more 
accurate stratification of the patients who are likely to benefit from EGFR 
targeting therapeutics and for monitoring treatment efficacy (Hatanpaa et al, 
2010).  
1.6.2 Notch signaling  
 Activation of the Notch signaling cascade involves proteolytic 
cleavage by γ-secretase and is critical for the maintenance of stem and 
progenitor cells in promoting self-renewal and repressing differentiation 
(Lathia et al, 2008). Aberrant Notch signaling has been implicated in the 
pathogenesis of multiple tumors including gliomas, and the overexpression of 
Notch and its ligands, Delta-like-1 and Jagged-1, is commonly associated 
with glioma survival and proliferation. The role of Notch signaling in GBMs 
has been widely characterized and it has been shown that downregulation of 
NOTCH1, Delta-like-1, or Jagged-1 leads to glioma cell apoptosis and 
translates into a prolonged survival in a mouse orthotopic brain tumor model 
(Purow et al, 2005). Fan et al. demonstrated that specific Notch targeting of 
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patient-derived GPCs by γ-secretase inhibitor (GSI) attenuated  neurosphere-
forming ability with marked decrease in the expression of stemness-related 
markers, increased sensitivity to chemotherapeutic agents in vitro and 
blocked tumor propagation in vivo, suggesting a potential dependence on 
Notch signaling in GPCs (Fan et al, 2010). Activation of Notch by upstream 
oncogenic stimuli and microenvironmental cues is essential for the 
maintenance of GPCs and the facilitation of tumor propagation, suggesting a 
role of Notch at the center of key regulatory GPC signaling networks.  
 Previous reports have demonstrated that exposure to radiation 
modulated the activation of Notch signaling in the CD44+/CD24-/low breast 
cancer stem cells (Phillips et al, 2006b). In addition, Notch signaling has been 
implicated in the radioresistance phenotype of GPCs where knockdown of 
NOTCH1 or NOTCH2 effected radiosensitivity of GPCs but not that of 
differentiated glioma cells (Wang et al, 2010), suggesting that inhibition of 
Notch signaling may not only deplete GPC frequency and engraftment 
potential but also reduce the radioresistance of GPCs. Furthermore, inhibition 
of the Notch cascade in irradiated GPCs brought about increased apoptotic 
marker caspase 3/7 and positive labeling of apoptotic marker Annexin V. 
Thus, these data suggest that, in the case of gliomas, Notch may be a 
possible target in stem-like glioma cells as GPCs express Notch family  genes 
and gliomaspheres have elevated Notch activity (Lee et al, 2006) and might 
be involved in evading apoptosis and promoting proliferation.  Therefore, 
targeting Notch and its components underlying the radioresistance of GPCs 
promise to confer sustained benefit for glioma therapeutics. 
1.6.3 Hedgehog-Gli signaling 
 The Sonic Hedgehog signaling pathway is one of the classic examples 
of cancer cells regulated by paracrine and autocrine mechanism, supporting 
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an intimate relationship between tumor cells and their stroma, the 
microenvironmental niche (Clement et al, 2007; Yauch et al, 2008). Indeed, 
this pathway is controversial but has been ascribed an autocrine mode of 
signaling in GPCs (Clement et al, 2007). This pathway is one of key 
regulatory pathways critical for the maintenance of several types of adult stem 
cells, including neural stem cells (Clement et al, 2007). The Hedgehog 
signaling cascade is commonly known to be expressed by tumor-associated 
endothelial cells and astrocytes in platelet-derived growth factor (PDGF)-
driven mouse models of GBM (Becher et al, 2008). The main components of 
this signaling pathway are the ligands (secreted Hedgehog proteins), the 
Patched receptor (Ptch, a 12-pass transmembrane protein), the intracellular 
transducing molecules Smoothened (Smo - a second transmembrane protein) 
and Gliotactin (Gli, zinc-finger transcription factors). Ligand-binding of 
Hedgehog to Ptch represses Smo inhibition, allowing the activation of the 
canonical Hedgehog pathway through Gli-dependent transcription of multiple 
targets, including N-myc, cyclin D, Ptch, Gli1, and Gli2.  
 Hedgehog signaling is highly deregulated in a small subpopulation of 
human medulloblastoma and Gli1, a key Hedgehog target, was highly 
expressed in primary GBMs and CD133+ GBMs (Bar et al, 2007b). 
Conventional sources of Hedgehog ligands include CD133+ GPCs and 
tumor-induced vasculature in GBMs (Clement et al, 2007). Several groups 
have investigated the role of Hedgehog-Gli signaling in GPCs and found that 
this signaling pathway regulates GPC function, self-renewal and 
tumorigenesis (Bar et al, 2007a; Clement et al, 2007; Ehtesham et al, 2007). 
Forced differentiation of gliomaspheres reduced both stemness and 
Hedgehog activity expression. However, not all GBMs have activated Shh 
signaling as determined by Gli expression (Bar et al, 2007b), indicating the 
presence of molecular subgroups of brain tumors in which targeting of Shh 
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would be ineffective. Treatment of GPCs with the Hedgehog inhibitor 
cyclopamine or Gli knockdown drastically depleted the GPCs by suppressing 
self-renewal ability and proliferation while increasing apoptotic cell death in 
vitro and inhibiting tumor propagation in vivo. Importantly, cyclopamine 
inhibition of Hedgehog-Gli signaling enhances the efficacy of TMZ to abolish 
GPC proliferation and improve the effect of radiation on GPCs. Taken 
together, these studies indicate that the Hedgehog-Gli module is critical for 
GPC maintenance and targeting this pathway with specific pharmacologic 
inhibitors may attenuate GPC self-renewal and offer improved therapy 
efficiency against gliomas.   
 Gli1 acts at the distal end of the Hedgehog pathway, where it 
regulates transcription in response to activation or inhibition of the pathway. 
Moreover, Gli activity correlates with tumor grade in a genetically engineered 
mouse model (Becher et al, 2008). As such, further investigation must be 
performed to explore its role in GPC growth, maintenance and GBM 
recurrence. Cui et al. investigated the role of Gli1 in primary and recurrent 
gliomas and its ability to confer chemosensitivity or chemoresistance of 
glioma cells (Cui et al, 2010). Overexpression of Gli1 associated with GPC 
chemoresistance, resulting in glioma perpetuation. Conversely 
downregulation of Gli1 enhanced the susceptibility of GPCs to the synergistic 
effects of cyclopamine and chemotherapeutic agents, promoting apoptotic cell 
death, thus suggesting that Gli1 is a key mediator of chemoresistance in 
GBMs with aberrant Hedgehog signaling. Moreover, the constitutive 
Hedgehog pathway activity contributes to the resistance of glioma cells to 
chemotherapeutic agents by promoting self-renewal and tumor regrowth 
following therapy in an autocrine and/or paracrine manner (Bar et al, 2007b). 
In contrast, abolishment of Hedgehog pathway activity abrogates tumor 
growth and restricts tumor recurrence, by downregulation of the expressions 
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of multidrug resistance protein-1 (MDR1), multidrug resistance associated 
protein-1 (MRP1), lung resistance-related protein (LRP), O-6-methylguanine-
DNA methyltransferase (MGMT), B-cell lymphoma 2 (Bcl-2) and Baculoviral 
IAP repeat-containing protein 5 (BIRC5 or Survivin), which play important 
roles in glioma chemoresistance and repopulation, thus providing a 
mechanism to explain the recurrence of some gliomas.  
 
1.7 WNT Signaling and Regulation 
 The Wnt proteins are a family of small (39-46 kDa) lipid-modified 
secreted cysteine-rich glycoproteins (Tanaka et al, 2002). The first Wnt gene 
was initially discovered by Roeland Nusse and Harold Varmus in 1982 
through viral mammary tumorigenesis experiments where they observed 
integration of the mouse mammary tumor virus (MMTV) into the promoter 
region of a gene called Int-1 (integration 1) could induce tumors (Nusse & 
Varmus, 1982). Int-1 is orthologous to the Drosophilia segment polarity gene 
Wingless (Wg) and the terms were combined to generate the name Wnt 
(Nusse et al, 1991). Since the identification of Int-1 (now termed WNT1), the 
gene family of WNT has grown to 19 paralogous members at present (The 
Wnt Homepage, http://www.stanford.edu/group/nusselab/cgi-bin/wnt/). 
 Wnt signaling plays diverse roles both during embryogenesis and 
normal stem cell development. It is crucial for embryonic patterning through 
the control of cell proliferation, determining the fate of stem cells, tissue 
homeostasis and the regulation of stem cell self-renewal. In somatic tissues, 
Wnt signaling is essential for the maintenance of normal architecture and 
function of many tissues through the regulation of stem cell renewal (He et al, 
2004; Reya et al, 2003; Willert et al, 2003).  
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 In the normal development of CNS, the tight control and regulation of 
neural stem and precursor cells’ proliferation are crucial. The loss of the 
glycoprotein Wnt1, a protein normally expressed in the caudal midbrain, leads 
to failure of neural precursor expansion, resulting in malformation and an 
almost complete loss of the mid/hindbrain region (McMahon & Bradley, 1990). 
In addition, ectopic expression of Wnt1 in the mid/hindbrain region enhances 
the proliferation of neural precursors mediated by the induction of cyclin D 
and the shortening of cell cycle (Panhuysen et al, 2004). These observations 
suggest the role of Wnt signaling regulation in normal developing brain. 
Furthermore, Wnt3a mutant mice displayed marked reduction in hippocampal 
layers due to decreased proliferative expansion of caudomedial cortical 
progenitor cells (Lee et al, 2000). Recent work by Lie et al. demonstrated that 
Wnt signaling is a crucial regulator of adult hippocampal stem/ progenitor 
cells (Lie et al, 2005). They showed that in vitro and in vivo overexpression of 
Wnt3a in adult hippocampal stem/progenitor cells increased neurogenesis, 
whereas Wnt inhibition resulted in almost complete abrogation of 
neurogenesis in vivo. In addition, Kalani et al. demonstrated the regulatory 
role of Wnt signaling in the self-renewal of neural stem cells (Kalani et al, 
2008). Importantly, the authors showed that Wnt signaling is required for the 
expansion of single-cell derived neural stem cell populations that are capable 
of giving rise to neural stem cells and other cells of multipotent lineages. 
Taken together, these observations highlight the importance of Wnt signaling 
in the normal development of neural stem/progenitor cells. 
 Wnt signaling cascades can be broadly classified into canonical and 
non-canonical pathways as determined by the composition of the 
Wnt/Frizzled complex. A critical and heavily studied Wnt pathway is the 
canonical Wnt/β-catenin signaling pathway, which functions by regulating the 
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amount of transcriptional co-activator β-catenin that controls key downstream 
developmental gene expression programs. The phosphorylation status and 
degradation of cytoplasmic β-catenin and its regulation by Wnt proteins are 
the essence of canonical Wnt/β-catenin signaling. Regulation of Wnt/β-
catenin signaling occurs at several different levels to ensure that cytoplasmic 
levels of free β-catenin protein remain low. For simplicity, the Wnt/β-catenin 
signaling activity can be viewed as being in a dichotomous state of either “Off” 
or “On” (Figure 1.2).  
1.7.1 Wnt/β-catenin signaling: “Off”-state 
 In the absence of Wnt ligands or stimulus, β-catenin is recruited into a 
multiprotein “destruction complex”. This destruction complex consists of Axin1 
(or Axin2 homologue) that forms the central scaffold of this complex and 
provides binding sites for β-catenin, adenomatous polyposis coli (APC), 
glycogen synthase 3β (GSK3β), casein kinase Iα (CKIα), and protein 
phosphatase 2A (PP2A). Once the complex is formed, it is stabilized by the 
GSK3β-mediated phosphorylation of Axin and APC. Within the stabilized 
complex, GSK3β phosphorylates the N-terminus of β-catenin. Phosphorylated 
β-catenin is then recognized by β-transducin repeat containing protein (β-
TrCP), an F-box-containing protein, which together with Skp1, Cullin, and 
Rbx-1 constitutes the ubiquitin ligase (E3). This, together with ubiquitin 
conjugating enzyme (E2) and ubiquitin activation enzyme (E1), causes 
ubiquitination of β-catenin at lysine resides, which is subsequently destroyed 
by the proteasome system. In the nucleus, prospective Wnt target genes are 
kept in a repressed state by interacting with T-cell factor (TCF) and lymphoid 
enhancer-binding protein (LEF) transcription factors, with associated co-
repressors. Hence, in the “Off”-state, cells maintain low cytoplasmic and 
nuclear levels of β-catenin. In addition, extracellular Wnt ligands can interacts 
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with a variety of endogenous antagonists, including secreted Frizzled-related 
protein (sFRP), Dickkopf (DKK) family of proteins, and Wnt-inhibitory factor-1 
(WIF-1). All these secreted proteins can inhibit Wnt/β-catenin by sequestering 
Wnt ligands and prevent receptor-mediated activation of the pathway. 
1.7.2 Wnt/β-catenin signaling: “On”-state  
 Wnt/β-catenin signaling is triggered by the interaction of Wnt ligands 
with Frizzled receptors in the presence of the transmembrane LRP5/6. The 
association of Wnt ligands with Fz receptors and LRP5/6 initiate the 
recruitment of phosphoprotein Dishevelled (Dvl) to the cell surface, which 
subsequently recruits Axin and the “destruction complex” to the cell 
membrane, where Axin directly binds to the cytoplasmic tail of LRP5/6. Axin is 
then degraded, which decreases β-catenin degradation and a consequent 
increase in β-catenin levels in the cytoplasm. The activation of Dvl also leads 
to the inhibition of GSK3β, which further reduces the phosphorylation and 
degradation of β-catenin. Therefore, activation of Wnt/β-catenin pathway 
involves increasing the post-translational stability of β-catenin, via the 
degradation of Axin and inhibition of GSK3β. As β-catenin levels rises in the 
cytoplasm, it is translocated into the nucleus where it competes with Groucho 
(a transcriptional co-repressor of TCF/LEF) for binding with the TCF/LEF 
proteins. The TCF/LEF proteins allow β-catenin and other co-activators to 
bind to the DNA, where it forms the basis of a large complex for activating 










1.8 Dysregulation of WNT Signaling in Tumorigenesis 
 Given the crucial roles of Wnt/β-catenin signaling in development and 
homeostasis, it came as no surprise that mutations of the Wnt pathway 
components are associated with many hereditary disorders, including 
cancers. The Wnt/β-catenin signaling pathway has been demonstrated to be 
the predominant driving force of stem cells of the colonic crypt, hematopoietic 
and central nervous system (Barker et al, 2007; Kalani et al, 2008; Reya et al, 
Figure 1.2. Overview of Wnt/β-catenin signaling. A, In the absence of Wnt 
(”Off”-state), cytoplasmic β -catenin forms a “destruction complex” with Axin, 
GSK3β, APC, and CKIα. Phosphorylation of β -catenin by CKIα primes 
subsequent phosphorylation events by GSK3β. Phosphorylated β-catenin is 
recognized by the E3 ubiquitin ligase β-TrCP, which targets β-catenin for 
proteosomal degradation. In the nucleus, Wnt target genes are repressed by 
transcriptional repressors such as Groucho and histone deacetylases 
(HDAC). B, In the presence of Wnt ligand (”On”-state), Fzd and LRP5/6 
forrms a receptor complex. The formation of Wnt-Fzd-LRP5/6 complex, 
together with the recruitment of the scaffolding protein Dvl, results in LRP5/6 
phosphorylation and activation and the recruitment of Axin to the cytoplasmic 
tail of the receptors. This disrupts the formation of the “destruction complex”, 
allowing β-catenin to accumulate in the nucleus where it functions as a 
coactivator for TCF/LEF to activate Wnt-responsive genes. 
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2003). In particular, tumor-initiating cells of the colon, breast and 
hematopoietic system have been shown to promote tumorigenesis through 
major contributions from aberrant Wnt/β-catenin signaling (Barker et al, 2009; 
Chen et al, 2007; Woodward et al, 2007; Zhao et al, 2007) 
 The association of dysregulated Wnt/β-catenin signaling with cancer is 
perhaps best document with colorectal cancer. APC represents the most 
frequently mutated gene among the Wnt components. Genetic defects in 
APCs results in a heritable syndrome, familial adenomatous polyposis (FAP), 
where individuals affected develop hundreds of polyps in the large intestine at 
an early age and ultimately succumb to colorectal cancer (Clements et al, 
2003). Another most commonly mutated proto-oncogene of the Wnt/β-catenin 
pathway is the β-catenin gene, CTNNB1. It is frequently reported that 
mutations of CTNNB1 occur in exon 3 and specifically disrupt GSK3β-
mediated phosphorylation. The effect of such mutations renders β-catenin not 
being able to be recognized by the “destruction complex” for degradation.  
1.9 WNT Signaling in Glioma 
 The fact that Wnt signaling is also dysregulated in multiple solid 
cancers suggests that it may also play a role in the maintenance of GPCs. A 
study by Pu et al. demonstrated that WNT2, an activator of the Wnt/β-catenin 
canonical pathway, was significantly overexpressed in gliomas and their 
expression levels correlated positively with malignancy (Pu et al, 2009). 
Similarly, higher grade gliomas were observed to express elevated CTNNB1 
expression (Liu et al, 2011b), which subsequently correlated with poorer 
prognostic impact in GBM patients (Liu et al, 2011c; Sareddy et al, 2009b). In 
addition, the expression of other Wnt regulators, including Dvl2, Dvl3, FRAT-
1, Pygo-2, TCF4, and LEF-1 and of specific Wnt target genes, CCND1 and 
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MYC, also increases with glioma grades. Of note, recent reports 
demonstrated that the knockdown of Dvl2 abrogated both the self-renewal 
ability and proliferation of gliomas and stimulated the differentiation of patient-
derived glioma samples. Tumor propagation in immune-compromised mice 
was repressed upon Dvl2 depletion.  
 In addition to regulation of the expression of the Wnt members, 
antagonists of the Wnt pathway are often repressed in GBMs and their 
expression is mostly inversely correlated with glioma grades. Frequent 
aberrant promoter hypermethylation of these Wnt antagonists, such as WIFs, 
sFRPs, and DKKs is significantly associated with GBMs. Furthermore, Zheng 
et al. identified a novel proto-oncogene PLAGL2, which is overexpressed in 
GBMs and induces GPCs proliferation and tumorigenic potential. PLAGL2 
stimulates the expression of Wnt-6, Fz-9 and Fz-2, inhibits differentiation, and 
increases proliferation of neural progenitors. PLAGL2 amplification also 
associates with elevated levels of CTNNB1 in GBMs, suggesting a possible 
role of PLAGL2 in GPCs via the regulation of Wnt signaling. Jiang et al. 
showed that hypermethylation of paternally expressed gene 3 (PEG3) 
promoter in glioma mitigates expression of PEG3 and correlates with high 
grade gliomas (Jiang et al, 2010). Upon PEG3 promoter hypermethylation, β-
catenin accumulates, resulting in GPC proliferation. A recent study by Zhang 
et al. showed that the interaction between the transcription factor Forkhead 
box M1 (FoxM1) and β-catenin promotes β-catenin nuclear localization, 
controls transcriptional activation of Wnt target genes expression and 
maintains GPC self-renewal (Zhang et al, 2011). Together, these findings 




1.10 Gap in knowledge 
In following chapters, we will address the following gaps in knowledge in the 
field of glioma and GPCs: 
1. We characterized patient-derived glioma-propagating cells (GPCs) 
 that are enriched in spheroid structures (gliomaspheres) and can be 
 reliably maintained through a combination of in vitro and in vivo serial 
 passaging. We seek to demonstrate that GPCs established from 
 patient tumors with similar histology are transcriptomically distinct, 
 highlighting molecular heterogeneity and the limitation of relying solely 
 on histology to diagnose and subsequently treat patients. In addition, 
 we address the question of whether using our modified method of 
 vitrification if we could reliably preserve and maintain the biological 
 phenotype and transcriptomic profiles of GPCs. This is important, as it 
 will greatly facilitate the study of GPCs as we have a reliable 
 establishment of a GPC repository for subsequent experimental 
 designs and studies. 
2. Secondly, we seek to determine the GPC contribution to patient 
 survival and prognosis by analyzing gene expression profiles of GPCs 
 derived from 2 major variant of human gliomas – the oligodendroglial 
 and GBM tumors. This is important as it will provide a direct link 
 between GPCs and disease progression, highlighting the clinical 
 relevance and applicability of GPCs. 
3. Next, we will test the hypothesis of whether Wnt/β-catenin signaling 
 (as identified in our oligodendroglial gene signature) is differentially 
 regulated between the oligodendroglial and GBM tumors. We sought 
 to investigate if the Wnt/β-catenin signaling is crucial in the survival 
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 and maintenance of GPCs through the use well-established 
 pharmacological and genetic methods. Importantly, we will investigate 
 the in vivo efficacy of β-catenin knockdown to show that Wnt/β-catenin 
 signaling is important in maintaining the tumorigenic capacity of 
 GPCs. 
4. Finally, we seek to find potential novel regulators of the Wnt/β-catenin 
 signaling implicated in differential regulation of Wnt/β-catenin signaling 











































CHAPTER 2 – MATERIALS AND METHODS 
2.1 Tissue Collection and Primary Gliomasphere Culture 
Graded brain tumor specimens were obtained with informed consent, as part 
of a study protocol approved by the institutional review board. In this study, 
NNI-1 was from a patient with recurrent GBM (grade IV) who had received 
radiation therapy, and NNI-2, 3, 4, 5, 10, 11 and12 were from patients with 
primary GBM who were treatment naive. NNI-7 and NNI-8 are GPC lines 
derived from patients with primary anaplastic oligoastrocytoma who were 
treatment-naive. All GPC lines presented in this thesis except NNI-10 and 
NNI-11 belong to the proneural subclass. NNI-10 and -11 GPCs represent the 
mesenchymal subclass based on the molecular classification by Lottaz et al. 
(Lottaz et al, 2010). Tumors were processed according to Gritti et al. (Gritti et 
al, 1996) with slight modifications. Cells were seeded at a density of 2, 500 
per cm2 in chemically defined serum-free selection growth medium consisting 
of basic fibroblast growth factor (bFGF; 20 ng/ml; Peprotech, New Jersey), 
epidermal growth factor (EGF; 20 ng/ml, Peprotech), heparin (5 μg/ml; Sigma-
Aldrich, St Louis), and serum-free supplement (B27; 1x; Gibco, Grand Island, 
NY) in a 3:1 mix of Dulbecco’s modified Eagle’s medium (DMEM; Sigma-
Aldrich) and Ham’s F-12 Nutrient Mixture (F12; Gibco). The cultures were 
incubated at 37oC in a water-saturated atmosphere containing 5% CO2 and 
95% air. To maintain the undifferentiated state of the gliomasphere cultures, 
growth factors were replenished every 2 days. Differentiation was carried out 
over 14 days in DMEM/F12 without growth factors, supplemented with 5% 
fetal bovine serum (FBS; Invitrogen, Carlsbad) and 1x B27. Successful 
gliomasphere cultures (1 to 4 weeks) were expanded by mechanical 
trituration using a flame-drawn glass Pasteur pipette, and cells were reseeded 
at 100,000 per ml in fresh medium.  
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All GPCs except Pollard lines used in this study were cultured as spheroid 
structures in serum-free media supplemented with bFGF and EGF. Although 
Pollard lines were cultured on laminin (Pollard et al, 2009), a recent molecular 
classification study showed that both culture methods preserved the biological 
and functional signaling pathways (Lottaz et al, 2010). This provides 
justification for our subsequent analyses.  
“Gunther” lines: GS-1, 3, 4, 5, 6, 7, and 8 are GBM-initiating cells whereas 
GS-2 was derived from a high-grade tumor with oligodendroglial features as 
previously described (Gunther et al, 2008). Cell lines were cultured for up to 
14 passages in vitro with preservation of transcriptomic profiles. “Pollard” 
lines: G144, 144ED, 166, 179, and GliNS2 are GBM-initiating cells whereas 
G174 was derived from a patient with anaplastic oligoastrocytoma as 
previously described (Pollard et al, 2009). Pollard lines could be cultured for 1 
year (>20 passages) with preservation of key stemness or differentiation 
expression, karyotypic hallmarks, and tumor propagation. 
2.2 Cryopreservation and thawing of gliomasphere cultures for 
viability count 
In the conventional cryopreservation method, 5, 000 gliomaspheres per ml of 
freezing media (50-100 μm diameter) were frozen in a slow-cooling protocol 
using a freezing container (Nalgene) in -80oC for 24 hours before transfer into 
-196oC liquid nitrogen storage for 30 days. Freezing media contained 
DMEM/F12 media supplemented with 10% dimethylsulfoxide (DMSO; Merck 
& Co., Whitehouse Station, NY) only; or 10% DMSO and 90% FBS. These 
samples were thawed at 37oC water bath for 1-2 minutes, washed with 
excess DMEM/F12 media before being cultured in chemically defined serum-
free selection growth medium supplemented with growth factors (DMEM/F12, 
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20 ng/ml each of bFGF and EGF, 1x B27 and 5 μg/ml heparin). Viability 
counts were carried out after incubation periods of 1, 5 and 10 days (Gunther 
et al, 2008). 
In the vitrification method (Figure 2.1 and Table 2.1), gliomaspheres from the 
same passage were subjected to either vitrification or continuous culturing 
(non-vitrified). Five thousand gliomaspheres (50-100 μm) were frozen in a 
rapid cooling protocol. Gliomaspheres were resuspended in 100 μl of holding 
medium (HM) of DMEM/F12 containing HEPES buffer (Gibco) with or without 
20% FBS before being transferred by pipetting into sequentially increasing 
concentrated vitrification solutions (VS1 and VS2). Gliomaspheres were 
incubated for 1 minute in 100 μl of VS1 consisting of 10% DMSO and 10% 
ethylene glycol (EG; Merck), followed by a 25-second incubation in 100 μl of 
VS2 consisting of 20% DMSO, 20% EG and 0.3 M sucrose. The mixture was 
immediately transferred into 0.78 mm inner diameter borosilicate glass 
capillaries (Harvard Apparatus), snap-frozen and stored in liquid nitrogen. All 
procedures were performed in an aseptic manner at room temperature.  
The following periods of freezing for vitrified cultures were evaluated prior to 
thawing: NNI-1 and NNI-2 for 30 days, NNI-5 for 8 months, NNI-4 for 1.5 
years and NNI-3 for 2.5 years. Thawing was performed in sucrose solutions 
of sequentially decreasing concentrations (SS1 and SS2). After removal from 
liquid nitrogen, the contents of the glass capillaries were released by reverse 
capillary action into SS1 containing HM supplemented with 0.2 M sucrose for 
1 minute. It was then transferred by pipetting into SS2 containing HM 
supplemented with 0.1 M sucrose and incubated for 5 minutes in HM alone. 
The mixture was washed with excess HM before being cultured in chemically 
defined serum-free selection growth medium supplemented with growth 
factors at abovementioned concentrations (DMEM/F12, bFGF, EGF, B27 and 
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heparin). Viability counts were carried out after incubation periods of 1, 5 and 







Table 2.1. Materials and solutions used for vitrification and thawing 







2.3 Small-molecule inhibitors and reagents 
The small-molecule inhibitor of Wnt signaling, Cercosporin (Lepourcelet et al, 
2004), IWP2 (Chen et al, 2009), IWR1 (Chen et al, 2009) and XAV939 
(Huang et al, 2009) were purchased from Sigma. CCT036477 (Ewan et al, 
2010) was manufactured and synthesized by Laviania Corporation according 
to the published chemical structure. The small-molecule inhibitors of Notch 
Figure 2.1. Outline of vitrification procedure. A, Gliomaspheres are 
collected as pellet form by centrifugation. B, Gliomaspheres in DMEM-
HEPES are transferred into VS1 solution for 1 min and subsequently into 
VS2 solution for an additional 25 sec. C, Suspension of gliomaspheres in 
vitrification solution is drawn into a fine borosilicate capillary using a 
micropipettor fitted with a 200 µl pipette tip. D, Capillary filled with 
suspension of gliomaspheres is immediately plunged into a cryovial 
containing liquid nitrogen. 
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signaling, γ-secretase inhibitor (Wolfe et al, 1998) and DAPT (Hovinga et al, 
2010) were purchased from Sigma. TGFβR1 inhibitor, SB525334 (Grygielko 
et al, 2005) was procured from TOCRIS bioscience. GPCs were treated at 10 
µM for IWP2, IWR1, XAV939, γ-secretase inhibitor, DAPT, and SB525334, 
and at IC50 concentrations for Cercosporin and CCT036477. TGFβR1, used 
at 200 pM, was obtained from R&D.  
2.4 Cell Viability Assays 
2.4.1 Dose-response curves and IC50 calculations 
Gliomaspheres were dissociated into single cells with AccutaseTM 
(eBioscience Inc., San Diego; non-trypsin-based) and seeded into 96-well 
plates, at a density of 200 cells/µl, with DMEM/F12 medium supplemented 
with growth factors. Cells were allowed to recover over two to three days prior 
to drug treatment. Cell viability post-drug treatment was assessed using 
alamarBlue® (Serotec, Oxford, UK). Briefly, cells were incubated with 10% 
culture volume of alamarBlue® for approximately 16 hours before absorbance 
readings were measured at 570 and 600 nm. Dose response curves for each 
line were generated using GraphPad Prism (GraphPad Software, Inc; USA) 
and IC50 values were computed from 12-point titration curves ranging from 
10-4 to 102 μM. 
2.4.2 Cell viability assessment post lentiviral transduction of GPCs 
Lentivirus-infected GPCs were plated into 96-well plates at a density of 2, 500 
cells/well. Cell viability was quantified using the alarma Blue® cell viability 
assay at 5, 10, and 15 days post-infection. Cell viability at each time point 




2.5 Quantitative real time RT-PCR 
Real-time polymerase chain reaction (PCR) was carried out according to the 
manufacturer’s protocol for the LightCycler Fast- Start MasterPLUS SYBR 
Green I real-time PCR kit (Roche Diagnostics, Basel, Switzerland, 
http://www.roche-applied-science.com). A standardized amount of 50 ng of 
cDNA was used for each PCR. The PCR was carried out with specific 
oligonucleotide primer pairs at the optimized annealing temperatures stated 
(supporting information Table 1). Cycle parameters on the LightCycler (Roche 
Diagnostics) were 38 cycles of 95°C for 10 sec, 55°C for 10 sec, and 72°C for 
5 sec. Each real-time PCR was done in triplicate, and the level of expression 
of each gene was determined relative to the normalizer gene, hypoxanthine 
phosphoribosyltransferase (HPRT). Gene-specific primers (with melting curve 
analysis performed to ensure a single product was formed) used in this study 





Table 2.2. Intron-exon-spanning, gene-specific primers used for 
quantitative real time RT-PCR 
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2.6 Immunofluorescence Analyses 
Gliomaspheres from vitrified and non-vitrified conditions were dissociated into 
single cells using AccutaseTM (eBioscience Inc., San Diego; non-trypsin-
based) and seeded at a cell density of 2 x 104 cells per well (stemness 
markers)/ 1 x 104 cells per well (differentiation markers) 1 x 104 cells per well 
(nuclear β-catenin staining) of laminin-coated (Sigma-Aldrich) eight-well 
culture slides (BD Biosciences, San Diego). Plated cells were fixed with 4% 
paraformaldehyde (Sigma-Aldrich) for 30 minutes, permeabilized with 0.1% 
Triton X-100 (Sigma-Aldrich) for 2 minutes, blocked with 5% FBS for 1 hour, 
all at room temperature and stained for the following markers. 
Stemness markers. The undifferentiated cells (stem state) were stained for 
Nestin (Chemicon), Oct4 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), 
Musashi-1 (Chemicon), and Ki-67 (Chemicon). As negative controls, isotypes 
of respective antibodies were used. In events where no appropriate isotype is 
available, incubation with secondary antibody conjugated to Alexa-Fluor-488 
or -594 (Molecular Probes, Eugene, OR) was carried out. The cells were then 
counterstained with 4’6-diamidino-2-phenylindole (DAPI, 100 mg/ml, Sigma-
Aldrich) to visualize the nuclei. 
Multipotentiality markers. Induction of differentiation was carried out with 
DMEM/F12 in the absence of growth factors and supplemented with 5% FBS 
and 1x B27. After 14 days, differentiated cells were stained for neurons 
(neuron-specific class III beta-tubulin, TuJ1; Chemicon), astrocytes (glial 
fibrillary acidic protein, GFAP; Dako, Glostrup, Denmark), and 
oligodendrocytes (O4; Chemicon).  
Nuclear β-catenin staining. Undifferentiated states of GPCs were stained 
for active β-catenin (8E7, 1:1000; Millipore, #05-665) overnight at 4oC and 
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incubated with Alexar-Fluor-488 secondary antibody. The cells were then 
counterstained with 4’6-diamidino-2-phenylindole (DAPI, 100 mg/ml, Sigma-
Aldrich) to visualize the nuclei. 
2.7 Limiting Dilution Assay 
Gliomaspheres were dissociated into single cells by AccutaseTM. The cells 
were then dispensed into each well of a 96-well plate at decreasing cell 
numbers of 100, 80, 60, 40, and 20. Sphere formation was scored 7 days 
after seeding. To carry out sequential minimal dilution assays, the secondary 
gliomaspheres were similarly dissociated into single cells and then dispensed 
into each well of a 96-well plate at similar decreasing numbers. Tertiary 
gliomasphere formation was scored 7 days after seeding. Sequential minimal 
dilution experiments were carried out for at least 3 passages.   
2.8 Gliomasphere Formation Assay 
For analysis of GPC frequency, gliomaspheres were dissociated into single 
cells by AccutaseTM (eBioscience) and 30 cells were subsequently flow-sorted 
into each well of 96-well plates. Cells were then treated with indicated 
amounts of drugs, or DMSO as a vehicle control. Gliomasphere-forming 
ability and gliomasphere sizes were determined after 7, 14, and 21 days. A 
bona fide gliomasphere is defined as a single sphere of diameter exceeding 
20 μm. Scoring and diameter measurements were performed using Nikon 
Eclipse Ti Microscopy, accompanied with digital camera (DS-Qi1) and NIS-
Element Imaging Software (Nikon Instruments Incoporation; New York, USA). 
2.9 Luciferase Reporter Assay 
L-Wnt-STF cells (obtained from A/Prof. Lawrence Lum, Department of Cell 
Biology, University of Texas Southwestern Medical Center, USA) were 
 48 
 
generated by transfecting L-Wnt cells (ATCC) with SuperTopFlash (STF) and 
SV-40 Renilla luciferase plasmids and selecting for clones resistant to G418 
and Zeocin. Briefly, 5, 000 L-Wnt-STF cells were seeded into each well of a 
96-well plate, and individual Wnt inhibitors were added 24 hr later into each 
well. Firefly and Renilla luciferase activities, as indicated by relative 
luminescence units (RLU) were determined 24 hr later using Dual-Glo 
luciferase assay kit (Promega) according to the manufacturer's instructions.  
2.10 Flow Cytometry 
Gliomaspheres were dissociated with AccutaseTM and stained with anti-
CD133/2-allophycocyanin (APC) and IgG1 isotype (negative control) 
according to manufacturer’s instructions (Miltenyi Biotech, Bergisch 
Gladbach, Germany). Dead cells were distinguished by propidium iodide 
staining. A total of 10000 events were acquired on the FACSCalibur (BD 
Biosciences). Data were plotted using FlowJo software (Treestar, Ashland, 
OR). 
2.11 Stereotaxic Intracranial Implantations of NOD/SCID gamma (NSG) 
Mice 
Mice were treated according to the guidelines of the Institutional Animal Care 
and Use Committee, National Neuroscience Institute, Singapore. 
Tumorigenicity was determined by injecting GPCs from dissociated 
gliomaspheres orthotopically in NOD/SCID gamma (NSG, NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ JAX®, The Jackson Laboratory, Maine) mice. Five 
hundred thousand cells in 2 μl of phosphate-buffered saline were delivered 
into the right frontal lobe (0.1 μl/ minute) by stereotaxic injection through a 
glass electrode connected to a Hamilton syringe (Narishige, Toyko). The 
coordinates used were +2 mm mediolateral, +1 mm anteroposterior and -2.5 
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mm dorsoventral. Mice were euthanized by means of transcardiac perfusion 
with 4% paraformaldehyde upon presentation of neurological deficits with 
ataxia, cachexia, lethargy, or seizure. Where secondary cultures were 
generated, non-perfused tumors were surgically removed, avoiding mouse 
tissue and dissociated into single cells using AccutaseTM and treated as 
described in our previous work (Chong et al, 2009). For intracranial 
transplantation of lentiviral transduced GPCs, 500,000 cells were lentivirally-
transduced with pLKO.1-β-catenin knockdown constructs [clones: shβcat1 
(TRCN0000003843) and shβcat2 (TRCN0000003844)] from Open 
Biosystems or a non-targeting (NT) control shRNA (SHC002, Sigma), and 
packaged with pLenti-X-packaging system according to the manufacturer’s 
instruction (Clontech). Animals were monitored for time to development of 
neurological deficits. Kaplan-Meier survival analyses were carried out using 
the log-rank test in GraphPad Prism software. 
2.12 Immunohistochemistry 
Hematoxylin-and-eosin staining and immunohistochemistry were performed 
on 5 μm-thick paraffin sections. Antibodies used for primary tumor or tumor 
xenograft paraffin sections included: (1) Mouse monoclonal anti-active β-
catenin (1:300, Millipore, #05-665); and (2) Rabbit polyclonal anti-CD133 
(1:500, Abcam, ab19898); anti-activated Notch (1:500, Abcam, ab8925); anti-
MITF (1:200, Sigma, HPA003259) and anti-phospho-Smad2 (Ser465/467) 
(1:50, Millipore, AB3849). 
2.13 Karyotypic Analysis of Gliomaspheres 
Two million cells from dissociated gliomaspheres were cultured in a T-25 flask 
(BD Biosciences). The cells were then treated within 3-5 days with 0.1 μg/ml 
colcemid (Invitrogen) for 24 hours. Metaphase-arrested cells were pelleted 
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(180g for 10 minutes) and hypotonic-treated with 0.075 M potassium chloride. 
Chromosomes were fixed in methanol:acetic acid (3:1), re-centrifuged and 
resuspended in fixative. Twelve μl of the fixed cell suspension was dropped 
on a clean, moistened glass slide and place on a hot plate at 48oC to obtain 
chromosome spreads. Spectral karyotyping (SkyPaint; Applied Spectral 
Imaging, Israel) was performed on metaphases according to the 
manufacturer’s instructions. 
2.14 Immunoblot analysis 
GPCs were harvested and pelleted prior to lysis with radio-
immunoprecipitation assay (RIPA) buffer containing 0.5% sodium 
deoxycholate, 1% NP-40 detergent, 0.1% sodium dodecyl sulphate, 0.15 M 
NaCl, 10 mM Tris-HCl (pH 7.4), with protease and phosphatase inhibitor 
cocktail tablets (Roche). Equal amounts of protein lysate were resolved by 
SDS-PAGE and electrotransferred onto polyvinylidene difluoride (PVDF) 
membranes. Membranes were processed according to standard procedures 
and proteins detected using the imaging system, SYNGENE G:Box, 
iChemiXT. The following antibodies were used: Anti-active β-catenin (8E7, 
1:1000; Millipore, #05-665), anti-β-catenin (1:1000, BD Transduction 
Laboratories, #610153), anti-cleaved Notch 1 (NICD; 1:1000; Cell Signaling, 
#2421), anti-phospho-Smad2 (Ser465/467; 1:1000; Cell Signaling, #3108), 
anti-Smad2 (1;1000; Cell Signaling, #3122), anti-phospho-Smad3 
(Ser423/425; 1:1000; Millipore, #07-1389), anti-Smad3 (1:1000; Cell 
Signaling, #9523), anti-MiTF (C5, 1:1000; Abcam, #ab12039) anti-β-actin 
(AC-15, 1:10000; Sigma Aldrich, A5441). Goat anti-mouse or anti-rabbit 
horseradish peroxidase (HRP)-conjugated secondary antibody (1:10000, ECL 
Amersham Biosciences; Buckinghamshire; UK) was used.  
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2.15 Co-immunoprecipitation assay 
Protein lysates were pre-cleared by incubating 1 mg of protein with sepharose 
beads (Protein A-Sepharose®; Zymed Laboratories Inc,; San Francisco; 
USA) for 30 min. Subsequently, protein lysates were incubated overnight with 
agitation at 4oC using 5 μg anti-β-catenin (E-5, Santa Cruz, #sc-7963) or anti-
LEF-1 (N-17, Santa Cruz, #sc-8591).  Fresh sepharose beads were then 
added to the protein-antibody mixture and incubated at 4oC with agitation for 
another 4 hrs for protein-antibody complex to bind to the beads. Sepharose 
beads were collected and washed 3 times with lysis buffer. The beads were 
subsequently resuspended in 5x SDS loading buffer and boiled for 10 
minutes prior to gel loading. 
2.16 Lentiviral Transduction 
Human lentiviral shRNA clones (Sigma Mission RNAi) targeting β-catenin 
[Clones: shβcat1 (TRCN0000003843) and shβcat2 (TRCN0000003844)], 
MITF [Clones: shMITF(C1) (TRCN0000019122) and shMITF(C2) 
(TRCN0000019123)], scrambled non-targeting control (SHC002) and 
TurboGFP positive control (SHC003) were purchased from Sigma. These 
vectors were co-transfected using the Lenti-XTM HTX Packaging System 
(Clontech, CA, USA) into HEK293FT cells according to the manufacturer’s 
instruction (Clontech). Viral titer of supernatant collected was determined 
using Lenti-X™ p24 Rapid Titer Kit (Clontech) according to manufacturer’s 
instructions. 
2.17 Statistical Analysis 
Data are expressed as means ± standard error of the mean (SEM) of at least 
3 independent experiments. Student’s t or Mann-Whitney U test was used 
where appropriate. P ≤ 0.05 was accepted as statistically significant.  
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Bioinformatics Analyses (with help from Edwin Sandanaraj, SICS) 
2.18 Processing of microarray data, gene signature generation and 
pathway analysis 
Affymetrix U133 Plus 2.0 CEL files were mas5 processed and quantile 
normalized in the R statistical software using the affy packages (Gautier et al, 
2004; Team, 2009).  Probes with ‘Absent’ call in all samples were removed.  
Microarray data were obtained from the Gunther (Gunther et al, 2008) and 
Pollard (Pollard et al, 2009) publications and were processed similarly.  To 
understand the transcriptomic differences between oligodendroglial gliomas 
and GBM, a linear model was fitted with batch correction using the limma 
package (Gentleman R, 2005).  Additionally, a linear model was applied to 
gene expression data of NNI-8 GPC cells and its primary tumor.  For both 
analyses, probesets with adjusted p-value ≤ 0.05 were considered significant 
and used as inputs for pathway analysis in MetaCore from GeneGo, Inc.  
Significantly enriched process networks and canonical pathways were 
analyzed and top ranking results were reported. All array platform gene 
annotation was derived from Biomart . Raw and processed data are available 
on the GEO public database: GSE31545 
To further interrogate the oligodendroglial feature of glioma, we defined an 
“oligodendroglial GPC signature” using a log ratio cut-off of 0.8. Similarly, the 
“NNI-8 GPC versus tumor” stemness signature was obtained by taking the 
top ranking differentially expressed probesets using the log ratio cut-off of 6. 
These signatures were used in the Connectivity Map analysis.   
2.18.1 Connectivity Map analysis 
We adapted the Connectivity Map method (Lamb et al, 2006) to score glioma 
gene expression databases based on the extent of pathway activation 
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associated with our GPC gene signature. (i) First, we defined an 
“oligodendroglial GPC signature” – a set of genes exhibiting altered 
expression between two cell states (oligodendroglial GPC versus GBM GPC), 
(ii) Second, we generated databases of reference gene expression profiles 
from 2 glioma databases – REMBRANDT and “Gravendeel” (Gravendeel et 
al, 2009; Madhavan et al, 2009), (iii) Third, using a non-parametric, rank-
based pattern matching procedure, we mapped the GPC signature onto each 
patient gene expression profile and calculated activation scores based on the 
strength of association to the GPC signature, and finally, (iv) The patients 
were sorted according to their pathway activation scores.  Two patient 
classes were identified, (+) and (-), where a positive activation score indicates 
that the patient gene expression profile is positively associated to the gene 
signature and vice versa. The two-tailed test p-values associated with each 
activation score were calculated as described in Lamb et al. (Lamb et al, 
2006).  P-values ≤ 0.1 were considered significant.  
2.18.2 Reference profile generation for Connectivity Map analysis 
Public GBM datasets with clinical data, in terms of survival length, histology, 
grade and age were obtained from the REMBRANDT database  and the GEO 
database in the case of the Gravendeel dataset (GSE16011).  To generate 
the reference profiles, all raw files were processed separately using the mas5.  
Expression values less than the threshold value of 50 were replaced with the 
threshold value.  Next, the data was quantile normalized and gene expression 
values were row-wise median centered.  Median centering each probeset 
allows us to study the range of gene expression values in a large dataset. 
2.18.3 Survival analysis 
Kaplan-Meier and Cox regression analysis of (+) and (-) groups were done in 
R using the survival package (Burkhardt et al, 2011).  For the REMBRANDT 
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dataset, only survival ranges were available.  Hence, the lower limit of the 
range was used in this analysis.   
2.18.4 Prediction of Phillips Classification in REMBRANDT and 
Gravendeel datasets 
To classify the REMBRANDT and Gravendeel samples according to the 
Phillips et al. classification (Phillips et al, 2006a), Affymetrix U133A probes for 
the Phillips molecular subtypes were extracted from the publication.  A 
shrunken centroid model was trained and tested on the Phillips dataset 
(Supplementary Table S1; overall error rate 0.12) using the R package pamr 
(Tibshirani et al, 2002).  Next, classification of the REMBRANDT and 
Gravendeel datasets was performed using the trained model. 
2.18.5 REMBRANDT SNP array processing and 1p/19q LOH analysis 
CEL files from the Affymetrix 100K SNP Arrays of oligodendroglioma and 
oligoastrocytoma patients were downloaded from the REMBRANDT database 
and all samples were normalized in dChip (Li & Wong, 2001; Lin et al, 2004).  
Genotyping calls were generated in the Affymetrix Genotyping Console 
(Affymetrix Inc.) software using the BRLMM algorithm.  Chromosome 1p and 
19q loss-of-heterozygosity inference was performed using an HMM algorithm 
in dChip with default parameters. 
2.18.6 Gene Set Enrichment Analysis (GSEA) 
The gene signature was further evaluated in molecular signature database 
using gene set enrichment approach. GSEA tool was downloaded from Broad 
Institute portal. The significantly enriched genesets in molecular signature 
































CHAPTER 3 – CRYOPRESERVATION OF GLIOMASPHERES 
DERIVED FROM HUMAN GLIOBLASTOMA MULTIFORME 
3.1 Introduction and objectives 
 Gliomas represent the most prevalent of primary adult malignant brain 
tumors, with GBM exhibiting the worst prognosis and mean survival period of 
15 months post-diagnosis (Louis et al, 2007). The highly recurrent, infiltrative 
and heterogeneous nature of the disease has prompted much research into 
the origin of gliomas to develop more effective therapeutic targeting. In 
lineage-tracing mouse modes, a cellular hierarchy exists where neural stem 
cells propagate tumor-causing mutations or deletions in key tumor suppressor 
genes (Alcantara Llaguno et al, 2009; Zheng et al, 2008). Such findings 
underscore the difficulty in eradicating GBM growth at its root. In vitro, glioma-
propagating cells (GPCs) derived from clinical material are purportedly 
enriched in tumor-initiating cells (Galli et al, 2004). This makes future studies 
using GPCs as a cellular platform very important for recapitulating the 
disease pattern. We and others have shown that patient-derived GPCs 
contain phenotypic, karyotypic and transcriptomic information that dictates 
primary tumor behavior (Chong et al, 2009; Foong et al, 2011; Ng et al, 
2012). Importantly, GPCs recreate orthotopic xenograft tumors that mirror the 
patient’s original tumor phenotypically and transcriptomically. In this chapter, 
we describe our foundational work at establishing a well-characterized GPC 
repository. 
 In many studies involving the prospective isolation of GPCs, only a 
small amount of clinical material is available, and this limitation is 
compounded by a lack of methods to preserve such cells at convenient time 
points. In gliomas for instance, it has been shown that in vivo serial passaging 
of gliomaspheres [spheroid structures containing a heterogeneous mix of 
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glioma stem and progenitor cells (Reynolds & Rietze, 2005; Singec et al, 
2006)] can provide a means to reliably maintain such primary cell lines (Galli 
et al, 2004). However, in practice it is not always possible to have access to 
suitably-aged immune-compromised animals to continuously maintain the 
stem and progenitor cells. Lee et al. demonstrated that tumor stem-like cells 
grown in serum-free condition closely mirrors the genotype, gene expression 
profile and biology of their parental tumors (Lee et al, 2006). In contrast, the 
frequently studied, commercially procured serum-grown glioma cells (typically 
purchased from American Type Culture Collection, ATCC) often contain 
karyotypic aberrations not found in the primary tumor (Li et al, 2008). 
Furthermore, we and others showed that xenografts established from patient-
derived GPCs, but not serum-grown glioma cells, recapitulate the patient’s 
original pathophysiology (Figure 3.9) (Chong et al, 2009; Li et al, 2008; Ng et 
al, 2012; Wakimoto et al, 2012). These observations bring into question the 
relevance of standard serum-grown cancer cell lines for studying the biology 
of human cancers and for screening new therapeutic agents. We therefore 
sought to explore a novel method of vitrification for gliomaspheres that is 
effective at preserving the cells’ biological and genetic properties. We believe 
this method could provide many researchers with the means to establish a 
repository of primary GPCs that can be readily tapped upon for expansion or 
experimental design. In addition, such a method would also allow 
investigators to return to the same experimental cell line passages to reduce 
variability in experimental replication. 
 We explored vitrification for the following reasons: Vitrification is a 
process of glass-like solidification in which an aqueous solution is prevented 
from crystallization by rapid cooling (Rall et al, 1987). Vitrification has been 
commonly used for the cryopreservation of embryos at different 
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developmental stages from various species such as murine, rabbit, sheep 
and bovine (Ali & Shelton, 1993; Kasai et al, 1992; Kasai et al, 1990; Saha et 
al, 1996). Furthermore, human and mouse multi-cell embryos have been 
successfully cryopreserved using this strategy (Mukaida et al, 1998). This 
highlights the feasibility of cryopreserving cell aggregates. In addition, it has 
been demonstrated that vitrified embryonic stem cells retained their 
pluripotency and viability upon thawing (Reubinoff et al, 2001). Taken 
together, vitrification could provide an effective means of storage of GPCs 
cultured as spherical structures (i.e. gliomaspheres). To assess the efficacy of 
such a method, we compared vitrification with the most commonly and easily 
utilized method in labs, i.e. serum-containing medium with 10% 
dimethylsulfoxide (DMSO). We scored for parameters such as sphere-forming 
ability (GPC frequency) and sphere size (proliferation). The neurosphere 
assay has been well-studied for the maintenance and propagation of neural 
stem cells (Reynolds et al, 1992), and has been successfully adapted for 
GPCs (Galli et al, 2004). Additionally, serial sphere propagation reliably 
maintains GPC frequency (Reynolds & Rietze, 2005). We also assessed the 
expression of stemness and differentiation markers, gene expression profiles, 
as well as the retention of karyotypic hallmarks, and the ability to engraft and 
form orthotopic tumors that recapitulate the pathophysiology of the patient’s 
original tumor. These criteria define GPCs phenotypically and functionally 







3.2 Vitrification maintains the morphology, viability and proliferation 
rate of gliomaspheres 
 An important criterion for efficacious vitrification is the preservation of 
cellular properties upon thawing after long-term cryopreservation. We 
analyzed essential properties such as viability, expression of stem cell 
markers and multipotentiality. All patients’ lines generate free-floating 
gliomaspheres except for NNI-4 and NNI-11 which generate semi-adherent 
spheres. Such morphological characteristics have previously been observed 
by others (Beier et al, 2007). The reasons are unclear but semi-adherent 
cultures, often displaying cells with neurite outgrowths, may represent more 
differentiated cells.  
 Gliomaspheres were frozen either conventionally in a slow-cooling 
protocol with 10% DMSO in the presence or absence of 90% FBS, or vitrified 
in 20% serum or serum-free medium by exposing glass capillaries containing 
gliomasphere aggregates to liquid nitrogen. The cell aggregates were then 
stored in liquid nitrogen for 30 days to as long as 2.5 years to mimic long-term 
storage prior to analyses. We assessed the viability of gliomaspheres at 1, 5 
and 10 days post-thawing from liquid nitrogen storage by counting the 
number of gliomaspheres measuring at least 50 – 100 µm in diameter 
(Gunther et al, 2008). Gliomasphere formation has previously been shown to 
indicate GPC frequency and proliferation (Diamandis et al, 2007; Gal et al, 
2007).  A visual scan of cellular morphology indicated that vitrification with low 
serum best maintains initial frozen gliomasphere size with little or no cell 
death, with cells remaining relatively undifferentiated for up to 15 days in 
culture (Figures 3.1  and 3.2). Cryopreservation by vitrification lacking serum, 
or by conventional freezing with 10% DMSO showed greater cell death and 
vastly smaller gliomaspheres compared to non-vitrified cultures, suggesting 
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sphere disintegration (Figure. 3.1). We could not recover sufficient cells for 
further analyses due to extensive cell death. Standard freezing with 90% FBS 
yielded the best viability and preservation of spheroid structures for all the 
samples except NNI-2 where vitrification with 20% serum yielded the best 
viability (Figure 3.2ii). However, the peripheries of all gliomaspheres 
cryopreserved in 90% FBS exhibited clear signs of differentiation by 5 and 10 
days post-thawing (Figure 3.1xi and xii). Our finding indicates that freezing 
with 10% DMSO + 90% FBS is an attractive alternative that should be 
explored in future studies. Encouraged by the good viability and lack of visual 
differentiation demonstrated by vitrified gliomaspheres, we proceeded with 
our analyses by comparing vitrified and non-vitrified samples. Proliferation 
rate as determined by using a standard alamarBlue® assay showed that all 
vitrified and non-vitrified gliomaspheres continued to proliferate at similar 
rates except for NNI-3 which displayed a moderate but significant change 












Figure 3.1. Vitrification results in greater viability and absence of 
differentiation in gliomaspheres after thawing. Gliomaspheres were 
frozen by various methods: i-iii, vitrification with 20% serum; iv-vi, 
vitrification without serum; vii-ix, 10% DMSO; x-xii, 10% DMSO + 90% 
serum. After storage in liquid nitrogen for 30 days (vitrification with 20% 
serum and without serum, 10% DMSO, and 10% DMSO + 90% FBS) and up 
to 2.5 years (vitrification with 20% serum only), the gliomaspheres were 
thawed and subjected to morphological analyses while in culture under 
serum-free conditions supplemented with growth factors. Shown are 
representative images obtained from one patient’s gliomasphere line, NNI-1. 
Note the appearance of extended processes (indicated by arrows) at the 
periphery of the spheroid structure (typical signs of differentiation) on days 5 
and 10 of the sample frozen with 90% FBS (arrows). Scale bar = 100 µm. 













Figure 3.2. Quantitative analysis of viability and signs of differentiation 
10 days post-thawing. Conventional cryopreservation with 10% DMSO + 
90% FBS yielded best viability post thawing in majority of the gliomasphere 
lines (i, iii, iv, v) except NNI-2 (ii). Signs of differentiation post-thawing were 
scored and the proportions were represented as grey bars for each freezing 
condition. Cryopreservation with 10% DMSO + 90% FBS showed highest 
number of differentiated gliomaspheres 10 days post-thawing (i, iv, v) 










Figure 3.3. Vitrification maintains the proliferative capacity of 
gliomaspheres. Patient’s gliomaspheres (i-v) were subjected to vitrification, 
and proliferation rate compared to gliomaspheres without vitrification (non-




3.3 Vitrification preserves the stemness expression and 
multipotentiality 
 Markers of the stemness state such as Nestin, Sox-2, CD133, 
Musashi-1 (Msi-1), Bmi-1, Nanog and Oct4 were assayed by quantitative real-
time qRT-PCR. Differentiation markers such as TuJ1, MOBP and GFAP were 
also evaluated as gliomaspheres are heterogeneous and comprise of more 
differentiated progenitors in addition to bona fide stem cells (Reynolds & 
Rietze, 2005; Singec et al, 2006). Nestin is expressed in neural precursors 
(Cai et al, 2002); Sox-2 is a gene known to play a role in maintenance of the 
neural progenitor state (Graham et al, 2003); CD133 is a marker for neural 
stem cells as well as glioma-propagating cells (Singh et al, 2004; Uchida et al, 
2000); Msi-1 is a marker for self-renewal (Kaneko et al, 2000) ; Bmi-1 is a 
Polycomb group (PcG) gene and epigenetic silencer that prevents premature 
growth arrest in most differentiated tissue cells and is essential for the self-
renewal of several types of adult stem cells (Lessard & Sauvageau, 2003; 
Park et al, 2003); Nanog is a transcription factor essential for the 
maintenance of an undifferentiated state (Ivanova et al, 2006), and Oct4 is a 
transcription factor implicated in maintaining the pluripotency of stem cells 
(Mountford et al, 1998). TuJ1 marks neurons, MOBP represents myelin-
associated oligodendrocytes basic protein and GFAP marks astrocytes.  
 We observed that vitrification preserved the expression of essential 
stem cell markers for patient samples NNI-2, NNI-4 and NNI-5 (Figures 3.4A, 
C and D). Between vitrified and non-vitrified samples, expressions of Nestin, 
CD133, Bmi-1, Nanog and TuJ1 for NNI-1 were minimally altered by less than 
two-fold (Figure 3.4B), but there was significant variation in virtually all genes 
examined for NNI-3 (Figure 3.4E). We will provide justification later for this 







 Additionally, we carried out immunofluorescent staining experiments 
to verify the stemness and multipotentiality profiles of the vitrified and non-
vitrified samples. All patients’ gliomaspheres demonstrated preservation of 
stem-like characteristics in vitrified and non-vitrified samples (Figures 3.5A 
and 3.6). As cell morphology changes accompany the induction of 
differentiation of neural stem cells, we assessed multipotentiality by scoring 
for neurons (TuJ1), astrocytes (GFAP) and oligodendrocytes (O4). All 
samples displayed the ability to differentiate into neurons, astrocytes and 
oligodendrocytes (Figures 3.5B and 3.6). Furthermore, we scored for 
differentiated cells staining positively for Nestin and Msi-1 stemness markers 
Figure 3.4. Vitrification preserves essential neural precursor gene 
expression. (A-E): Quantitative real-time RT-PCR analysis of five patients’ 
gliomaspheres. The undifferentiated states of both vitrified and non-vitrified 
gliomaspheres were analyzed for the presence of stem/progenitor and 




to determine the retention of self-renewal in otherwise normally terminal 
differentiated neural lineages, an aberrant developmental feature previously 
observed by others (Galli et al, 2004; Hemmati et al, 2003; Yuan et al, 2004). 
We also scored for cells co-expressing GFAP and TuJ1. All patients’ 
gliomaspheres when differentiated showed no significant differences between 
the vitrified and non-vitrified states, supporting that vitrification preserves the 
multipotentiality property of the cells (Figure 3.6). We observed that all 
samples displayed 70-95% Nestin- and Msi-1-stained cells despite being 
cultured under differentiating conditions (Figure 3.5B). This may in turn 
reflect an aberrant regulatory pathway in cancer stem cells. Differentiated 
cells were detected that co-stained for GFAP and TuJ1; notably, NNI-4 
differentiated cells expressed the highest proportion of such cells (Figure 
3.6). Others have also demonstrated the co-existence of such normally 
distinct neural development pathways (Galli et al, 2004; Hemmati et al, 2003; 





Figure 3.5. Vitrification preserves stemness and differentiation 
markers expression. Immunofluorescent staining of representative 
vitrified patient sample NNI-1 with (A) stem cell/precursor or proliferative 
markers (Nestin, Msi-1, Oct4, and Ki-67) and (B) multipotentiality markers 








Figure 3.6. Vitrification maintains stemness and multipotentiality in 
GPCs. Quantification of immunofluorescent staining in five gliomasphere 
lines (NNI-1, 2, 3, 4, and 5) with or without vitrification. Stemness and 
multipotentiality markers were scored. p>0.05 for all sample pairs, indicating 





3.4 Vitrified gliomaspheres demonstrate secondary sphere formation 
and self-renewal potential 
 For an effective cryopreservation method, GPCs must be reliably 
maintained and not subject to cell death upon thawing and expansion. To 
investigate the stem cell frequency and self-renewal potential of 
gliomaspheres, we dissociated gliomaspheres into single cells and dispensed 
into 96-well plates at decreasing cell numbers and then scored for secondary 
sphere formation after 7 days (Figure 3.7A). Cell clustering played no 
apparent role in sphere formation as cells were plated at clonal densities 
(Singec et al, 2006). As gliomaspheres are heterogeneous and the 
neurosphere assay does not distinguish initially proliferating neural precursors 
from bona fide stem cells with self-renewal potential, we sought to carry out 
sequential minimal dilution assays for at least three passages, which 
confirmed that these single-cell derived gliomaspheres possess the potential 
to grow infinitely, underscoring self-renewal as an important criterion for 
glioma-propagating cells. The proportion of sphere-forming cells remained 
stable throughout the course of culture (>6 months), indicating asymmetrical 
cell divisions (Lathia et al, 2011). There was no significant difference between 
the vitrified and non-vitrified samples of all patients’ gliomasphere lines except 
for NNI-3, indicating that the vitrification procedure does not reduce the 
secondary sphere-forming ability of these cells (Figure 3.7A). This implies 
that GPC frequency is maintained through vitrification. Moreover, the CD133-
expressing population within the spheres that is often associated with tumor-
initiating potential was also maintained throughout the course of culture (>6 








Figure 3.7. Vitrification preserves self-renewal capability and CD133 
expression in gliomaspheres. A, Gliomaspheres were dissociated into single 
cells, plated at decreasing cell numbers, and analyzed for their ability to form 
secondary gliomaspheres. p>0.05 for all sample pairs (except NNI-3, *p<0.05; 
**p<0.01) indicating that vitrified and non-vitrified samples maintained self-renewal 
capability; n=3. B, Gliomaspheres were dissociated into single cells and stained 
with CD133/2 antibody conjugated to APC according to the manufacturer’s 
instructions (Miltenyi Biotec). Percentage of CD133 expression was determined by 
fluorescence-activated cell sorting. Each vitrified or non-vitrified sample was gated 




3.5 Vitrification preserves the karyotypic hallmarks of glioblastoma 
multiforme 
 To conclusively demonstrate the tumor origin of our gliomaspheres, as 
well as to ascertain if vitrification preserves the karyotypic integrity and 
hallmarks of GBM, we karyotyped all patients’ gliomaspheres before and after 
the vitrification process. Our data indicate that all gliomaspheres were of 
tumor origin, preserved their karyotypic integrity as well as maintained the 
hallmarks of GBM in both vitrified and non-vitrified samples (Figure 3.8). 
Notably, typical GBM primary tumor features such as polysomy of 
chromosome 7 (where EGFR is located) and loss of chromosome 10 (where 
PTEN is located) were present, which is consistent with a previous report by 
Wakimoto et al. (Wakimoto et al, 2012). In addition, Lee et al. reported that 
GPCs cultured under serum-free conditions preserved the karyotypic profiles 
of the primary tumors (Lee et al, 2006). In contrast, conventional serum-
grown cells contained chromosomal aberrations not reflective of the primary 
tumors (Li et al, 2008). These findings underscore the importance of studying 
GPCs and we now have a method to reliably cryopreserve these cells. 
Interestingly, we observed aneusomy of chromosomes 12 and 13 across all 
five patients’ gliomaspheres. We were able to detect additional karyotypic 
changes in NNI-3 non-vitrified cells (Supplementary Figure S1) that had 
been in vitro passaged for the longest period compared to all other lines (> 50 
passages). It is probable that this resulted in changes in proliferation rate, 
surface marker expression, self-renewal potential and gene expression as 
previously shown, likely resulting in cell line transformation. We believe this 
highlights the importance of the vitrification method in being able to freeze 
down low passage cells, and thaw them only when needed for further 









Figure 3.8. Vitrified gliomaspheres maintain karyotypic integrity and 
GBM hallmarks. Single 2 x 105 cells from dissociated gliomaspheres were 
karyotyped by metaphase-fluorescent in situ hybridization (mFISH) 
analyses according to the manufacturer’s instructions (MetaSystems 
XCyte mFISH). Arrows indicate polysomy of chromosome 7 and loss of 




3.6 GPC-derived xenograft tumors recapitulate glioma 
pathophysiology in NOD-SCID gamma mice 
 The ability of GPCs to serially transplant and reform gliomas that 
recapitulate the original tumor pathophysiology provides unequivocal 
evidence for the definition of a cancer-initiating cell (Vescovi et al, 2006). 
Accordingly, we were able to recapitulate glioma disease patterns when we 
orthotopically implanted our vitrified gliomaspheres in immune-compromised 
mice (Figure 3.9). In this case, the NOD-SCID gamma (NSG) mouse was 
chosen for its superior ability at engrafting clinical material (Quintana et al, 
2008).  
 When we implanted NNI-1 and NNI-8 gliomaspheres, we obtained 
tumors that demonstrated extensive infiltration into the surrounding cerebral 
cortex, a pathognomonic feature of human GBMs (Galli et al, 2004; Singh et 
al, 2004) (Figure 3.9A). Intriguingly, when we implanted NNI-8 (a GPC line 
derived from a patient with anaplastic oligoastrocytoma) into NSG mice, we 
obtained glioma xenografts that were highly infiltrative and displayed the 
typical “fried egg” histology of oligodendroglial cells with “chicken wire” 
patterning of the stroma, recapitulating features present in oligodendroglial  
tumors (Cairncross et al, 1998). This emphasizes the ability of patient-derived 
GPCs to capture primary tumor behavior. This is further validated in the effort 
by The Cancer Genome Atlas (TCGA) which demonstrated that orthotopic 
xenografts established from clinical material, but not commercially procured, 
serum-grown cells (Figure 3.9B), formed xenografts that mirrored the primary 













Figure 3.9. Vitrified gliomaspheres form tumor xenografts that 
recapitulate glioma pathophysiology. A, Anaplastic oligoastrocytoma 
GPC intracranial xenograft exhibited extensive infiltration, hemorrhaging 
and displayed the typical “fried egg” morphology and “chicken wire” 
patterning of stroma. Also note the migration of glioma cells along the 
white matter tract (black arrow head), typically found in patients with 
invasive glioma. Scale bar = 20 µm. B, Intracranial xenograft established 
from serum-grown U87MG displayed spatially constrained, well-lineated 




3.7 Gene expression studies demonstrate the clustering of vitrified 
and non-vitrified gliomaspheres, and histologically similar GBM tumors 





 Verhaak et al. showed for the first time that histologically similar GBM 
tumors can be molecularly classified into four subgroups, each with distinct 
gene expression, genomic aberrations and clinical history (Verhaak et al, 
2010). Such findings indicate that gene expression drives glioma disease 
progression and outcome. For vitrification to be an efficient cryopreservation 
method, we would expect that vitrified and non-vitrified gliomaspheres should 
Figure 3.10. Vitrification preserves transcriptomic profiles of 
gliomaspheres. Dendrogram determined by unsupervised hierarchical 
cluster analysis of five patients’ gliomaspheres (V, vitrified and NV, non-
vitrified) cultivated under serum-free conditions supplemented with 
growth factors (S-suffix) or differentiated by withdrawal of growth factors 
with addition of serum (D-suffix). Samples with the T-suffix represent the 




generate transcriptomic profiles that cluster together, indicating the genetic 
stability of the samples. We therefore performed microarray gene expression 
analyses on all five patient’s gliomasphere lines (NNI-1, 2, 3, 4, and 5; vitrified 
and non-vitrified) as well as on their differentiated counterparts (vitrified and 
non-vitrified) and primary patient tumor specimens. This gene expression 
data was also subsequently utilized in Chapter 4. Indeed, unsupervised 
clustering analysis showed that the vitrified form of each sample in the stem/ 
progenitor or differentiated state, clustered together with its respective non-
vitrified form (Figure 3.10). This supports our study that vitrification preserves 
the transcriptomic profile of GPCs.  
 Intriguingly, through Principal Component Analysis (PCA) map which 
allows us to view molecular grouping with a third dimension, thereby 
separating planes of cell groups, we observed that histologically similar GBM 
tumors yielded GPCs with very distinct transcriptomic profiles (Figure 3.11). 
This molecular heterogeneity has in recent years been emphasized in many 
cancer types (Atlas, 2008; Gerlinger et al, 2012; Ooi et al, 2009), and alludes 





  Figure 3.11. Vitrification preserves genetic profiles of 
gliomaspheres, which are transcriptomically distinct from primary 
tumors and differentiated cells. Principal component analysis (PCA) 
map of gliomaspheres (free-floating and semi-adherent) and primary 
tumors showed that histologically similar GBM tumors yielded GPCs with 




 Tissue repositories have traditionally been maintained either as frozen 
samples stored in liquid nitrogen tanks, or embedded in paraffin wax. While 
both methods of storage allow the retrieval of cellular material, it is static as it 
does not allow the isolation and subsequent cultivation of live cells from the 
stored tumor. In our study, we present data for the first time on a modified 
vitrification method for patient-derived brain tumor gliomaspheres which 
enriches for tumor-propagating cells, more commonly referred to as “cancer 
stem cells”. Such a method evaluates essential stem cell-like properties, 
multipotentiality capacity, genotypic profile and ability to recapitulate glioma 
pathophysiology. Vitrification now provides a solution to the long-term storage 
of tumor-propagating cells without the need to maintain a constant supply of 
suitably-aged immune-compromised animals to in vivo serially passage the 
cells. With the vitrification approach, a glass-like solidification of the freezing 
solution is achieved by using a high concentration of cryoprotectant and rapid 
cooling. This method eliminates cell injury due to ice crystal formation. 
Although various cryopreservation techniques have been developed for a 
range of cells such as human or mouse embryonic stem cells (Ha et al, 2005; 
Reubinoff et al, 2001) and mouse neural precursor cells (Hancock et al, 2000; 
Milosevic et al, 2005; Tan et al, 2007), these studies have largely relied on 
gross morphological appearances and have ignored examining the genetic 
profiles and quantitative analysis of cell types (both stem and differentiated 
forms) of samples. For validation of vitrification as a method of 
cryopreservation for GPCs, the cellular heterogeneity of tumor cells and their 




 Standard freezing techniques with high serum content have been 
used in many cellular systems due to their less complex preparatory steps. 
Previous work has evaluated the use of such a method in the 
cryopreservation of human embryonic stem cells which resulted in 
differentiated outgrowths (Ha et al, 2005). Here, we demonstrated that 
although freezing with 90% FBS yielded the best viability of gliomaspheres; it 
also resulted in differentiated outgrowths. Serum contains many unknown 
growth factors and cytokines that can induce differentiation of stem cells 
when applied at high concentrations (Ha et al, 2005; Richards et al, 2004). 
Nevertheless, given the significantly better viability by the method, slow 
freezing with high serum presents an attractive alternative that should be 
explored in future studies.  
 Taken together, we have demonstrated that vitrification maintains 
essential stem/progenitor-like properties, multipotentiality and transcriptomic 
profiles. Importantly, the vitrified cells retain the capacity to form tumor 
xenografts that recapitulate glioma pathophysiology. This validates GPCs as 








































CHAPTER 4 – PROGENITOR-LIKE TRAITS CONTRIBUTE TO 
PATIENT SURVIVAL AND PROGNOSIS IN OLIGODENDROGIAL 
TUMORS 
4.1 Introduction and objectives 
 Although our earlier findings indicated that in vitro low passage GPCs 
recapitulate the phenotypic and karyotypic profiles, as well as tumor 
morphology of the primary tumor, the contribution to patient survival and 
clinical outcome is unclear. To make sense of targeting GPCs and their self-
renewing function in any therapeutic design, we must first show that GPCs 
are clinically relevant, and that their presence in the primary tumor affects 
disease progression. In other words, we ask if GPCs contain genomic and 
transcriptomic information that dictates primary tumor behavior. The 
plausibility of this hypothesis has been shown in lung cancer stem cells using 
a mouse model (Curtis et al, 2010). In that instance, the combination of 
KRAS, TP53 and EGFR mutations in lung cancer stem cells determines the 
cell lineage and histotype specificity of the primary tumor, suggesting that the 
oncogenotype of GPCs drives primary tumor behavior.  
 We explored this hypothesis in 2 major brain tumor variants, GBM and 
oligodendroglial tumors, the latter of which has significantly better prognosis 
and increased chemosensitivity (Cairncross et al, 1998; Louis et al, 2007). 
Recent works have shown that these 2 tumor types are molecularly 
heterogeneous, with each subclass distinguished by unique gene expression, 
genetic aberrations, and clinical profile (Atlas, 2008; French et al, 2005; 
Gravendeel et al, 2009; Verhaak et al, 2010). These findings highlight that 
gene expression drives disease progression and survival outcome. 
Accordingly, we used gene expression analyses to explore the clinical 
relevance of GPCs isolated from GBM and oligodendroglial tumors, by 
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tapping into our own data, as well as that from publicly available GPC 
collections (Chong et al, 2009; Gunther et al, 2008; Pollard et al, 2009) to 
enlarge the statistical pool of cells. We subsequently interrogated their clinical 
contribution in 2 large patient glioma databases, REMBRANDT (Madhavan et 
al, 2009) and “Gravendeel” (Gravendeel et al, 2009). We adapted the 
Connectivity Map method (Lamb et al, 2006) to determine strengths of 
association between the GPC gene signature (that distinguished 
oligodendroglial from GBM GPCs) and individual patient gene expression 
data. This method is advantageous as it allows us to make connections 
between different data platforms and biological information through the 
common vocabulary of genome-wide expression profiling. Since then, the 
Connectivity Map has been successfully applied to determine the degree of 
oncogenic pathway activation in gastric cancer (Ooi et al, 2009). We also 
recently successfully used this method to define the tumor suppressor 
function of Parkin in glioma (Yeo et al, 2012). Furthermore, as the 1p/19q co-
deletion status is currently a clinical indicator for enhanced chemosensitivity 
of oligodendrogliomas and consequently better prognosis (Cairncross et al, 
1998), we asked if our molecularly defined GPC signature performed better. 
This would shed light on the value of molecular signatures over current 
clinical indicators in patient prognosis and treatment regimens. Finally, we 
validated the pathway networks identified by our gene signature using a panel 
of prospectively collected primary tumors. Our study in this chapter supports 
that GPC genomic and transcriptomic information dictates primary tumor 






4.2 An oligodendroglial GPC signature is defined 
 We first determined differentially regulated genes between 3 
oligodendroglial GPCs (NNI-8, GS-2, G174) and 17 GBM GPCs collectively 
obtained from our study (Chong et al, 2009), as well as that of Gunther et al. 
(Gunther et al, 2008), and Pollard et al. (Pollard et al, 2009) (Figure 4.1). This 
differential gene list, “oligodendroglial GPC signature”, is shown in 
Supplementary Table S2. An analysis of the associated pathway networks 
using MetaCore from GeneGo Inc. revealed that the signature is enriched in 
the Wnt, Notch and TGFβ signaling pathways (Figure 4.2). Interestingly, 
Notch (Fan et al, 2010; Zhu et al, 2011), TGFβ (Anido et al, 2010; Penuelas 
et al, 2009), and the recently published Wnt (Zhang et al, 2011; Zheng et al, 
2010) signaling pathways have been shown to be crucial in maintaining the 







Figure 4.1. Study flowchart. Oligodendroglial GPCs (NNI-8, GS-2, G174) 







4.3 Functional validation of the Wnt, Notch, and TGFβ pathways in 
GPCs 
 Although the Wnt, Notch, and the TGFβ pathways regulate GBM GPC 
survival, their relation to the 2 glioma variants – oligodendroglial versus GBM 
GPCs, is unclear. In the previous section 4.2, we showed that the 
oligodendroglial gene signature is enriched for the Wnt, Notch, and TGFβ 
signaling pathways (Figure 4.2); however, their precise activation or 
downregulation remains to be tested. To assess pathway activation in GPCs 
(NNI-4, 7, 8, 10, 11 and 12), we carried out two assays: (i) immunoblot 
analysis of key pathway components; and (ii) dependence on pathway by 
using well-established pharmacological inhibitors. NNI-7 and NNI-8 
oligodendroglial GPCs showed increased sensitivity to Wnt pathway 
Figure 4.2. GeneGo process networks. Top-ranking process networks 




inhibitors, Cercosporin (Lepourcelet et al, 2004) and CCT036477 (Ewan et al, 
2010), compared with the other 2 of 3 GBM GPCs (NNI-11 and NNI-12) 
tested, consistent with the highest level of active β-catenin (nuclear-localized) 
detected (Figure 4.3Ai). Gliomasphere frequency was significantly reduced 
upon pathway inhibition, indicating that GPCs were effectively targeted 
(Figure 4.3Bi).  
 Next, we assessed the Notch signaling pathway activation in our 
GPCs. Using γ-secretase inhibitor (Wolfe et al, 1998) and DAPT (Hovinga et 
al, 2010), we observed that NNI-7 and NNI-8 oligodendroglial GPCs were 
more sensitive to pathway inhibition compared with NNI-4, -11, and -12 GBM 
GPCs (Figure 4.3Bii). Again, these findings were consistent with the 
immunoblot analysis showing the highest level of Notch intracellular domain 
(NICD) detected in NNI-8 GPCs (Figure 4.3Aii).  
 Finally, we tested the TGFβ signaling pathway by using SB525334 
(Grygielko et al, 2005). Interestingly, all three GBM GPCs showed sensitivity 
to SB525334 with up to 80% inhibition in NNI-4 (Figure 4.3Biii). A less clear 
pattern of phospho-Smad2 and phospho-Smad3 levels was observed upon 
TGFβ1 stimulation (Figure 4.3Aiii). This may reflect the redundant roles of 
various Smad proteins in GPC regulation (Penuelas et al, 2009). Our data 
indicate that GPC-forming capacity and gliomasphere size were preferentially 
targeted in GBM GPCs. 
 Collectively, our data indicate, albeit a limited panel of GPCs used, 
that Wnt and Notch signaling pathways are upregulated in NNI-7 and NNI-8 









Figure 4.3. Functional validation of the Wnt, Notch and TGFβ 
signaling pathways in GPCs. A, Representative immunoblot analyses 
of key signaling components of the Wnt, Notch and TGFβ pathways 
using (i) active β-catenin, (ii) NICD, and (iii) pSmad2/3 respectively. 
Densitometric values of activated components compared to their 
respective controls are shown from representative immunoblots (n=3). B, 
Pathway dependence was assessed using well-established 
pharmacological agents: (i) Cercosporin and CCT036477 for Wnt, (ii) γ-
secretase inhibitor and DAPT for Notch, and (iii) SB525334 for TGFβ 
signaling pathways in a gliomasphere forming assay over 21 days (to 
detect slow-growing GPCs). Fresh aliquots of drugs and media 
supplemented with growth factors were replenished every 7 days; 





4.4 The oligodendroglial GPC signature stratifies glioma patient 
survival 
 We rationalized that our hypothesis would imply that oligodendroglial 
GPCs confer a better prognosis in their primary tumors compared to GBM 
GPCs, likely because of pathway activation programs depicted in their 
transcriptomic profiles [since gene expression drives glioma disease 
progression (Verhaak et al, 2010)]. Thus, moving forward, we utilized the 
Connectivity Map to analyze the strength of association of the 
oligodendroglial GPC signature with individual patient gene expression data 
from REMBRANDT and Gravendeel. We assigned positive “(+)” and negative 
“(-)” activation scores with significant P values (Supplementary Table S3) 
and observed that the gene signature separated (+) and (-) patient cohorts 
that make up 30% to 50% of all patients in each database (Table 4.1). Most 




 Patients with better survival composed of (+) association (i.e. more 
oligodendroglial GPC association) whereas poorly surviving patients tended 
to be of (-) association (i.e. more GBM GPC association; REMBRANDT P-
value, 1.93 E-05; Gravendeel P-value, 0.0082). The (+) activation score also 
contained more low-grade gliomas, especially enriched for 
oligodendrogliomas; whereas the (-) activation score enriched for high-grade 
Table 4.1. Summary of results from Connectivity Map, Logrank and Cox 
Regression Analysis for all patient samples. (+) represents patients with 
concordance to oligodendroglial GPC signature; (-) represents patients with 




gliomas with mainly GBMs. Cox regression analysis indicated that the GPC 
gene signature served as a significant prognostic indicator and the positive 
score patients (oligodendroglial GPC-like) in REMBRANDT had 54% lower 
risk of death; the HR (95% confidence interval, CI) was 0.462 (0.322 - 0.664) 
in a univariate model (P = 2.90 E-05) (Table 4.1). Consistently, the positive 
score patients in Gravendeel were associated with 47% lower risk of death 
and the HR (95% CI) was 0.535 (0.334 – 0.856) in a univariate model (P = 
0.009). This association remains significant in REMBRANDT after adjusting 
for other clinical factors such as age and tumor grade (P = 2.22 E-05).  
 Although we did not detect a significant multivariate analysis P-value 
in the Gravendeel data set, this does not mean the absence of GPC 
transcriptome contribution to patient survival as shown in the REMBRANDT 
data set. First, most glioma databases are retrospectively generated and 
therefore, this limits our ability to assess the true predictive value of the gene 
signature. Second, a significant P-value was observed in the univariate 
analysis, highlighting the relevance of the gene signature as an alternative 
prognostic tool. Collectively, these results suggest that GPCs contribute to 
disease progression and survival outcome, thus representing that these cells 







Figure 4.4. Oligodendroglial GPC signature stratifies patient survival. 
Patient survival is shown in all glioma patients in A, REMBRANDT; and B, 
Gravendeel databases. Tumor grade (“Grade”) and molecular classification 
(“Phillips”) distribution corresponding to (+) and (-) classes are shown below 




4.5 The oligodendroglial GPC signature correlates with “Phillips” 
molecular classification of gliomas 
 We next attempted to strengthen our findings based on the 
Connectivity Map by asking whether our GPC-derived gene signature could 
predict glioma survival outcome similar to other existing molecular-based 
classification schemes. This would be important to further validate the 
significance of the GPC-derived gene signature in relation to disease 
progression. We applied as an independent gene expression-based 
approach, the “Phillips” classification of gliomas (Phillips et al, 2006a) which 
molecularly categorizes the tumors into three subclasses: proneural, 
proliferative, and mesenchymal. We observed that the (+) activation score 
enriched for the proneural subclass, whereas the (-) activation score tended 
to be proliferative or mesenchymal (Figure 4.4; Supplementary Table S4). 
The proneural subclass typically consists of lower grade gliomas with 
oligodendroglial features, frequently associated with better prognosis; in 
contrast, the mesenchymal subclass characterizes highly aggressive, 
recurrent gliomas such as GBM. Interestingly, recent work in a transgenic 
mouse model suggested that oligodendrogliomas are more chemosensitive 
because their cells-of-origin are oligodendrocyte precursor cells (OPCs), 
compared with the more resistant neural stem cells and astrocytes in GBM 
(Persson et al, 2010). We therefore find it intriguing that all cultured patient-
derived GPCs from multiple studies are transcriptiomically consistent with this 
hypothesis; however, we cannot definitively pinpoint the identity of GPCs due 
to their human origin. It should be noted that we chose the “Phillips” molecular 
classification scheme since that original work subclassed all gliomas (Grades 
1 to IV of astrocytic lineage), a situation analogous to our REMBRANDT and 
Gravendeel patient glioma databases. 
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 As our method above compared GPCs from a better surviving 
histology (oligodendroglial tumor) to a worse histology (GBM), we could have 
artificially biased our findings without assessing the true contribution of the 
GPC in a primary tumor. We therefore in addition derived a “stemness” gene 
signature by comparing NNI-8 GPCs to its primary tumor (Note: not 
comparing to another GPC; Supplementary Tables S5-7). This, we 
rationalized, would allow an assessment of the GPC traits within the bulk 
tumor mass, and if its presence contributed to eventual disease progression 
and survival outcome. This “stemness” gene signature similarly stratified 
patient survival, with the (+) class enriched for lower grade tumors of 
proneural classification, whereas the (-) class enriched for higher grade 
tumors with mesenchymal features (Figure 4.5). Collectively, our data 
support that patient-derived oligodendroglial GPC’s contribute to a favorable 
















Figure 4.5. “NNI-8 GPC versus primary tumor” gene signature 
stratifies patient survival. Patient survival is shown in all glioma patients 
in A, REMBRANDT; and B, Gravendeel databases. Tumor grade (“Grade”) 
and molecular classification (“Phillips”) distribution corresponding to (+) and 











Figure 4.6. Oligodendroglial GPCs express OPC markers. 
Oligodendroglial tumor GPCs (OA) of NNI-8 and Pollard reflect higher 
immature OPC marker expression: Olig2, Nkx2.2 and GalC, in comparison 
to GBM GPCs (GBM). The Gunther line expresses mature oligodendrocyte 




4.6 The oligodendroglial GPC signature is enriched in the Wnt, 
Notch, and TGFβ pathways in patient glioma databases 
 Our previous findings indicate that the oligodendroglial GPC signature 
is enriched in the Wnt, Notch, and TGFβ signaling pathways (Figure 4.2); 
however, their precise activation or downregulation remains unclear. On the 
basis of our in vitro data in a limited but unique GPC collection (Figure 4.3), 
we suggested that oligodendroglial GPCs were more sensitive to Wnt and 
Notch inhibition, whereas GBM GPCs tended to be responsive to TGFβR1 
inhibition. In recognizing the limitations posed by a small GPC panel, as with 
any such studies to-date, we sought to understand whether our GPC-derived 
conclusions bore similar significance in primary tumors of REMBRANDT and 
Gravendeel. We rationalized that our hypothesis would suggest the similar 
regulation of signaling pathways as predicted by our GPCs in Figure 4.3 and 
the sheer number of patients in REMBRANDT (N = 298) and Gravendeel (N = 
276) would provide firm evidence. Accordingly, using Gene Set Enrichment 
Analysis (Subramanian et al, 2005), we observed the following (Table 4.2): (i) 
The (-) activation score patients defined by our Connectivity Map, which 
correlate inversely with the oligodendroglial gene signature (i.e., more GBM 
GPC-like) in both databases, showed upregulated TGFβ1 response pathways 
upon closer analysis of the gene modules, further supported by 
downregulation of this pathway in Gravendeel (+) cohort. This is consistent 
with our in vitro data which suggest that GBM GPCs respond more strongly to 
TGFβR1 inhibition than oligodendroglial GPCs (Figure 4.3Aiii and Biii). 
Furthermore, Gravendeel (-) patients showed upregulation of the Nutt_GBM 
versus AO (anaplastic oligodendrogliomas) gene module, providing an 
independent verification that our GBM versus oligodendroglial GPCs mirror 
their primary tumor transcriptomic profile; (ii) The (+) patient cohort in 
Gravendeel showed upregulation of Wnt signaling pathway, again consistent 
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with our in vitro data where NNI-7 and NNI-8 oligodendroglial GPCs were 
more sensitive to Wnt inhibition (Figure 4.3Ai and Bi); and (iii) The 
REMBRANDT (-) patients showed upregulation of Notch signaling. Upon 
closer analysis, this upregulation comprised the Notch inhibitor, Numbl 
homolog, which acts to inhibit Notch signaling. This is thus consistent with our 
in vitro findings where NNI-7 and NNI-8 oligodendroglial GPCs were more 
sensitive to Notch pathway inhibitors (Figure 4.3Aii and Bii).  
 Furthermore, we analyzed a panel of primary tumors by 
immunohistochemical staining and observed similar pathway regulation 
(Figure 4.7); that is, GBM tumors exhibited elevated p-SMAD2 expression (P 
= 0.0122) whereas oligodendroglial tumors displayed elevated NICD 
expression (P = 0.0331) and a trend toward elevated active β-catenin (3 of 4 
tumors). We also analyzed the enrichment of core stem cell programs 
(embryonic, hematopoietic, and neural stem cell) in the patient cohorts (Shats 
et al, 2011). The (+) patients display an enrichment of progenitor-like 
behaviour with lower tumor grade, whereas (-) patients resemble the CD34+ 
leukemia-initiating and propagating cells (Table 4.2). These data, derived in 
large patient glioma datasets, independently suggest that core stem cell 
programs do contribute to the survival-correlated (+) and (-) patient cohorts. 
Collectively, we show that predictions made by our oligodendroglial GPC 
signature produced congruent data in GPCs, primary tumors, and patient 
databases. This thus supports our hypothesis that GPCs mirror their primary 





















Figure 4.7. Analysis of Wnt, Notch and TGFβ signaling 
pathways in primary patient tumors. A, active β-catenin; B, 
Notch intracellular domain (NICD); and C, p-Smad2 were 





4.7 The oligodendroglial GPC signature defines molecular 
heterogeneity within oligodendroglial tumors 
 Among the major subtypes of gliomas, oligodendrogliomas are 
distinguished by their remarkable sensitivity to chemotherapy, with 
approximately two thirds of anaplastic (malignant) oligodendrogliomas 
responding dramatically to combination treatment with procarbazine, 
lomustine, and vincristine (termed PCV). Anaplastic oligodendrogliomas are 
also distinguished by a unique constellation of molecular genetic alterations, 
including coincident loss of chromosomal arms 1p and 19q in 50-70% of 
tumors (Cairncross et al, 1998). Cairncross et al. demonstrated that combined 
loss involving chromosomes 1p and 19q is statistically significantly associated 
with both chemosensitivity and longer recurrence-free survival after 
chemotherapy. 
 Accordingly, we interrogated this GPC gene signature in patients with 
oligodendroglial tumors. The (+) class enriched for lower grades associated 
with the 1p/19q co-deletion (Figure 4.8). Interestingly, patients without loss-
of-heterozygosity (LOH) at 1p/19q (yellow) were spread throughout both 
classes, indicating that our oligodendroglial gene signature detected 
molecular heterogeneity and survival profiles that cannot be accounted for by 
the 1p/19q status alone. Although these retrospective data cannot determine 
whether the gene signature is an independent predictor of survival; 
furthermore, the 1p/19q status is specifically related to PCV chemotherapy; 
nevertheless, these data do suggest that the signature is a positive prognostic 
















Figure 4.8. Oligodendroglial GPC gene signature is associated with 
lower tumor grade and 1p/19q co-deletion. Patient survival is shown in all 
glioma patients in A, REMBRANDT; and B, Gravendeel databases. Tumor 
grade (‘Grade’) and 1p/19q co-deletion distribution corresponding to (+) and 
(-) classes are shown below the activation score graphs. Of note, patients 
without loss of heterozygosity (LOH) at 1p/19q were spread throughout both 
classes, indicating that the oligodendroglial gene signature can detect 
molecular heterogeneity and survival profiles that cannot be accounted for by 





 GPCs mirror the phenotypic and molecular fingerprint of the primary 
tumors (Lee et al, 2006; Wakimoto et al, 2012). Consequently, they serve as 
a useful in vitro platform to carry out further investigations. However, much 
less is known about their direct contribution to disease progression and 
survival outcome. In this chapter, we attempted to address this gap in 
knowledge by: (i) Tapping into our own and publicly available GPC gene 
expression and determining the differential gene list between 2 major 
variants, oligodendroglial GPCs versus GBM GPCs for which distinct patient 
survival patterns are seen in their primary tumors; (ii) Using a rank-based, 
pattern-matching approach, the Connectivity Map (CMAP), to interrogate the 
strength of association between the oligodendroglial gene signature and 
individual patient gene expression profiles, as gene expression drives glioma 
disease outcome (Verhaak et al, 2010); (iii) Drawing connections between (+) 
or (-) patients, tumor grade, and primary tumor molecular classification. 
 We found that oligodendroglial GPCs could be distinguished from 
GBM GPCs by Wnt, Notch, and TGFβ regulation. Although these findings are 
not entirely novel in that these pathways were previously implicated in GBM 
GPCs, their relation between the 2 major variants – oligodendroglial versus 
GBM GPCs is unclear. Our in vitro analysis showed that Wnt and Notch 
pathways were upregulated in NNI-7 and NNI-8 oligodendroglial GPCs, 
whereas TGFβ signaling was upregulated in GBM GPCs. Moreover, these 
pathways were similarly detected in primary tumors. Interestingly, Lottaz and 
colleagues showed that mesenchymal GPCs map into the mesenchymal 
class of primary tumors and exhibit upregulated TGFβ signaling pathway 
(Lottaz et al, 2010). In recognizing that a limited number of patient specimens 
were available for our in vitro and primary tumor analyses, we sought to tap 
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into major patient glioma gene expression and molecular signature databases 
to substantiate our hypothesis that GPCs contribute to disease outcome. 
Indeed, using our oligodendroglial gene signature, our GSEA study indicated 
that patients with GBM (i.e. CMAP-) are enriched in the TGFβ signaling 
module, whereas patients with oligodendroglial tumors (i.e. CMAP+) are 
enriched in the Wnt and Notch signaling pathways. Moreover, CMAP+ 
patients display a progenitor-like transcriptomic program that correlates with 
lower tumor grade, consistent with the idea previously established in a 
transgenic mouse model of oligodendroglioma that identified the more 
lineage-committed oligodendrocyte progenitor cell as the tumor cell-of-origin 
(Persson et al, 2010). Furthermore, these cells are more sensitive to standard 
chemotherapeutic drugs than neural stem cells or astrocytes.  
 In summary, our study is important because it provides clinical 
evidence that GPCs contain signaling pathways that dictate primary tumor 
progression, consequently impacting on survival outcome. These findings 
emphasize the relevance of in vitro cultured GPCs as investigational tools. 
Interestingly, our oligodendroglial gene signature stratified survival of 
oligodendroglial tumor patients without 1p/19q LOH, suggesting that the 
previously “untreatable” class can now be further subdivided into drug-
sensitive and –resistant patients. This indicates that our gene signature 
detects molecular heterogeneity in patients with oligodendroglial tumors that 
cannot be accounted for by the 1p/19q status alone. This further highlights 
the limitation of morphology-based histological analyses to diagnose and treat 
patients. Although oligodendroglial tumors are traditionally more 
chemosensitive than GBM tumors and would seemingly render our findings 
expected, our study is important because we provide a direct clinical link 
between these controversial GPCs and their primary tumors. Essentially, we 
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show that GPCs of different histologies not only mirror the phenotype and 
molecular fingerprint of their primary tumor, but also contain transcriptomic 
profiles that reflect the different survival outcomes. Therefore, clinically 
amendable molecular tests may be developed by profiling unsorted bulk 
tumor cells because disease progression is in part, a manifest of the 
activation of stemness-related pathways. Our findings further suggest 
effective glioma treatment by targeting these signalling pathways which 
operate at the level of self-renewing GPCs. Taken together, we provide 















































CHAPTER 5 – SMALL MOLECULE INHIBITORS OF THE WNT 
PATHWAY TARGET GLIOMASPHERE FREQUENCY AND 
PROLIFERATION 
5.1 Introduction and objectives 
 The Wnt/β-catenin signaling pathway has been implicated in various 
cancers (Barker & Clevers, 2006; Polakis, 2007). More importantly, Wnt 
signaling has been reported to play a role in the establishment and 
maintenance of cancer stem cells (CSCs) of the hematological and 
gastrointestinal systems (Reya & Clevers, 2005). Increasing reports for the 
existence of rare CSCs that initiate and sustain tumors have spurred efforts to 
identify novel therapeutic strategies for selectively targeting these cells. CSCs 
have been shown to be resistant to several chemotherapeutic agents (Eyler & 
Rich, 2008). Hence, identifying compounds that target signal transduction 
pathways (e.g. Wnt, Notch, TGFβ) controlling CSC self-renewal and 
maintenance would open up new possibilities for combinatorial therapeutic 
options that may improve current large majority of strategies that target 
general mechanisms of rapid cell growth. It may be that the often slow-
growing, long-term self-renewing cellular fraction may be responsible for 
initiating and sustaining tumor growth. 
 There is much evidence for a cellular hierarchy in cancers of the 
hematopoietic and colorectal origins and recent studies implicate a role for 
Wnt in maintaining their pluripotency. Jamieson et al. showed that excessive 
Wnt signaling was present in the granulocyte-macrophage progenitors 
isolated from patients with chronic myelogenous leukemia (CML), and their 
self-renewing and proliferation capacity was attenuated by ectopic expression 
of Axin, an inhibitor of the Wnt pathway (Jamieson et al, 2004). In addition, 
Vermeulen and colleagues showed that Wnt signaling activity level in colon 
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CSCs was heterogeneous and that cells with high Wnt signaling activity 
possessed stem cell-like clonogenic potential (Vermeulen et al, 2010). 
Importantly, the authors further demonstrated that high Wnt activity was 
observed preferentially in colon CSCs located close to stromal 
myofibroblasts, suggesting that microenvironmental cues regulated Wnt 
signaling activity in these cells. Earlier, we and others showed that Wnt 
signaling is active and is required for the survival and maintenance of GPCs 
(Ng et al, 2012; Zhang et al, 2011; Zheng et al, 2010). These studies form the 
rationale for the development of new therapeutic agents targeting the Wnt 
signaling pathway in glioma.  
 In recent years, several small molecule inhibitors of the Wnt pathway 
have been identified (Table 5.1). Lepourcelet et al. identified several 
antagonists that disrupt the β-catenin/TCF complex of the Wnt signaling 
pathway via a high throughput screening (HTS) of 7000 natural compounds 
for inhibitory activity (Lepourcelet et al, 2004). Notably, they identified two 
fungal derivatives, PKF115-854 and CGP049090 (also known as 
Cercosporin), both of which disrupted the interaction of TCF and β-catenin 
and consequently inhibited colon cancer cell proliferation and interfered with 
β-catenin-mediated axis duplication in vivo.  In another study, Emami et al. 
screened a small molecule library of 5000 compounds using a cell-based 
assay and identified a small molecule ICG-001 that showed activity in 
downregulating β-catenin/TCF target genes (Emami et al, 2004). The authors 
showed that ICG-001 bound to the CREB-binding protein (CBP, a 
transcriptional activator of the Wnt pathway that binds to β-catenin) and 





 More recently, Chen et al. conducted a screen of 200, 000 compounds 
using mouse L-cells stably expressing the Super (8x) TOPFLASH Wnt 
reporter and a Wnt3A expression vector via multiple cell-based screening 
strategy (Chen et al, 2009). Compounds with inhibitory activity were further 
subcategorized into two groups based on their site of action within the Wnt/β-
catenin signaling pathway: (i) inhibitors of Wnt production (IWPs), and (ii) 
inhibitors of Wnt response (IWRs). IWPs inhibit the secretion of the Wnt 
ligands through binding to porcupine (Porcn), an important component of the 
Wnt ligand secretion that mediates addition of a palmitoyl group to Wnt ligand 
proteins in the endoplasmic reticulum. IWRs, on the other hand, bind directly 
to Axin and stabilize it, which eventually leads to β-catenin degradation.  
 In addition, Huang et al. also demonstrated that stabilization of Axin by 
a small molecule inhibitor, XAV939 mediates Wnt signaling inhibition (Huang 
et al, 2009). Using a protein affinity capture technique, they identified 
Tankyrases (TNKS1 and 2) as targets of XAV939. Axin is stabilized through 
destruction of Tankyrases. Disruption of Tankyrase-mediated ADP-
ribosylation activity resulted in increased Axin protein stability, possibly 
through changes in Axin ubiquitinylation status. Furthermore, the authors 
showed that the mode of action of IWR-1, previously reported by Chen et al., 
is similar to XAV939. In addition, Ewan et al. identified several novel small 




molecules that target distinct levels of the Wnt signal transduction pathway 
(Ewan et al, 2010). Of note, they identified CCT036477 that blocks 
transcription at the β-catenin/TCF level and showed the strongest phenotypic 
effects in vivo where it blocked development of zebrafish and Xenopus 
embryos and expression of Wnt target genes.  
 In this chapter, we explore the use of Wnt inhibitors to study the 
effects of pharmacological inhibition of Wnt/β-catenin signaling in GPCs.  
5.2 Screening for potential Wnt inhibitors  
 To quantify compounds that specifically inhibit Wnt/β-catenin pathway, 
we screened a modest but well-characterized collection of small molecules 
using L-Wnt-STF cells (kind gift of A/Prof. Lawrence Lum, Southwestern 
Medical Center, USA) that stably express a well-characterized Wnt-
responsive firefly luciferase (FL) reporter plasmid (SuperTopFlash or STF), 
control reporter Renilla luciferase (RL), and an expression construct encoding 
for the Wnt protein (Wnt3A) (Figure 5.1A) (Chen et al, 2009).  
 L-Wnt-STF cells were exposed to Wnt inhibitory molecules for 24 
hours prior to measurement of reporter activities using standard luciferase 
assay. We procured several well-published small molecule inhibitors of Wnt 
(Cercosporin, IWP2, IWR1, XAV939, and CCT036477) that have well-
described mechanisms of action (Chen et al, 2009; Ewan et al, 2010; Huang 
et al, 2009; Lepourcelet et al, 2004).  
 We observed that all small molecules showed dose-dependent 
inhibition of luciferase expression (Figure 5.1B). We then proceeded to 
determine the half maximal inhibitory concentrations (IC50) for all Wnt 
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inhibitors on our GPC lines so as to determine working concentrations for 






Specifically, we adopted the method published by Diamandis et al. to 
determine the IC50 of the Wnt inhibitors (Figure 5.2A) (Diamandis et al, 
2007). We observed that well-characterized Wnt inhibitors targeting the 
production of Wnt ligands (IWP2) and the stabilization of Axin-destruction 
complex (IWR1 and XAV939) did not affect the cell viability of GPCs up to a 
Figure 5.1. Screening of small molecule inhibitors of the Wnt/β-catenin 
signal transduction pathway. A, Schematic diagram illustrating the 
identification of potential Wnt/β-catenin antagonists using L-Wnt-STF cells. 
Compounds of known concentrations were incubated with L-Wnt-STF cells 
that stably harbor Wnt-responsive firefly luciferase (FL) and internal control 
Renilla luciferase (RL) reporters for 24 hours prior to measurement of 
luciferase activity. B, Well-described Wnt inhibitors showed concentration-
dependent inhibition of FL activity that was normalized to control RL activity. 




maximal concentration of 10 µM (Table 5.2). In contrast, compounds 
(Cercosporin and CCT036477) that target the downstream components of the 
Wnt signaling pathway i.e. the β-catenin/TCF complex significantly reduced 
the cell viability of GPCs with oligodendroglial GPCs demonstrating lower IC50 
values compared to GBM GPCs (Figures 5.2B and C). This data is 
consistent with our earlier findings that oligodendroglial GPCs possess an 
elevated Wnt pathway compared to GBM GPCs. 
 
 
Table 5.2. Half-maximal inhibitory concentrations (IC50) of several well-
characterized Wnt inhibitors in gliomaspheres. IC50 values are presented in 
micromolar units; N.D., Not determined at maximal concentration of 10 µM 












Figure 5.2. Standard assay for measuring half-maximal inhibitory 
concentrations (IC50) and dose-response curves in GPCs. A, Schematic 
diagram illustrating the generation of dose-response curves and IC50 values 
for Wnt compounds of GPC lines. Briefly, gliomaspheres (100-150 µm) were 
collected and enzymatically digested for 5 min at 37oC using Accutase. 
Viable cells were plated at cell densities (20 cells/µl) in 96-well plates and 
recovered for two to three days prior to drug treatment. After two days of 
initial drug treatment, cells were supplemented with additional fresh aliquots 
of drug and growth medium and incubated for an additional three days before 
quantification of viability by standard alamarBlueTM assay.  B, Dose-response 
curves of Wnt inhibitor, Cercosporin for four GPC lines (NNI-4, 8, 11, and 
12). Cercosporin concentrations were titrated across a series of ten half-log 
dilutions, n=4. C, Representative images of GPCs treated with Cercosporin 
at their respective IC50 concentrations after 5 days. Note the disintegration of 




5.3 Wnt inhibitors mitigate GPC frequency and proliferation in vitro   
 Several surface markers such as CD133, CD15 (SSEA-1) and nestin 
have been shown to enrich for GPCs (Bar et al, 2007b; Singh et al, 2004; Son 
et al, 2009). However, surface markers often do not reflect the bona fide 
properties of cancer stem cells as marker expression has been shown to 
change with disease state and progression (Quintana et al, 2008; Shackleton 
et al, 2009). In addition, conventional short-term viability assays also detect 
the majority of fast-growing progenitors and thus mask the minority frequency 
of bona fide cancer stem cells. Consequently, there is a need to rely on 
functional assays such as the neurosphere assay described earlier to 
measure GPC frequency (Rich & Eyler, 2009).   
 We plated GPCs at clonal density (30 cells/well of a 96-well plate) to 
allow spheres to arise from single GPCs, termed clonogenicity (Kalani et al, 
2008). We treated GPCs with Wnt inhibitors over an extended time frame of 
over 7, 14 and 21 days using their respective IC50 values for each GPC line. 
Interestingly, we observed a variable trend of the Wnt inhibitory effects on our 
GPCs. Our data illustrated that IWR1 and XAV939, both of which inhibit Wnt 
signaling by stabilizing the Axin-degradation complex and IWP2 which inhibits 
Wnt signaling via the blocking of Wnt ligand production in cells had barely any 
effect on the gliomasphere-forming capacity and proliferation (Figures 5.3B 
and C). In contrast, using Cercosporin and CCT036477 which target the β-
catenin/TCF complex, we effectively abrogated the self-renewal and 
proliferation capacity of GPCs (Figures 5.3B and C). This observation 
corroborates with a recent work demonstrating that FoxM1 directly interacts 
with β-catenin and is necessary and sufficient for its nuclear localization and 










Figure 5.3. Well-characterized small molecule inhibitors of Wnt/β-catenin 
pathway abrogates gliomasphere-forming ability and proliferation in vitro. 
A, Schematic diagram demonstrating the measurement of gliomasphere-
forming capacity and proliferation using the neurosphere assay. Gliomaspheres 
were collected and enzymatically dissociated prior to plating into 96-well plates 
at clonal density (0.3 cells/µl) via fluorescent-activated cell sorting (FACS). 
Cells were allowed to recover prior to initial drug treatment at their IC50 doses. 
The number and size of secondary gliomaspheres formed were quantified 7, 
14, and 21 days post drug treatment and replenishment. B, Gliomasphere-
forming capacity of GPCs was measured after 7, 14, and 21 days post 
incubation with respective well-characterized Wnt inhibitors. Notably, Wnt 
inhibitors targeting β-catenin/TCF complex (Cercosporin and CCT036477) were 
more effective at reducing GPC frequency. *p<0.05, **p<0.01, ***p<0.001 
compared to respective DMSO controls (n=5). C, Individual gliomasphere sizes 
(an approximate of proliferation) were measured and categorized post 




 Furthermore, we also observed that oligodendroglial GPCs (NNI-8) 
were more sensitive to Wnt inhibitors that target the β-catenin/TCF complex 
(i.e. Cercosporin and CCT036477) as compared to the GBM GPCs (NNI-11 
and NNI-12). This is consistent with the levels of active β-catenin (nuclear-
localized) detected as previously shown in chapter 4. In summary, our data 
show that GPCs can be effectively targeted specifically at the terminal stages 
of Wnt signaling, rather than at the Wnt ligand production stage. This finding 
is important to grasp as the site of inhibition likely points to the genetic lesion 
in glioma cells that maintains elevated Wnt signaling. Knowing the genetic 
lesion is important for effective glioma therapeutic design. 
5.4 Common activating mutations of the Wnt pathway are not 
present in GPCs 
 We earlier demonstrated that GPCs were more sensitive to 
pharmacological compounds that disrupt the β-catenin/TCF complex, 
suggesting that genetic lesion that resulted in the hyperactivated Wnt activity 
in GPCs may lie between the destruction complex (Axin-GSK3β-APC) and 
the β-catenin/TCF complex. In addition, we also showed that inhibition of the 
upstream components of the Wnt pathway that involves Wnt ligand 
production did not affect GPC frequency and proliferation. Since mutations in 
the Wnt pathway should serve as a guide in determining where the 
prospective lesion(s) may be located and where inhibitors would be expected 
to work, we sought to determine the commonly known Wnt pathway 
mutations in cancers that resulted in hyperactivation of the Wnt pathway via 
direct sequencing.  
 Activating mutations in the Wnt pathway have been described in 
various cancers (Polakis, 1999; Polakis, 2000). Loss-of-function mutations in 
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the tumor suppressor, adenomatous polyposis coli (APC) and gain-of-function 
mutations in the amino-terminal region of the proto-oncogene CTNNB1 that 
encodes for β-catenin are two commonly found mutations in colorectal and 
gastric cancers (Clements et al, 2002; Rowan et al, 2000). Interestingly, it 
was observed that in colorectal cancer, β-catenin mutations are mutually 
exclusive to those that harbor APC mutations and the frequency of detecting 
a mutation in CTNNB1 increases in colorectal tumors lacking APC mutations 
(Iwao et al, 1998; Sparks et al, 1998).  
 CTNNB1 mutations commonly occur at serine/ threonine residues 
encoded in exon 3 of the β-catenin gene (Hart et al, 1998; Polakis, 2000). 
These mutations abrogate the phosphorylation-dependent interaction of β-
catenin with β-TrCP, a component of an E3 ubiquitin ligase that makes direct 
contact with amino terminal sequence in β-catenin. Hence, β-catenin is 
stabilized and allowed to accumulate in the nucleus and activate Wnt 
signaling.  We specifically screened for these “hotspot” mutations (in exon 3) 
by direct PCR sequencing of 6 GPC lines and observed absence of common 
CTNNB1 mutations when compared to the human wild-type CTNNB1  exon 3 
DNA sequence (Figure 5.4).  
 Mutations of the APC protein are frequently located in the mutation 
cluster region (MCR) (codon 1286-1513) on exon 15 (Miyoshi et al, 1992; 
Polakis, 2000). Since the majority of somatic mutations in APC occur within 
the MCR, we sequenced the MCR as 3 overlapping fragments. Again, no 
mutations were identified between codons 1286 and 1513 (Supplementary 







Figure 5.4. Common activating “hotspot” mutations of CTNNB1 
are absent in GPCs. Electropherograms showing absence of 
common mutations located at serine-33 (S33), serine-37 (S37), 





 Taken together, our data demonstrate that GPCs are sensitive to 
small molecule inhibitors of Wnt pathway that target the β-catenin/TCF 
complex. In addition, we also show that oligodendroglial GPCs are more 
sensitive to Wnt inhibition compared to GBM GPCs. Common APC and 
CTNNB1 hyperactivating mutations are absent, suggesting that novel 
mechanism(s) modulating the β-catenin/TCF complex exist in GPCs. This 
















































CHAPTER 6 – GENETIC KNOCKDOWN OF BETA-CATENIN 
ABOLISHES IN VITRO AND IN VIVO TUMORIGENIC POTENTIAL 
6.1 Introduction and objectives 
Earlier, we showed that oligodendroglial GPCs are more sensitive to β-
catenin/TCF inhibition than GBM GPCs, suggesting the possibility of 
effectively eradicating GPCs via the Wnt pathway. Although this therapeutic 
approach may seem redundant in the case of oligodendrogliomas which are 
typically chemosensitive and already have a better prognosis, the important 
finding we wish to point out is: The oligodendroglial gene signature detected 
Wnt sensitive and resistant patients within the cohort that does not have the 
1p/19q co-deletion status. This essentially means that the previously 
“untreatable” class is now amenable to Wnt inhibitory therapy if the patients 
demonstrate positive association with the signature despite lack of LOH at the 
1p/19q locus (CMAP+). 
 The Wnt/β-catenin signaling pathway has been shown to be the 
predominant driving force of stem cells of the colonic crypt, hematopoietic and 
central nervous systems (Barker et al, 2007; Kalani et al, 2008; Reya et al, 
2003). In particular, cancer stem cells of the colon (Barker et al, 2009), breast 
(Chen et al, 2007; Woodward et al, 2007) and hematopoietic system (Zhao et 
al, 2007) have been shown to cause tumorigenesis via aberrant Wnt 
signaling. Wnt activation has been shown to play a role in the progression of 
gliomas (Sareddy et al, 2009a) although clarification of its role at the level of 
GPCs has only recently begun.  Here, using genetic approaches, we seek to 
understand the role and function of the Wnt/β-catenin pathway in GPCs. 
Functional assays to measure GPC frequency and mouse models were 
utilized. Additionally, this would serve as validation of our previous findings 
that Wnt/β-catenin is active in a subset of GPCs. 
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6.2 GPCs are effectively transduced by lentiviruses 
 For the purpose of our study, we selected lentiviruses as a genetic 
manipulation tool to investigate Wnt regulation in GPCs. Lentiviruses are 
highly efficient at infection and stable integration of the desired target gene of 
interest or short hairpin RNA (shRNA) into a cell system (Fuerer & Nusse, 
2010). Lentiviral particles infect both dividing and quiescent cells efficiently as 
their pre-integration complex (i.e. viral shell) can enter the intact membrane of 
the nucleus of the target cell. This makes them ideal for genetic manipulations 
in slowly-dividing stem-like GPCs. In addition, lentiviral-mediated transduction 
has frequently been used as a tool in the study of GPC survival and 








Figure 6.1. pLKO.1-based lentiviral vector maps. A, pLKO.1-puro non-
targeting control vector containing a shRNA insert that does not target 
human and mouse genes, serving as a negative control in experiments. B, 
pLKO.1-puro-CMV-TurboGFPTM vector containing a gene encoding 
TurboGFP, under the control of the CMV promoter. It is useful as a positive 
transduction control in experiments. Abbreviations: U6, U6 promoter; cPPT, 
central polypurine tract; hPGK, human phosphoglycerate kinase eukaryotic 
promoter; puroR, puromycin resistance gene for mammalian selection; 
WPRE, Woodchuck Hepatitis Post-Transcriptional Regulatory Element; 
SIN/3’LTR, 3’ self-inactivating long terminal repeat; f1 ori, f1 origin of 
replication; ampR, Ampicillin resistance gene for bacterial selection; pUC ori, 
pUC origin of replication; 5’ LTR, 5’ long terminal repeat; Psi, RNA packaging 




 As initial optimization and monitoring of the transduction efficiency of 
the lentiviral transduction system using the pLKO.1-puro-based vector 
(Figure 6.1A), we performed our knockdown in parallel with a control clone 
SHC003 (Figure 6.1B), a TurboGFP-containing, non-targeting lentiviral 
vector of similar backbone as pLKO.1. This enables visualization of the green 
fluorescent protein (GFP) that can be quantified by immunofluorescent 








Figure 6.2. pLKO.1-based lentiviral vector effectively transduces 
GPCs. GPCs were transduced with pLKO.1-puro-CMV-TurboGFP vector 
and transduction efficiency monitored by visualization of green fluorescent 





6.3 Wnt/β-catenin signaling is active in GPCs 
 To investigate the biological function of Wnt/β-catenin regulation of 
GPCs, we first determined expression of active β-catenin, the key 
downstream effector of the canonical Wnt signaling pathway. We ascertained 
the protein expression levels of nuclear-localized activated β-catenin 
(dephosphorylated on Ser-37 or Thr41) and demonstrated that 
oligodendroglial GPC, NNI-8 and a subset of GBM GPCs possessed active 
Wnt/β-catenin signaling pathway (Figure 6.3A). In addition, we show, by 
immunofluorescent staining of active β-catenin in vitro that active β-catenin 
was nuclear-localized (Figure 6.3B), a key hallmark of active Wnt/β-catenin 




Figure 6.3. Wnt/β-catenin signaling is active in GPCs. A (Similar to 
Figure 4.3 A(i)), Representative immunoblot analyses of active β-
catenin (dephosphorylated at Ser-37 and Thr-41) in oligodendroglial 
(NNI-8) and GBM (NNI-4, 10, 11, 12) GPCs; n=3. B, Representative 
immunofluorescent staining images of active β-catenin in GPCs showed 





 In addition, we assessed the activity of Wnt signaling in vivo using a 
selectable, fluorescent detectable lentiviral vector (7TGC) that can monitor 
successfully transduced GPCs with mCherry, and the status of Wnt activity by 
eGFP expression driven by the TCF promoter (Fuerer & Nusse, 2010). 
Specifically, we transduced GPCs with 7TGC and transplanted the cells into 
immunocompromised mice (NOD-SCID gamma, NSG) and harvested the 
brains after the mice displayed neurological deficits. Interestingly, we 
observed significant active Wnt signaling in vivo, as indicated by the presence 
of both mCherry- and eGFP-positive cells in the glioma xenografts (Figure 
6.4). Collectively, we demonstrate strong evidence that Wnt/β-catenin 



















Figure 6.4. Wnt signaling is active in human xenografted gliomas. 
A, Schematic diagram of the 7xTCF-eGFP//SV40-mCherry vector 
(7TGC) LTR: Long Terminal Repeat, H: packaging signal, RRE: Rev 
Response Element, cPPT: central PolyPurine Tract, WPRE: Woodchuck 
hepatitis Post-transcriptional Regulatory Element, dPPT: distal 
PolyPurine Tract, SIN: Self Inactivated (LTR). B, Mouse brains implanted 
with GPCs expressing 7TGC were harvested and examined under 
immunofluorescence for mCherry (detecting successfully transduced 





6.4 Wnt/β-catenin activity is diminished in shβ-catenin-transduced 
GPCs 
 To investigate if the Wnt signaling pathway is crucial in the survival 
and maintenance of GPCs, we carried out β-catenin knockdown by utilizing 
lentiviral short hairpin RNAs (shRNAs) to achieve high multiplicity of infection 
(MOI). We have selected β-catenin as the knockdown target because it 
represents the key downstream effector of the canonical Wnt signaling 
pathway. Two different sequences of shRNA directed against β-catenin, and 
a non-targeting (NT) shRNA were used for each experiment to control for 
potential off-target shRNA effects. Both β-catenin shRNA constructs (shβcat1 
and shβcat2) significantly and effectively knocked down the protein levels of 
β-catenin in GPCs compared to non-targeting control (Figure 6.5A). 
 In addition, we performed qRT-PCR analyses of known downstream 
Wnt target genes to determine the effectiveness of the knockdown constructs 
on canonical Wnt/β-catenin signaling pathways. AXIN2, TCF7L2, and BIRC5 
are classic examples of known direct downstream target genes of the Wnt 
signaling pathway (Roose et al, 1999; Yan et al, 2001; Zhang et al, 2001). 
Accordingly, we demonstrated that knockdown of β-catenin significantly 
down-regulated the expression of these Wnt target genes after 48 hours post-
transduction compared to non-targeting control, providing evidence that the 
lentiviral constructs shβcat1 and shβcat2 are effective at down-regulating the 















Figure 6.5. Targeting β-catenin using lentiviral shRNAs effectively 
reduces β-catenin protein expression and associated Wnt-target 
genes. A, Representative immunoblot analyses of active β-catenin 
protein expression of 4 GPC lines expressing NT, shβcat1, or shβcat2 
constructs. Densitometric values of active β-catenin protein normalized 
to β-actin are shown from representative immunoblots; n=3. B, 
Quantitative real-time RT-PCR analyses of Wnt-target genes in 3 
representative GPC lines expressing NT, shβcat1, or shβcat2 constructs. 
All values were given as the mean ± SEM (n=3) and were normalized to 
HRPT control. NT control vectors were set as 1 and expression profiles 
of shβcat1 or shβcat2 vectors were presented as a multiple (fold change) 






6.5 β-catenin depletion reduces self-renewal capability and viability 
of GPCs 
 As gliomasphere formation is a key behavior of GPCs and is used as 
a measure of stem cell self-renewal, we proceeded to investigate the effects 
of Wnt inactivation in GPCs by scoring for secondary gliomasphere formation 
(an estimation of self-renewing GPCs) and assessing gliomasphere number 
(GPC frequency) and size (an indication of proliferation potential). Targeting 
β-catenin expression markedly decreased the ability of GPCs to form 
gliomaspheres as indicated by the reduction in gliomasphere-forming number 
and consequently efficiency (Figure 6.6A) and the size of the gliomaspheres 
formed (Figure 6.6B). Gliomaspheres that formed from β-catenin-targeted 
GPCs were significantly smaller than those forming from non-targeting (NT) 
GPCs, suggesting decreased proliferation (Figure 6.6B). In addition, β-
catenin knockdown resulted in significant decrease in GPC viability compared 
to NT control as determined by the cell viability assay (Figure 6.6C). These 
data provide firm evidence for the role of β-catenin in maintaining the self-
renewal properties of GPCs and suggest that targeting β-catenin decreases 















Figure 6.6. Targeting β-catenin expression in GPCs reduces cell 
growth associated with decreased proliferation and gliomasphere-
forming capacity. A, Targeting β-catenin expression significantly 
attenuated the efficiency of GPCs to form gliomaspheres; **p<0.01, 
***p<0.001 (n=3). B, Upper panels, representative images demonstrating 
reduced gliomasphere sizes and formation in GPCs transduced with β-
catenin targeting shRNAs (shβcat1 or 2) constructs compared to non-
targeting (NT) control. Scale bar = 50 µm. Lower panels, gliomasphere size 
distribution of GPCs transduced with β-catenin targeting shRNAs (shβcat1 
or 2) constructs compared to non-targeting (NT) control after 14 days. 
***p<0.001 compared to NT control. C, β-catenin knockdown with 2 distinct 
lentiviral shRNA constructs resulted in decreased cell viability as assessed 
by the cell titer assay. *p<0.05, **p<0.01 compared to NT control at the 





6.6 Targeting β-catenin increases survival of mice bearing 
xenografts established from patient-derived GPCs 
 Based on the requirement of β-catenin for self-renewal, growth and 
survival in GPCs in vitro, we examined the role of β-catenin expression in 
tumorigenicity. GPCs were infected with NT control lentivirus or lentivirus 
targeting β-catenin (shβcat1 and 2). Five hundred thousand cells of each 
group were injected into the right frontal lobes of NOD-SCID gamma (NSG) 
mice. Our data showed a significant, improved survival in all mice implanted 
with GPCs expressing shβcat1 and shβcat2 compared to NT control (Figure 
6.7A). All mice bearing NT infected cells developed neurological deficits after 
2.5 months and displayed large tumors with pleomorphic cells, consistent with 
high grade glial malignancy (Figure 6.7B). Collectively, these data 
demonstrate that β-catenin is required for maintaining the tumorigenic 










Figure 6.7. Targeting β-catenin decreases GPC tumorigenic 
potential and increases the survival of mice bearing intracranial 
human glioma xenografts. A, Kaplan-Meier curves demonstrate 
increased survival with β-catenin targeting in NSG mice injected with 
500,000 GPCs. ***p<0.001 for shβcat1 or 2 groups compared to NT 
group with log-rank analysis of survival curves (n=8). B, 
Representative images of mice brains bearing NT, shβcat1 or 2; n=8; 





6.7  Summary 
 The Wnt/β-catenin signaling pathway is aberrantly activated in human 
cancers and is critical for cancer formation and maintenance. A key feature of 
Wnt signaling activation is the nuclear localization of β-catenin. In this 
chapter, we identified Wnt/β-catenin signaling pathway as being active in 
GPCs, consistent with observations made by other investigators (Zhang et al, 
2011; Zheng et al, 2010). In addition, we demonstrated that targeting β-
catenin expression in GPCs using shRNAs significantly reduces proliferation 
and gliomasphere-forming capacity. More importantly, targeting β-catenin 
expression increases the survival of mice bearing intracranial patient-derived, 
glioma xenografts. Taken together, our findings provide evidence for targeting 
the Wnt pathway as a therapeutic strategy; and more importantly, an effective 
approach that eradicates the slow-growing, self-renewing tumor-initiating and 
































CHAPTER 7 – MITF/ΒETA-CATENIN/LEF-1 AXIS REGULATES 
SELF-RENEWAL AND PROLIFERATION POTENTIAL OF GLIOMA-
PROPAGATING CELLS THROUGH WNT SIGNALING 
7.1 Introduction and objectives 
 In previous chapters, we demonstrated that Wnt signaling is crucial in 
the maintenance of self-renewal and proliferation of GPCs. In addition, we 
showed that oligodendroglial GPCs present higher sensitivity towards β-
catenin/TCF pathway inhibition compared to the majority of GBM GPCs. We 
attempted to address this higher β-catenin/TCF activation status in GPCs by 
screening for common “hotspot” mutations reported to cause Wnt signaling 
dysregulation in cancers. However, we did not observe any common hotspot 
mutations in CTNNB1 and APC in GPCs. To further elucidate the mechanism 
by which oligodendroglial GPCs display higher Wnt/β-catenin status 
compared to GBM GPCs, we further analyzed our initial differential gene list 
(shown in chapter 4) and observed that microphthalmia-associated 
transcription factor (MITF) was among the top most differentially regulated 
genes with a significant log2 fold change of 2.33 (absolute fold change, 5.03) 
between the oligodendroglial and GBM GPCs (Supplementary Table 2). In 
addition, we looked at the individual expression levels of MITF of 
oligodendroglial and GBM GPCs across 3 GPC databases (Chong et al, 
2009; Gunther et al, 2008; Pollard et al, 2009) and observed that MITF is 
upregulated in oligodendroglial GPCs compared to majority of GBM GPCs 
(Figure 7.1A). To confirm our observations, we performed a qRT-PCR for 
MITF and validated that MITF is significantly upregulated in the 
oligodendroglial GPC (NNI-8) compared to GBM GPCs (NNI-1, 2, 3, 4, and 5) 
(Figure 7.1B).  
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 MITF is a transcription factor belonging to the family of basic helix-
loop-helix and leucine-zipper (bHLH/LZ) proteins and is a master regulator of 
melanocyte development and function (Hodgkinson et al, 1993). In addition, it 
has been demonstrated that MITF is a frequently amplified oncogene in 
melanomas (Ugurel et al, 2007). Importantly, MITF has been shown to 
interact with LEF-1, a nuclear mediator of Wnt signaling, to enhance the 
transcription from the dopachrome tautomerase (DCT) gene promoter, an 
early melanoblast marker (Yasumoto et al, 2002). It has also been 
demonstrated that β-catenin is a significant regulator of melanoma cell 
growth, with MITF as a critical downstream target (Widlund et al, 2002).  
 These observations suggest that MITF may play an important role in 
the differential regulation of Wnt signaling between the oligodendroglial and 
GBM GPCs.  In this chapter, we explore the role of MITF as an important 





Figure 7.1. MITF expression is higher in oligodendroglial GPCs 
compared to GBM GPCs. A, MITF gene expression of oligodendroglial 
and GBM GPCs in 3 major GPC databases; p=0.00222. B, Quantitative 
real time RT-PCR analysis of MITF mRNA expression in oligodendroglial 
(NNI-8) and GBM (NNI-1, 2, 3, 4, and 5) GPCs. **p<0.01, ***p<0.001 




7.2 MITF positively correlates and interacts with CTNNB1 in 
oligodendroglial GPCs 
 We performed genome-wide pair-wise correlation coefficient analysis 
to evaluate potential genes having inverse relationship in oligodendroglial and 
GBM GPCs collated from 3 GPC databases (including ours) to enhance 
statistical power. Specifically, we identified 160 genes having entirely 
opposite correlation in GBM and oligodendroglial GPCs. Interestingly, among 
these 160 genes, we identified that the MITF gene has a positive correlation 
of coefficient 0.7 with CTNNB1 in the oligodendroglial GPCs but with a 
negative correlation of -0.6 in GBM GPCs (Figure 7.2). This data provides 
further support that the β-catenin/LEF1-MITF signaling axis is inversely 





Figure 7.2. MITF correlates positively and negatively with 
CTNNB1 in oligodendroglial and GBM GPCs respectively. Pair-
wise correlation of MITF and CTNNB1 in GPCs reveal positive 
correlation of 0.7 in oligodendroglial GPCs and a negative 




 In addition, we also detected the endogenous levels of MITF protein 
by immunoblot analysis in a panel of GPCs and demonstrated that 
oligodendroglial GPC (NNI-8) possesses higher MITF protein expression 
compared to the GBM GPCs (Figure 7.3). This suggests that MITF may play 
an important role in the differential regulation of Wnt/β-catenin signaling 
between the oligodendroglial and GBM GPCs. Interestingly, NNI-11, a GBM 
GPC, demonstrated high MITF protein level. This may suggest that MITF 
protein level stratifies a group of GBM and oligodendroglial GPCs 











Figure 7.3. Endogenous MITF protein expression is higher in 
oligodendroglial GPC compared to majority of GBM GPCs. 
Representative immunoblot analyses of MITF protein expression of 
oligodendroglial (NNI-8) and GBM (NNI-1, 2, 5, 10, 11, and 12) GPC 
lines. Densitometric values of MITF protein normalized to β-actin are 




 Furthermore, to confirm observations made by others that MITF 
interacts with components of the Wnt signaling pathway i.e. β-catenin and 
LEF-1, we performed a co-immunoprecipitation (co-IP) between the three 
proteins in lysates of NNI-8 oligodendroglial GPCs where endogenous MITF 
is relatively higher than majority of the GBM GPCs. MITF formed a complex 
with β-catenin (Figure 7.4A) and LEF-1 (Figure 7.4B) in NNI-8 
oligodendroglial GPCs, consistent with published literature (Schepsky et al, 









Figure 7.4. Co-immunoprecipitation of MITF with β-catenin and LEF-1 
in GPCs. Co-immunoprecipitation assays were performed to test the 
interaction between A, MITF and β-catenin and B, MITF and LEF-1.   
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7.3 MITF expression is higher in patients with oligodendroglial 
tumors  
 To demonstrate that GPCs contribute to primary tumor progression, 
we analyzed a panel of patient tumors by immunohistochemical staining and 
observed similar trend of higher MITF expression in oligodendroglial tumors 
compared to GBM tumors (Figure 7.5A and B). This is consistent with earlier 
observations where we detected higher MITF mRNA and protein expression 
in oligodendroglial versus GBM GPCs. Once again, we show that GPCs 
mirror their primary tumors and contribute to disease progression.  
 
 
Figure 7.5. MITF expression is higher in oligodendroglial patient 
tumors. A, MITF protein expression was immunohistochemically 
detected and scored in patient tumors of GBM and oligodendroglial 
features. B, Representative immunohistochemical staining sections of 
MITF in primary patient tumors (arrows indicate positive MITF staining). 
Scale bar = 50 µm. 
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 In addition, we also looked into patient glioma database – 
REMBRANDT, to determine the levels of MITF in CMAP+ and CMAP- 
patients (described in chapter 4). Interestingly, CMAP+ patients (more 
oligodendroglial GPC association) significantly exhibit higher levels of MITF 
compared to CMAP- patients (more GBM GPC association) in REMBRANDT 
glioma database (Figure 7.6). This indicates that patient tumors with 
oligodendroglial features are more likely to express more MITF. Collectively, 
these results suggest that MITF is differentially regulated between 










Figure 7.6.  MITF microarray gene expression is higher in CMAP+ 
patients. CMAP+ patients (consisting mainly of lower grade oligodendroglial 
tumors) expressed higher MITF expression compared to CMAP- patients 
(consisting mainly of higher grades III and IV astrocytic and GBM tumors) in  
REMBRANDT (p-values = 0.00386 and 1.47E-05 for MITF probes 207233 




7.4 Lentiviral-mediated knockdown of MITF strongly abrogates self-
renewal and proliferation in oligodendroglial GPCs  
 Although our findings demonstrate that MITF is significantly up-
regulated in oligodendroglial GPCs, no studies to-date have suggested a 
functional role for MITF in GPCs. As MITF physically interacts with β-catenin 
and LEF-1, the crucial mediators of the Wnt/β-catenin signaling pathway, we 
first assessed the ability of MITF to regulate GPC cell growth by targeting 






 To control for potential off-target shRNA effects, two different 
sequences of shRNA directed against MITF and a non-targeting (NT) shRNA 
were used. Transduction with MITF shRNA reduced MITF mRNA and protein 
level in GPCs in comparison to the non-targeting control (Figure 7.7). MITF 
targeting profoundly impacted GPC growth in oligodendroglial GPC (NNI-8) 
Figure 7.7. Targeting MITF using lentiviral shRNAs effectively reduces 
MITF mRNA and protein expression. A, Quantitative real-time RT-PCR 
analyses of MITF mRNA in GPC expressing NT, shMITF(C1), or shMITF(C2) 
constructs. All values were given as the mean ± SEM (n=3) and were 
normalized to HRPT control. NT control vectors were set as 1 and expression 
profiles of shMITF(C1) or shMITF(C2) vectors were presented as a multiple 
(fold change) of target gene expression. ***p<0.001 compared to NT control. 
B, Representative immunoblot analyses of active β-catenin protein expression 
of NNI-8 GPC expressing NT, shMITF(C1), or shMITF(C2) constructs. 
Densitometric values of MITF protein normalized to β-actin are shown from 




as demonstrated by the marked reduction in viability over time (Figure 7.8) 






 Cancer stem cells are functionally defined through their capacity for 
sustained self-renewal. As the growth and survival of GPCs was affected by 
MITF knockdown, we next examined whether MITF was crucial for self-
renewal. To more definitively evaluate this possibility, we utilized the in vitro 
indicator of self-renewal in normal and cancer stem cells as described before 
- the neurosphere assay. We found that targeting MITF in GPCs decreased 
gliomasphere formation more profoundly in oligodendroglial GPCs than GBM 
GPCs in comparison to their respective non-targeting controls (Figure 7.9A). 
Gliomaspheres that did form from MITF-targeted GPCs were much smaller in 
oligodendroglial GPCs than GBM GPCs when compared to those forming 
from their respective non-targeting GPCs (Figure 7.9B), suggesting 
decreased proliferation. Hence, the formation of gliomaspheres is significantly 
Figure 7.8. Targeting MITF decreases GPC growth. MITF knockdown 
with 2 distinct lentiviral shRNA constructs (C1 and C2) resulted in 
decreased cell viability as assessed by the cell titer assay. **p<0.01, 
***p<0.001 compared to NT control at the same time point (n=3). Note the 
more pronounced cell death in oligodendroglial GPC (NNI-8) compared to 




mitigated by the loss of MITF, especially in oligodendroglial GPCs, indicating 














Figure 7.9. Targeting MITF expression in GPCs reduces 
gliomasphere-forming capacity and proliferation.  A, Targeting MITF 
expression significantly attenuated the efficiency of GPCs to form 
gliomaspheres (effect was especially more prominent in NNI-8 
oligodendroglial GPCs); **p<0.01, ***p<0.001 (n=3). B, Representative 
images demonstrating reduced gliomasphere sizes and formation in 
NNI-8 GPCs transduced with MITF targeting shRNAs (C1 or C2) 





 Taken together, our results demonstrate that MITF is implicated in the 
differential regulation of Wnt/β-catenin signaling between oligodendroglial and 
GBM GPCs through interaction with β-catenin and LEF-1. In addition, we 
demonstrate that oligodendroglial GPCs are more sensitive to MITF inhibition 
compared to GBM GPCs as shown by the marked reduction in self-renewal 
capacity and proliferation. Our findings present MITF as a novel target 
molecule that is crucial in the maintenance of self-renewal and growth 

















































CHAPTER 8 – GENERAL DISCUSSION 
8.1 Discussion 
 When we first explored the field of glioma-propagating cells (GPCs), 
there was considerable attention to their importance. First, several teams 
showed that clinically derived GPCs contain phenotypic and karyotypic 
hallmarks found in the primary tumor (Lee et al, 2006; Wakimoto et al, 2012). 
Second, xenografts established from GPCs recapitulate the patient’s original 
pathophysiology. Such findings emphasize that GPCs may present a relevant 
cellular platform for further studies. However, we also noted that at the 
National Neuroscience Institute which sees most of the brain tumor cases in 
Singapore, we lacked a constant supply of clinical material that would be 
typically found in larger populations such as China or USA. Moreover, to 
serially passage such tumors in immune-compromised mice would mean 
gene expression drifts towards mesenchymal and proliferative features 
(Hodgson et al, 2009). This is further compounded by a lack of a constant 
supply of mice at the right age for individual tumors that come along. To 
address this issue, with knowledge that extensive serial passage changes 
karyotype of cells and effects transformation, we evaluated several 
cryopreservation techniques with a few criteria in mind: 
1. Svendsen et al. have elegantly documented the need to passage normal 
neural stem cells (NSCs) as spheroid structures in serum-free medium 
(Svendsen et al, 1998). Essentially, they showed that if NSC spheroids 
were dissociated into single cells, senescence eventually occurred with 
loss of proliferation. In contrast, if spheroid structures were cut into 
smaller spherical structures using a mechanical method, the spheres 
proliferated exponentially. These findings highlight the importance of cell-
cell contact in promoting the survival of NSCs. We now know that 
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intercellular contact through integrins and extracellular matrix proteins 
such as laminin are vital to maintaining clinically derived GPCs in culture 
(Lathia et al, 2010; Pollard et al, 2009). 
2. Effective freezing and thawing techniques should enable the efficient 
preservation of stocks of early passage cells, as well as the conservation 
of specific clones that are developed from the original cell lines such as 
genetically modified clones. Slow-freezing and rapid thawing methods 
are most commonly used; however, while these methods are sufficiently 
adequate for mouse cells, they perform very poorly with cells of human 
origin, and most cells either differentiate or die (Reubinoff et al, 2001).  
3. We explored vitrification because it has been used successfully to 
preserve embryos and embryoid bodies (spherical structures), and has 
been highly efficient in bovine species, pig and hamster, all of which 
poorly withstand freezing and thawing by other methods (Lane et al, 
1999; Yokota et al, 2000).  
 With the vitrification approach, a glass-like solidification of the freezing 
solution is achieved by using a high concentration of cryoprotectant and rapid 
cooling. While this approach can eliminate cell injury due to ice crystal 
formation, the high concentration of cryoprotectant may induce significant 
toxic and osmotic damage. The concentrations of cryoprotectants required to 
achieve vitrification are inversely related to the rate of cooling. Therefore, an 
increased speed of cooling can lessen the cryoprotectant-induced toxicity, as 
it minimizes the exposure time to these toxic compounds and allows their use 
at reduced concentrations. Our data illustrates for the first time the effective 
cryopreservation of clinically derived GPCs by vitrification (Chong et al, 2009). 
Importantly, we characterized preservation of essential features similar to the 
primary tumor, such as marker expression, GPC frequency, karyotype and 
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transcriptomic profiles. The advance we made in our Stem Cells publication 
include documenting gene expression changes and xenograft morphologies, 
compared to an earlier work which focused on only phenotypic features of 
cryopreserved NSC spheroid structures (Tan et al, 2007). This is an important 
approach since in 1996, The Cancer Genome Atlas project was initiated, 
which subsequently proved that gene expression drives brain tumor disease 
progression and clinical outcome (Atlas, 2008; Verhaak et al, 2010). 
Essentially, we showed that histologically similar tumors could yield GPCs 
with very different transcriptomic profiles, possibly accounting for the 
frequently observed inter-patient heterogeneity to treatment response. 
Indeed, we now know that genome-informed therapeutic decisions have 
proven to be valid in several cancers (Ooi et al, 2009; Wiedemeyer et al, 
2010). 
 It is with this knowledge that we continued to ask if our GPCs, besides 
showing primary tumor hallmarks, contain gene expression-driven activation 
pathways that dictate primary tumor behavior. We rationalized that this would 
be a major advance, since we would directly connect GPCs (or “cancer stem 
cells”) to their primary tumor. If this were so, individual patient-derived GPCs 
(and their matching xenografts) would be an extremely valuable resource to 
recapitulate the entire patient molecular heterogeneity spectrum. We 
hypothesized that GPCs could contribute to brain tumor disease progression 
and patient survival outcome. For this, we chose to study 2 major brain tumor 
variants with disparate clinical outcomes: oligodendroglial versus 
glioblastoma multiforme (GBM) tumors. Recognizing that no number of GPC 
lines collected would be meaningful; we sought to increase our statistical 
power by combining GPC information from several investigators. This serves 
2 purposes: First, we have a bigger dataset to work with, improving 
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robustness of conclusions, and second, by aligning our GPC collection with 
others (Gunther et al, 2008; Pollard et al, 2009), we could validate our cell line 
repository using published molecular classification systems. Indeed, our data 
highlights that transcriptomic programs in oligodendroglial GPCs dictate 
signaling pathways that confer better prognosis compared to GBM tumors. 
Importantly, our gene signature prognosticated patient survival independently 
of current clinical indicators of age and histology, underscoring that GPCs 
contain molecular patterns that contribute to the heterogeneity of tumors. This 
highlights the limitation of relying solely on morphology-based histological 
methods to diagnose and subsequently treat patients. Our bioinformatical 
method using the Connectivity Map (CMAP) was first executed successfully in 
a collaborative work with A/Prof. Lim Kah Leong on evaluating the tumor 
suppressor role of Parkin in glioma (Yeo et al, 2012). Here, our study taps 
into the multi-data platform capability of CMAP and we analyzed patterns of 
association between our GPC gene signature and individual patient gene 
expression information. This approach assumes that patients with gene 
expression likeness to the GPC gene signature will demonstrate features 
related to for example, the oligodendroglial or GBM GPCs, and be linked to 
performance of that signature in patient tumors. This thus provides a direct 
connection of cancer stem cells in the context of their primary tumor. We 
therefore show that GPCs are clinically relevant and contribute to clinical 
profiles, and most importantly, gene expression drives brain tumor disease 
progression and patient survival outcomes. This message of molecular 
heterogeneity as defined by gene expression is well-supported in the 
analyses of primary tumors by large efforts such as TCGA, the Phillips 
classification scheme and that by Fine and colleagues (Li et al, 2009; Phillips 
et al, 2006a; Verhaak et al, 2010). It should be noted that it is no trivial task to 
assess these schemes compared to one another to determine superiority, 
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simply because while the signatures hold true in prognostic databases, no 
true predictive datasets are available to query each classification method 
appropriately. Thus, our study utilized the most common Phillips classification 
scheme applicable to gliomas of all grades (Phillips et al, 2006a). We had 
attempted to align our GPC gene signature to TCGA classification scheme 
but the CMAP was not significantly associated, most likely arising from our 
internal observations that CMAP usually works well with only databases of 
heterogeneous histologies (TCGA contains only GBM tumors). This was also 
seen in Ooi et al. which used CMAP to interrogate against different gastric 
cancer subtypes (Ooi et al, 2009). Our data showed that the gene signature 
prognosticated survival independently of the 1p/19q co-deletion status of 
oligodendrogliomas, the latter of which confers enhanced sensitivity to 
chemotherapeutic agents. Although this finding would seemingly render our 
work less meaningful, given that oligodendrogliomas are already well-
treatable with PCV therapy, we want to highlight that we could further detect 
sensitive and resistant patient cohorts without LOH at 1p/19q. This means 
that the previously “untreatable” patients could now be treated according to 
their pathway activation if they fell into the sensitive profile. This is a 
significant advance as incomplete surgical resection of brain tumors often 
means that chemotherapy is the remaining option to combat the infiltrative 
and recurrent nature of the disease. 
 Our GPC gene signature enriched for the Wnt, TGFβ and Notch 
signaling pathways. Wnt and Notch are upregulated in oligodendroglial 
tumors, while TGFβ is upregulated in GBM tumors. Although there is 
significant knowledge that these pathways do regulate glioma growth, their 
activation between these 2 major variants is unknown (Fan et al, 2010; 
Penuelas et al, 2009; Zheng et al, 2010). The knowledge gleaned from our 
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study includes: (1) GPCs contribute to disease progression, (2) Tumors can 
now be viewed as manifestations of their pathway activation as defined by 
gene expression information, and (3) Genome-informed approaches may 
guide therapeutic choices. To prove point (3), we subjected GPCs to small 
molecules targeting each of these pathways and showed GPC response as 
predicted. Next, to draw the link between GPC response and primary tumor 
behavior, we interrogated large patient databases and showed that pathway 
activation, in terms of core programs, mapped similarly. We then focused on 
the Wnt pathway because its role in GPCs is relatively unknown. We adopted 
the approach of using well-characterized small molecule Wnt pathway 
inhibitors to assess GPC response. We highlight that although our study did 
not investigate the GPC-specificity of these inhibitors, these published Wnt-
inhibitors has been shown to be effective and specific to cancer cell lines 
harboring hyperactivated Wnt/β-catenin signaling pathway as compared to 
their normal counterparts (Ewan et al, 2010; Lepourcelet et al, 2004). 
Furthermore, Chen et al. reported that the in vivo use of the Wnt inhibitor, 
IWR1, did not incur permanent damage of normal stem cell function with 
transient repression of Wnt signaling. This suggests the practicability of these 
inhibitors in a clinical setting (Chen et al, 2009). Notably, any inhibitors 
targeting Wnt secretion were ineffective, while inhibitors targeting the β-
catenin stage were highly effective against GPC proliferation. This is an 
interesting result for a few reasons: (1) Cancers of the breast, for instance, 
are typically responsive to Wnt secretion inhibition (Proffitt et al, 2012), while 
(2) Glioma cells are most likely to manifest genetic lesions leading to Wnt 
pathway activation late in the pathway, at the β-catenin/TCF stage. Knowing 
this is important to select the appropriate Wnt pathway inhibitor for the 
treatment of gliomas. Indeed, during the progress of our work, 2 other 
publications arose on assessing β-catenin/TCF role in gliomas (Zhang et al, 
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2011; Zheng et al, 2010). We add incremental knowledge in demonstrating 
Wnt regulation in specifically GPCs, the cells that sustain tumor growth. In 
addition, the dependence on the downstream Wnt signaling pathway in 
GPCs, more specifically, the β-catenin/TCF cascade, suggests that β-
catenin/TCF complex formation may be uncoupled from Wnt ligand 
production and the Axin degradation complex activity. Furthermore, as β-
catenin mutations are not the cause of heightened β-catenin/TCF activity in 
GPCs, these lead us to suggest that β-catenin signaling activity can be 
modulated by Wnt-independent mechanisms including post-translational 
modifications or regulation of nuclear localization of β-catenin. The forkhead 
box M1 (FoxM1) transcription factor has been shown to interact with β-catenin 
and directs its nuclear import in glioma formation (Zhang et al, 2011). In 
addition, insulin growth factor-2 (IGF-2) can induce redistribution of β-catenin 
from the plasma membrane to the nucleus and cause transcriptional 
activation of β-catenin/TCF target genes (Morali et al, 2001). Novak et al. 
demonstrated that increased expression of integrin-linked kinase (ILK), an 
ankyrin repeat containing serine-threonine protein kinase leads to 
translocation of β-catenin into the nucleus and transactivates β-catenin/LEF 
activity of intestinal and mammary epithelial cells (Novak et al, 1998). Other 
mediators of Wnt-independent mechanisms that result in modulation of β-
catenin signaling activity include IGF-1 , growth factor Gas6, vascular 
endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and G-
proteins (Carmeliet et al, 1999; Goruppi et al, 2001; Hiscox & Jiang, 1999; 
Kawasaki et al, 2000; Papkoff & Aikawa, 1998; Playford et al, 2000).  
 Moving forward, we then validated these findings genetically both in 
vitro and in vivo and implicated MITF as a downstream effector of β-
catenin/TCF. Importantly, we showed that β-catenin and MITF are both 
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upregulated in oligodendroglial tumors compared to GBM tumors, providing 
clinical evidence for our GPC-driven hypothesis that cancer stem cells dictate 
primary tumor behavior. 
8.2 Future Directions 
Our study has been described in 2 manuscripts of which I am co-first author 
of (Chong et al, 2009; Ng et al, 2012). We plan to perform the following 
experiments to complete and publish the work on MITF as a downstream 
effector of β-catenin/TCF activation. Briefly: 
1. We will determine that MITF is downstream of β-catenin/TCF activation 
by assessing the rescue ability of MITF overexpression in a TCF- or LEF- 
dominant negative (dn) background. We have these plasmids from our 
collaboration with Prof. David Virshup. We will assess effects on GPC 
frequency and proliferation. 
2. We will determine these similar rescue effects in vivo using the orthotopic 
xenograft mouse model, using NOD-SCID gamma mice. We expect to 
see poor survival for implanted vehicle cells, and best survival with MITF 
knockdown (2 clones plus 1 non-targeting control), TCF- or LEF-dn 
expression. In contrast, this good survival should be reversed with MITF 
overexpression (Figure 8.1). Briefly, we will stereotaxically implant 10 
NOD-SCID gamma mice per arm and monitor the time to development of 
neurological deficits. We calculated the number of mice we need 
on http://www.biomath.info/power/index.htm. We will sacrifice the animals 
by transcardiac perfusion with 4% paraformaldehyde. Mouse brains will 
be embedded in paraffin sections and analyzed as previously described 
(Ng et al, 2012). Kaplan-Meier survival curves will be calculated using the 




3. Recognizing that no number of GPC lines or the animal model is perfect 
at recapitulating the tumorigenic process, we will assess MITF role in 
patient tumor databases with gene expression information. We will 
determine MITF-associated core modules and determine patient cohorts 
associated with favorable or worse profiles, correlating with low and high 
MITF respectively, as shown by our earlier gene expression and 
immunohistochemistry data. We have previously successfully performed 
such a bioinformatical approach when evaluating PLK1 role in glioma 
(Foong et al, 2012). This MITF-associated gene module approach 
enables us to examine gene events upstream and downstream of β-
catenin/TCF. We will also identify patient molecular subclasses amenable 
to MITF inhibitory therapy. Notably, we had observed that 
oligodendroglial or GBM GPCs that exhibited high MITF could be 
effectively targeted, suggesting that MITF may be a better predictor of 
response than histology, albeit a modest pool of cells. This approach that 
we will employ will present a significant advance in that we will have 
statistical power of hundreds of patients in the database to verify our 
hypothesis that patient subclasses can be identified who will be 
amenable to anti-MITF therapeutic approaches. 
 
Figure 8.1. Hypothetical Kaplan-
Meier survival analysis to determine 
rescue effects using overexpression 




We show that GPCs contain transcriptomic programs that dictate pathway 
activation in the primary tumor. This genome-informed approach can direct 
treatment strategies and identify patient cohorts most likely to receive 
treatment benefit. Collectively, our work establishes that GPCs are clinically 
relevant, and contribute to glioma disease progression and patient survival 
outcome. Furthermore, our data highlight the limitation of current morphology-
based histologic analyses in tumor classification, consequently impacting on 
treatment decisions. In addition, given the importance of Wnt/β-catenin 
signaling pathway in human cancers in general, our findings not only 
improved the understanding of the molecular mechanisms underlying β-
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Supplementary Figure S1. Spectral karyotyping analyses. Data for all 
other patients’ gliomaspheres are shown. A total of 15-20 metaphases were 
karyotyped for each sample. Arrows indicate polysomy of chromosome 7 
and loss of chromosome 10. Asterisks indicate aneusomy of chromosomes 
12 and 13. Karyotypic changes were observed in NNI-3 non-vitrified sample 




Supplementary Figure S2. Common mutations of APC in the 
mutation cluster region (MCR) are absent in GPCs. 
Electropherograms showing absence of mutations in majority of GPCs 
sequenced between codons 1255 and 1513 (Fragments A-C). We 
observed a degenrate base substitution (circled in red) on codon 1493 






Supplementary Table S1. Confusion Matrix for cross-validation of Phillips classification signature. Mes, 




Mes PN Prolif Class Error Rate 
Actual 
Mes 30 0 5 0.14285714 
PN 2 34 1 0.08108108 
Prolif 4 0 24 0.14285714 












Supplementary Table S2. Probesets in the oligodendroglial GPC gene signature. 
Probeset ID Entrez Gene ID 
Gene 
Symbol Description Log Fold-Change 
212507_at 23505 TMEM131 transmembrane protein 131  -0.931307621 
241612_at 27022 FOXD3 forkhead box D3  1.372986027 
201368_at 678 ZFP36L2 zinc finger protein 36, C3H type-like 2  -1.105289687 
201369_s_at 678 ZFP36L2 zinc finger protein 36, C3H type-like 2  -0.904474969 
201564_s_at 6624 FSCN1 fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus)  -1.072722937 
220231_at 10842 C7orf16 chromosome 7 open reading frame 16  2.645835821 
228035_at 65975 STK33 serine/threonine kinase 33  -1.243243529 
215241_at 63982 ANO3 anoctamin 3  1.090294876 
218163_at 28985 MCTS1 malignant T cell amplified sequence 1  1.017692402 
231840_x_at 90624 LYRM7 Lyrm7 homolog (mouse)  0.891245471 
206067_s_at 7490 WT1 Wilms tumor 1  0.827289917 
218988_at 55508 SLC35E3 solute carrier family 35, member E3  1.67648345 
205386_s_at 4193 MDM2 Mdm2 p53 binding protein homolog (mouse)  1.884030655 
211832_s_at 4193 MDM2 Mdm2 p53 binding protein homolog (mouse)  1.788934315 
1553426_at 285668 C5orf64 chromosome 5 open reading frame 64  -1.147145398 
211138_s_at 8564 KMO kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)  1.260883191 
205306_x_at 8564 KMO kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)  1.335650833 
241765_at 1368 CPM carboxypeptidase M  3.226405764 
243403_x_at 1368 CPM carboxypeptidase M  2.660052824 
225591_at 26260 FBXO25 F-box protein 25  1.023236638 
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1557260_a_at 84911 ZNF382 zinc finger protein 382  1.763574339 
209565_at 7737 RNF113A ring finger protein 113A  0.993408597 
235502_at 5515 PPP2CA protein phosphatase 2, catalytic subunit, alpha isozyme  1.026294597 
243282_at 54520 CCDC93 coiled-coil domain containing 93  -0.893187785 
226462_at 29091 STXBP6 syntaxin binding protein 6 (amisyn)  1.408107909 
236290_at 220164 DOK6 docking protein 6  0.808537521 
214440_at 9 NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase)  1.762236745 
50400_at 196743 PAOX polyamine oxidase (exo-N4-amino)  1.059361819 
237029_at 3081 HGD homogentisate 1,2-dioxygenase  0.971522564 
244829_at -- C6orf218 chromosome 6 open reading frame 218  1.411926375 
227109_at 120227 CYP2R1 cytochrome P450, family 2, subfamily R, polypeptide 1  1.414119526 
225846_at 54845 ESRP1 epithelial splicing regulatory protein 1  1.270624793 
219121_s_at 54845 ESRP1 epithelial splicing regulatory protein 1  1.120675543 
213638_at 221692 PHACTR1 phosphatase and actin regulator 1  1.535840464 
215000_s_at 9637 FEZ2 fasciculation and elongation protein zeta 2 (zygin II)  -0.957606762 
242989_at 6801 STRN striatin, calmodulin binding protein  -1.055129989 
204077_x_at 9583 ENTPD4 ectonucleoside triphosphate diphosphohydrolase 4  0.815264939 
218870_at 55843 ARHGAP15 Rho GTPase activating protein 15  1.017607164 
221427_s_at 81669 CCNL2 cyclin L2  -0.850386591 
222999_s_at 81669 CCNL2 cyclin L2  -0.954468271 
205512_s_at 9131 AIFM1 apoptosis-inducing factor, mitochondrion-associated, 1  0.954516011 
207344_at 10566 AKAP3 A kinase (PRKA) anchor protein 3  2.654311598 
244825_at 57477 SHROOM4 shroom family member 4  1.054431061 
205281_s_at 5277 PIGA phosphatidylinositol glycan anchor biosynthesis, class A  0.836793751 
226764_at 152485 ZNF827 zinc finger protein 827  -0.996757033 
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1554509_a_at 80013 FAM188A family with sequence similarity 188, member A  1.293780634 
206334_at 8513 LIPF lipase, gastric  1.947198374 
204644_at 10495 ENOX2 ecto-NOX disulfide-thiol exchanger 2  0.879076665 
218807_at 10451 VAV3 vav 3 guanine nucleotide exchange factor  -1.573828653 
223423_at 26996 GPR160 G protein-coupled receptor 160  1.266788929 
215153_at 9722 NOS1AP nitric oxide synthase 1 (neuronal) adaptor protein  -0.882741057 
1563512_at 9722 NOS1AP nitric oxide synthase 1 (neuronal) adaptor protein  -1.07867364 
37512_at 8630 HSD17B6 hydroxysteroid (17-beta) dehydrogenase 6 homolog (mouse)  1.128384226 
212631_at 8417 STX7 syntaxin 7  1.113525058 
225308_s_at 85461 TANC1 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1  -0.854227497 
200665_s_at 6678 SPARC secreted protein, acidic, cysteine-rich (osteonectin)  -1.027737524 
229000_at 58492 ZNF77 zinc finger protein 77  0.944812365 
204759_at 1102 RCBTB2 regulator of chromosome condensation (RCC1) and BTB (POZ) domain 
containing protein 2  
-1.668131465 
221289_at 1750 DLX6 distal-less homeobox 6  1.041848794 
206552_s_at 6863 TAC1 tachykinin, precursor 1  1.705027503 
222767_s_at 79794 C12orf49 chromosome 12 open reading frame 49  0.808709328 
204713_s_at 2153 F5 coagulation factor V (proaccelerin, labile factor)  1.431619627 
204714_s_at 2153 F5 coagulation factor V (proaccelerin, labile factor)  1.504311671 
206426_at 2315 MLANA melan-A  0.890635292 
206427_s_at 2315 MLANA melan-A  1.431212371 
206135_at 9705 ST18 suppression of tumorigenicity 18 (breast carcinoma) (zinc finger protein)  1.131230985 
206058_at 6539 SLC6A12 solute carrier family 6 (neurotransmitter transporter, betaine/GABA), 
member 12  
1.091850355 
1561969_at 131368 ZPLD1 zona pellucida-like domain containing 1  1.316003453 
 184 
224999_at 1956 EGFR epidermal growth factor receptor  -1.990616663 
201983_s_at 1956 EGFR epidermal growth factor receptor  -2.165112816 
204238_s_at 10591 C6orf108 chromosome 6 open reading frame 108  1.111934072 
242727_at 221079 ARL5B ADP-ribosylation factor-like 5B  1.32300753 
235356_at 374354 NHLRC2 NHL repeat containing 2  0.931504627 
231569_at 203562 TMEM31 transmembrane protein 31  1.032880572 
205647_at 5893 RAD52 RAD52 homolog (S. cerevisiae)  -0.833601355 
202746_at 9452 ITM2A integral membrane protein 2A  3.632094429 
202747_s_at 9452 ITM2A integral membrane protein 2A  3.720860606 
228891_at 10507 SEMA4D sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) 
and short cytoplasmic domain, (semaphorin) 4D  
0.981611103 
207540_s_at 6850 SYK spleen tyrosine kinase  1.381598219 
204011_at 10253 SPRY2 sprouty homolog 2 (Drosophila)  -0.96891126 
221035_s_at 56155 TEX14 testis expressed 14  0.988947099 
209848_s_at 6490 PMEL premelanosome protein  1.830948971 
215643_at 223117 SEMA3D sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3D  
0.977345169 
203122_at 51112 TTC15 tetratricopeptide repeat domain 15  -1.208989641 
231068_at 146802 SLC47A2 solute carrier family 47, member 2  -1.501602291 
239738_at 117154 DACH2 dachshund homolog 2 (Drosophila)  1.361110621 
225651_at 7325 UBE2E2 ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog, yeast)  1.451235296 
244419_at 2487 FRZB frizzled-related protein  1.045474278 
219212_at 51182 HSPA14 heat shock 70kDa protein 14  0.825224502 
206375_s_at 8988 HSPB3 heat shock 27kDa protein 3  1.769496044 
219099_at 57103 C12orf5 chromosome 12 open reading frame 5  1.237422609 
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222613_at 57102 C12orf4 chromosome 12 open reading frame 4  1.105505079 
212954_at 8798 DYRK4 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4  1.57075808 
226066_at 4286 MITF microphthalmia-associated transcription factor  2.334568409 
208606_s_at 54361 WNT4 wingless-type MMTV integration site family, member 4  0.859407907 
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Supplementary Table S3A. Activation scores, associated p-value and metadata of REMBRANDT samples identified as (+) or (-) based 





p-value Age Survival 
(mths) 
Status Histology Grade 
HF0505 0.749457969 1 0.0271 35 3.2 1 GBM IV 
HF1246 0.732100118 0.976839461 0.003 65 0.2 1 ASTROCYTOMA II 
E08021 0.731966357 0.976660984 0.0097 40 81.5 1 OLIGODENDROGLIOMA III 
HF1269 0.694346941 0.926465486 0.0014 55 13 1 GBM IV 
HF0599 0.688132241 0.918173226 0.0444 70 42.8 1 OLIGODENDROGLIOMA II 
E10193 0.680597094 0.908119098 0.0269 50 34.2 NA GBM IV 
HF1502 0.654386806 0.873146771 0.0595 70 6.4 1 OLIGODENDROGLIOMA III 
HF1032 0.640376005 0.854452194 0.0471 40 28.1 1 ASTROCYTOMA III 
HF1227 0.632969918 0.844570269 0.018 50 251.7 0 OLIGODENDROGLIOMA II 
E09688 0.624472362 0.833232 0.0144 55 50.8 1 MIXED II 
E09787 0.622652421 0.830803657 6.00E-04 55 86.5 0 GBM IV 
HF0180 0.616102353 0.822063916 0.0479 35 0.3 1 GBM IV 
E09956 0.603754355 0.805588012 0.001 70 21 1 GBM IV 
HF1587 0.590356299 0.787711017 0.0511 30 75.3 0 ASTROCYTOMA III 
E10184 0.586292819 0.782289125 0.0947 30 28.3 1 GBM IV 
HF0087 0.586151619 0.782100723 0.0099 60 78.8 1 ASTROCYTOMA III 
E09606 0.584952923 0.780501305 0.0162 30 13.3 1 GBM IV 
E09515 0.584812915 0.780314493 0.0474 35 65.4 0 ASTROCYTOMA II/III 
E09278 0.58381164 0.778978494 0.0363 40 36.6 0 GBM IV 
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HF0963 0.575711213 0.768170114 0.04 10 10.6 1 GBM IV 
HF1493 0.57332728 0.764989237 0.0684 65 41.9 1 OLIGODENDROGLIOMA III 
E10252 0.569847595 0.760346302 0.0644 55 53 1 GBM IV 
E09670 0.566785165 0.756260108 0.0575 75 14.2 1 GBM IV 
E09454 0.565155368 0.754085474 0.0828 55 18 1 GBM IV 
E09846 0.559234143 0.746184798 0.0508 65 14.3 1 GBM IV 
HF0285 0.558833826 0.745650656 0.0393 80 14.4 1 OLIGODENDROGLIOMA II 
E10312 0.557733116 0.744181981 0.0856 35 37.9 1 GBM IV 
HF1677 0.557606793 0.744013429 0.0491 50 63.5 0 ASTROCYTOMA II 
E09930 0.557353343 0.743675251 0.0686 50 5.1 1 GBM IV 
HF0026 0.554987055 0.740517919 0.0633 60 57.1 1 ASTROCYTOMA II 
HF0252 0.554987055 0.740517919 0.0552 35 123.1 0 ASTROCYTOMA II 
E09938 0.554812915 0.740285564 0.0303 45 25.2 1 GBM IV 
E09893 0.554807183 0.740277916 0.0153 40 111.9 1 OLIGODENDROGLIOMA III 
E10072 0.550695692 0.734791963 0.0179 65 37.2 0 OLIGODENDROGLIOMA II/III 
E09513 0.544168132 0.726082255 0.0911 55 13.4 1 OLIGODENDROGLIOMA II/III 
HF0251 0.5391027 0.719323462 0.0012 65 22.7 1 OLIGODENDROGLIOMA III 
E09920 0.537674994 0.717418476 0.0367 25 59.4 1 ASTROCYTOMA III 
HF1058 0.530737231 0.708161435 0.0242 40 18 1 GBM IV 
HF1511 0.526839197 0.702960298 0.0256 25 56.6 1 ASTROCYTOMA II 
E09262 0.525938162 0.701758049 0 50 13.6 1 MIXED II/III 
HF0434 0.52223726 0.696819944 0.0083 60 6.1 1 ASTROCYTOMA II 
HF1667 0.519023712 0.692532115 0.0019 60 2.5 1 GBM IV 
HF0445 0.515744412 0.688156552 0.0388 40 47.2 1 GBM IV 
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E09212 0.507821892 0.677585553 0 40 7.1 1 ASTROCYTOMA II/III 
E09601 0.503894105 0.672344716 0.0034 70 13.2 1 GBM IV 
E09921 0.497126104 0.663314188 0.0602 40 36.4 0 ASTROCYTOMA II/III 
HF1489 0.496517546 0.662502191 0.0539 50 68.3 1 ASTROCYTOMA II 
E10258 0.488339677 0.651590479 0.0539 50 20.6 1 GBM IV 
HF0936 0.488324253 0.651569899 0.0039 55 5.1 1 ASTROCYTOMA II 
E09988 0.484443639 0.646392006 0.0127 70 64.6 1 OLIGODENDROGLIOMA III 
HF0962 0.483030037 0.644505839 0.0278 45 116.5 0 OLIGODENDROGLIOMA II 
E09605 0.480872441 0.641626964 0.0053 45 59.3 1 GBM IV 
HF1492 0.468710079 0.625398754 0.0344 30 2.2 1 GBM IV 
HF0953 0.466790317 0.622837219 0.0829 35 44.6 1 ASTROCYTOMA II 
E09818 0.464049666 0.619180375 0.0338 30 38.1 0 ASTROCYTOMA II/III 
E09531 0.462403898 0.61698443 8.00E-04 55 19.3 1 ASTROCYTOMA II/III 
E09664 0.461318096 0.615535648 0.0155 40 27.1 1 OLIGODENDROGLIOMA II/III 
HF0022 0.459908744 0.613655152 0.0678 20 133.9 0 ASTROCYTOMA II 
HF0914 0.452628786 0.603941522 0.032 40 146.9 0 ASTROCYTOMA II 
E10551 0.451868661 0.602927288 0.0669 65 12.3 1 GBM IV 
E09907B 0.443791064 0.59214937 0.0024 60 55.2 1 GBM IV 
HF1345 0.433641331 0.578606606 0.0145 15 83.5 0 ASTROCYTOMA II 
HF1588 0.431310239 0.575496235 0.0735 40 75.2 0 ASTROCYTOMA II 
E09802 0.429940365 0.573668415 0.0306 80 32.2 1 GBM IV 
HF1585 0.425210527 0.567357403 0.031 25 19.9 1 GBM IV 
HF0520 0.422798129 0.564138546 0.0122 40 8.7 1 GBM IV 
E09852 0.422437933 0.563657938 0.0288 50 48.3 1 GBM IV 
 189 
HF0108 0.420665649 0.561293184 0.0404 35 132 0 ASTROCYTOMA III 
E09192 0.404265925 0.53941107 0.0641 75 13.4 1 GBM IV 
HF0024 0.4034404 0.538309574 0.0562 45 5.8 1 GBM IV 
E09471 0.399568094 0.533142766 0.0065 70 27.2 1 ASTROCYTOMA II 
E10026 0.398363859 0.531535958 0.0281 65 15.4 1 GBM IV 
HF0608 0.398032902 0.531094363 0.0107 50 10.6 1 ASTROCYTOMA II 
E09690 0.389382233 0.519551795 0.0354 75 62.3 0 GBM IV 
E09647 0.382230723 0.510009552 0.0426 55 19.3 1 GBM IV 
E10144 0.380705674 0.507974683 0.0099 50 25.9 1 GBM IV 
HF1409 0.379186615 0.505947806 0.0143 50 12.7 1 ASTROCYTOMA III 
E09661 0.376503249 0.502367397 0.0076 65 48.5 0 OLIGODENDROGLIOMA II 
E09867 0.368241369 0.49134359 0.0267 75 38.7 0 OLIGODENDROGLIOMA II 
HF0778 0.363984009 0.485663005 0.0013 65 8.1 1 ASTROCYTOMA II 
HF1262 0.357766443 0.477366921 0.0163 30 23.7 1 GBM IV 
HF1178 0.356451664 0.475612614 0.0369 35 15.8 1 GBM IV 
HF0152 0.341086864 0.455111398 0.0564 30 131.5 0 ASTROCYTOMA III 
HF0543 0.334896186 0.44685119 0.049 30 67.6 0 GBM IV 
HF0996 0.322142945 0.429834571 0.0493 50 120.5 0 GBM IV 
HF0138 0.306071311 0.408390229 0.0594 60 1.2 1 GBM IV 
HF1509 -0.299523658 -0.386689141 0.0852 40 2.7 1 GBM IV 
HF1517 -0.304781874 -0.393477569 0.0358 55 8.3 1 GBM IV 
HF1078 -0.31280225 -0.403831985 0.0685 50 22.8 1 GBM IV 
HF0790 -0.317019359 -0.40927633 0.0439 45 7.5 1 GBM IV 
HF0855 -0.323567174 -0.417729649 0.0293 55 13.7 1 ASTROCYTOMA II 
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HF0510 -0.336784038 -0.434792801 0.0494 45 19.6 1 OLIGODENDROGLIOMA II 
HF0894 -0.337132125 -0.435242187 0.0477 40 14.1 1 GBM IV 
HF0835 -0.34490649 -0.445278998 0.0021 20 45.3 1 OLIGODENDROGLIOMA II 
E10031 -0.352909446 -0.455610923 0.0213 55 27.5 1 GBM IV 
HF0327 -0.362469071 -0.467952531 0.0057 75 19.6 1 OLIGODENDROGLIOMA II 
E09917 -0.367243861 -0.47411685 0.0036 50 6.1 1 GBM IV 
HF0960 -0.383971676 -0.495712688 0.033 45 88.7 1 OLIGODENDROGLIOMA II 
HF0408 -0.387273163 -0.499974953 4.00E-04 30 15.8 1 GBM IV 
HF1090 -0.395275411 -0.510305964 0.0306 50 8.5 1 OLIGODENDROGLIOMA III 
HF0450 -0.407202966 -0.525704601 0.0508 30 29.5 1 ASTROCYTOMA II 
E09791 -0.416213927 -0.537337876 0.0619 60 13.4 1 GBM IV 
E09730 -0.419038557 -0.540984511 0.0168 40 61.7 1 GBM IV 
HF0442.5 -0.422172569 -0.545030563 0.0252 30 19.6 1 GBM IV 
HF1122 -0.440157815 -0.568249762 0.0091 40 7.3 1 GBM IV 
HF1534 -0.445761091 -0.575483669 0.0165 20 7.8 1 GBM IV 
HF1057 -0.450285554 -0.581324812 1.00E-04 55 24.5 1 OLIGODENDROGLIOMA III 
HF1671 -0.453315816 -0.585236922 0.0711 50 13.3 1 GBM IV 
HF0031 -0.462637223 -0.597270985 0.0601 35 0.5 1 GBM IV 
E10300 -0.46358746 -0.598497754 0.0218 60 9.4 1 GBM IV 
HF0702 -0.480207693 -0.619954703 0.0205 50 8.5 1 ASTROCYTOMA III 
E10102 -0.485464009 -0.626740679 0.014 45 38.8 0 GBM IV 
E10271 -0.485974839 -0.627400166 0.0716 30 12.5 1 GBM IV 
HF0460 -0.491378375 -0.634376206 0.0796 45 10.7 1 OLIGODENDROGLIOMA III 
E09348 -0.496743594 -0.641302777 0.0536 35 18.5 1 GBM IV 
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E09139 -0.497586056 -0.642390407 0.028 45 36.5 1 GBM IV 
HF1186 -0.500533627 -0.646195762 0.0111 30 20.1 1 ASTROCYTOMA III 
HF1185 -0.506307341 -0.653649705 0.0285 25 95.2 0 ASTROCYTOMA III 
HF1344 -0.506640166 -0.654079386 0.061 60 9 1 ASTROCYTOMA II 
HF0990 -0.508177096 -0.656063585 0 NA 88.3 1 GBM IV 
HF1608 -0.510846262 -0.659509514 0.0827 60 7.9 1 GBM IV 
E10483 -0.513600598 -0.663065399 0.0754 25 66.4 1 ASTROCYTOMA II 
HF1538 -0.521697579 -0.673518713 0.0756 55 3.2 1 GBM IV 
HF1286 -0.530642368 -0.685066558 0.0333 75 13.2 1 ASTROCYTOMA III 
HF1618 -0.537184 -0.693511895 0.022 50 2.4 1 GBM IV 
HF0816 -0.543687185 -0.701907595 0.0361 60 46.7 1 OLIGODENDROGLIOMA III 
E50074 -0.546405102 -0.705416463 0.0368 50 5.4 1 GBM IV 
HF1382 -0.551104735 -0.711483754 0.0141 35 48.3 1 GBM IV 
E09967 -0.574153706 -0.741240291 0.002 45 4.4 1 GBM IV 
E09610 -0.57500937 -0.742344965 0.0061 55 12.5 1 GBM IV 
E10227 -0.601182757 -0.776135166 0.008 45 12.6 1 GBM IV 
HF0066 -0.601470694 -0.776506897 0.0016 50 9.1 1 GBM IV 
HF0986 -0.603858685 -0.779589825 2.00E-04 15 62.4 1 GBM IV 
HF1139 -0.628805522 -0.811796533 0.0117 40 15.8 1 GBM IV 
HF1191 -0.64276171 -0.829814163 7.00E-04 25 0.3 1 GBM IV 
HF1150 -0.651136485 -0.840626112 0 70 21.2 1 ASTROCYTOMA III 
HF0142 -0.6526464 -0.842575432 0.0021 25 0.3 1 GBM IV 
E09833B -0.661856328 -0.854465576 0.0192 45 20.8 1 GBM IV 
HF1297 -0.665978187 -0.859786953 0 60 17.2 1 GBM IV 
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E09966 -0.678273537 -0.875660417 0.0042 55 17.7 1 ASTROCYTOMA III 
HF0184 -0.681526594 -0.879860159 0 65 12 1 OLIGODENDROGLIOMA III 
HF1628 -0.684914765 -0.884234334 0.084 70 14.6 1 GBM IV 
E10284 -0.686683443 -0.886517721 0.0026 55 4.8 1 GBM IV 
E10267 -0.686925784 -0.886830587 0.004 75 12 1 GBM IV 
HF1077 -0.702421737 -0.906836074 5.00E-04 45 73.4 1 GBM IV 
HF1490 -0.722523361 -0.932787546 0.073 65 4 1 ASTROCYTOMA III 
HF1589 -0.774585129 -1 0.0162 25 3.3 1 GBM IV 
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Supplementary Table S3B. Activation scores, associated p-value and metadata of Gravendeel samples identified as (+) or (-) based on the 






p-value Age Survival 
(yrs) 
Status Histology Grade CHR1p CHR19q EGFR 
GSM405355 0.801064034 1 0.0074 73 1.19 1 ASTROCYTOMA II NA NA NA 
GSM405256 0.737876569 0.921120582 0.0866 38 4.79 1 ASTROCYTOMA II no 
LOH 
no LOH wild type 
GSM405461 0.716299484 0.894185051 0.0947 49 0.76 1 GBM IV LOH LOH wild type 
GSM405246 0.682859857 0.852441038 0.0305 33 6.31 1 GBM IV LOH LOH NA 
GSM405203 0.66280444 0.827405066 0.0025 39 8.92 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405212 0.658658913 0.82223004 0.02 23 17.49 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405370 0.643329952 0.803094291 0.0192 47 1.61 1 GBM IV no 
LOH 
no LOH wild type 
GSM405318 0.634974336 0.792663644 0.0118 62 6.21 0 OLIGODENDROGLIOMA III no 
LOH 
no LOH NA 
GSM405216 0.615021607 0.76775586 0.0045 52 3.28 1 GBM IV NA no LOH wild type 
GSM405207 0.605455573 0.755814201 0.0052 44 8.12 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405409 0.59181949 0.738791739 0.0477 54 10.36 1 OLIGODENDROGLIOMA III LOH LOH NA 
GSM405324 0.566705887 0.707441431 0.0436 14 0.67 1 GBM IV no 
LOH 
no LOH amplification 
GSM405234 0.554016145 0.691600324 4.00E-
04 
58 0.62 1 GBM IV NA NA NA 
GSM405283 0.538231934 0.671896267 0.0183 38 4.07 1 OLIGOASTROCYTOMA III LOH LOH wild type 
GSM405205 0.533253927 0.665682023 0.0317 48 3.24 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405386 0.521886757 0.651491935 0.0114 54 3.76 1 OLIGODENDROGLIOMA II LOH LOH wild type 
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GSM405325 0.519420906 0.648413715 0.0449 43 3.65 1 OLIGOASTROCYTOMA III NA NA wild type 
GSM405441 0.517104497 0.64552205 0.0178 45 3.27 0 OLIGODENDROGLIOMA II LOH LOH wild type 
GSM405204 0.516167462 0.644352312 0.0954 34 8.59 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405320 0.515438603 0.643442448 0.017 70 0.6 1 GBM IV NA NA wild type 
GSM405411 0.507483079 0.633511251 5.00E-
04 
38 0.05 1 ASTROCYTOMA III LOH no LOH NA 
GSM405217 0.506733901 0.632576024 0.0389 33 6.77 0 GBM IV NA no LOH wild type 
GSM405314 0.504431242 0.629701523 2.00E-
04 
54 0.65 1 GBM IV no 
LOH 
LOH wild type 
GSM405343 0.489292619 0.610803379 0.0816 67 NA 0 GBM IV NA NA wild type 
GSM405457 0.486971348 0.607905645 0.0523 71 0.3 1 OLIGODENDROGLIOMA III no 
LOH 
no LOH wild type 
GSM405287 0.486856457 0.607762221 0.0345 44 6.87 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405330 0.483717775 0.603844081 0.0869 33 0.71 1 GBM IV no 
LOH 
NA wild type 
GSM405261 0.476668599 0.595044314 0.0015 60 0.98 1 OLIGODENDROGLIOMA III no 
LOH 
no LOH NA 
GSM405227 0.47341699 0.590985202 0.07 48 4.77 1 OLIGODENDROGLIOMA III NA NA NA 
GSM405243 0.470390141 0.587206667 0.0156 61 0.88 1 GBM IV NA NA NA 
GSM405395 0.464586642 0.579961928 0.0425 55 3.76 1 OLIGOASTROCYTOMA II LOH LOH wild type 
GSM405382 0.459041423 0.573039611 0.0015 44 4.86 1 OLIGOASTROCYTOMA III LOH LOH NA 
GSM405420 0.458788616 0.572724023 0.0413 50 3 1 OLIGODENDROGLIOMA III no 
LOH 
no LOH wild type 
GSM405278 0.458173812 0.571956538 2.00E-
04 
58 0.73 1 GBM IV NA NA amplification 
GSM405462 0.454461768 0.567322647 0.0601 50 7.52 1 ASTROCYTOMA II LOH LOH NA 
GSM405415 0.438470443 0.547360042 0.0062 67 0.5 1 GBM IV no 
LOH 
no LOH NA 
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GSM405301 0.426132041 0.531957526 0.0979 65 0.3 1 GBM IV NA NA NA 
GSM405465 0.420244949 0.524608435 0.0242 69 0.63 1 GBM IV NA no LOH NA 
GSM405211 0.419707136 0.523937062 0.0445 35 1.83 1 OLIGODENDROGLIOMA III LOH LOH NA 
GSM405342 0.417912408 0.521696632 0.0872 47 2.99 1 OLIGODENDROGLIOMA III NA NA wild type 
GSM405396 0.416841065 0.520359231 0.0331 77 0.02 1 GBM IV no 
LOH 
no LOH NA 
GSM405403 0.415940255 0.519234715 0.0034 38 0.04 1 ASTROCYTOMA III NA NA NA 
GSM405333 0.40417074 0.504542362 0.0697 58 9.11 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405249 0.40304092 0.503131964 0.002 23 0.04 1 GBM IV NA NA wild type 
GSM405475 0.39505561 0.493163584 0.0501 34 1.05 1 GBM IV NA NA wild type 
GSM405481 0.392048822 0.489410092 0.0018 34 10.37 0 PILOCYTIC 
ASTROCYTOMA 
I NA NA NA 
GSM405268 0.385988137 0.481844298 0.0039 48 0.64 1 GBM IV no 
LOH 
no LOH amplification 
GSM405311 0.381022431 0.47564541 0.0427 43 7.48 0 ASTROCYTOMA II NA NA NA 
GSM405265 0.377448173 0.471183522 0.0795 32 1.81 1 ASTROCYTOMA III NA NA wild type 
GSM405483 0.373761793 0.466581668 0.0012 32 0.19 0 PILOCYTIC 
ASTROCYTOMA 
I NA NA NA 
GSM405334 0.364091978 0.454510454 0.0214 57 1.47 1 OLIGODENDROGLIOMA III no 
LOH 
no LOH wild type 
GSM405321 0.363960116 0.454345846 0.0406 34 3.97 1 ASTROCYTOMA III NA NA wild type 
GSM405459 0.36310793 0.453282028 0.0099 64 1.14 1 GBM IV no 
LOH 
no LOH NA 
GSM405210 0.348355938 0.434866532 0.0782 39 10.28 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405464 0.340105521 0.424567209 0.0132 55 0.56 1 GBM IV NA NA NA 
GSM405250 0.317464016 0.39630292 0.0848 31 1.48 1 ASTROCYTOMA II NA NA NA 
GSM405466 0.302478925 0.377596437 0.0725 67 0.28 1 GBM IV no no LOH NA 
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LOH 










0.0271 43 1.96 1 OLIGOASTROCYTOMA III no 
LOH 





0.0206 33 6.62 0 GBM IV no 
LOH 





0.0328 56 1.05 1 GBM IV no 
LOH 

























0.0096 33 3.7 0 OLIGOASTROCYTOMA II no 
LOH 





0.0174 70 0.02 0 GBM IV no 
LOH 





0.0365 33 3.2 1 ASTROCYTOMA II no 
LOH 





0.0297 63 0.47 1 GBM IV no 
LOH 










0.0413 79 0.53 1 OLIGOASTROCYTOMA III no 
LOH 
no LOH amplification 

















0.034 71 0.91 1 GBM IV no 
LOH 














0.0131 65 1.31 1 OLIGOASTROCYTOMA III no 
LOH 
























































0.0052 71 0.79 1 GBM IV no 
LOH 
















0.0752 70 0.4 1 GBM IV NA NA amplification 
GSM405341 -
0.745003928 
-1 0.0565 71 0.63 1 OLIGOASTROCYTOMA III NA NA amplification 
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Supplementary Table S4. Contingency tables for classification of (+) and (-) patient based on Phillips molecular subtypes. 
 
 
(a)      REMBRANDT Dataset 
 Mesenchymal Proneural  Proliferative Total 
(-) 32 5 24 61 
(+) 16 60 10 86 
Total 48 65 34 147 
             X-squared = 9.609, df = 2, p-value = 0.008193 
 
  
(b)     Gravendeel Dataset 
 Mesenchymal Proneural  Proliferative Total 
(-) 8 5 21 34 
(+) 8 27 23 58 
Total 16 32 44 92 








Supplementary Table S5. Probesets in the NNI-8 GPC versus Primary Tumor stemness gene signature. 
 
Probeset ID Entrez Gene ID 
Gene 
Symbol Description Log Fold Change 
1553635_s_at 200132 TCTEX1D1 Tctex1 domain containing 1  -6.215791136 
209156_s_at 1292 COL6A2 collagen, type VI, alpha 2  -6.493620158 
209448_at 10553 HTATIP2 HIV-1 Tat interactive protein 2, 30kDa  -6.42297587 
222484_s_at 9547 CXCL14 chemokine (C-X-C motif) ligand 14  -8.105582051 
202018_s_at 4057 LTF lactotransferrin  -8.54583883 
230422_at 2359 FPR3 formyl peptide receptor 3  -7.35868863 
203032_s_at 2271 FH fumarate hydratase  6.389162912 
204122_at 7305 TYROBP TYRO protein tyrosine kinase binding protein  -7.451463342 
213975_s_at 4069 LYZ lysozyme  -8.567997622 
204570_at 1346 COX7A1 cytochrome c oxidase subunit VIIa polypeptide 1 (muscle)  -6.10959307 
204158_s_at 10312 TCIRG1 T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 
subunit A3  
-6.005341469 
209183_s_at 11067 C10orf10 chromosome 10 open reading frame 10  -6.05532165 
209047_at 358 AQP1 aquaporin 1 (Colton blood group)  -6.969067359 
205572_at 285 ANGPT2 angiopoietin 2  -7.511111563 
236034_at 285 ANGPT2 angiopoietin 2  -6.482834194 
235639_at 28513 CDH19 cadherin 19, type 2  6.235154529 
209901_x_at 199 AIF1 allograft inflammatory factor 1  -6.32542485 
213095_x_at 199 AIF1 allograft inflammatory factor 1  -7.499645133 
215051_x_at 199 AIF1 allograft inflammatory factor 1  -7.64616928 
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1555460_a_at 25800 SLC39A6 solute carrier family 39 (zinc transporter), member 6  6.466383357 
220311_at 29104 N6AMT1 N-6 adenine-specific DNA methyltransferase 1 (putative)  6.090119758 
203240_at 8857 FCGBP Fc fragment of IgG binding protein  -6.279670112 
202628_s_at 5054 SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor 
type 1), member 1  
-6.169187776 
201743_at 929 CD14 CD14 molecule  -9.061228844 
225400_at 116461 TSEN15 tRNA splicing endonuclease 15 homolog (S. cerevisiae)  6.564806667 
219386_s_at 56833 SLAMF8 SLAM family member 8  -6.439653705 
218345_at 55365 TMEM176A transmembrane protein 176A  -7.028336131 
219167_at 51285 RASL12 RAS-like, family 12  -7.447403055 
225502_at 81704 DOCK8 dedicator of cytokinesis 8  -6.431728356 
234023_s_at 55835 CENPJ centromere protein J  6.500186173 
209619_at 972 CD74 CD74 molecule, major histocompatibility complex, class II invariant chain  -6.392605538 
223434_at 2635 GBP3 guanylate binding protein 3  -7.428950443 
207054_at 3617 IMPG1 interphotoreceptor matrix proteoglycan 1  -7.236493758 
205374_at 6588 SLN sarcolipin  -6.139099986 
203535_at 6280 S100A9 S100 calcium binding protein A9  -6.508034002 
203571_s_at 10974 C10orf116 chromosome 10 open reading frame 116  -6.322842462 
204128_s_at 5983 RFC3 replication factor C (activator 1) 3, 38kDa  6.363690078 
218559_s_at 9935 MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian)  -6.671432912 
201842_s_at 2202 EFEMP1 EGF containing fibulin-like extracellular matrix protein 1  -6.040243322 
212268_at 1992 SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), member 1  -6.972772922 
209723_at 5272 SERPINB9 serpin peptidase inhibitor, clade B (ovalbumin), member 9  -6.55138368 
223620_at 2857 GPR34 G protein-coupled receptor 34  -7.926594277 
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219607_s_at 51338 MS4A4A membrane-spanning 4-domains, subfamily A, member 4  -8.180055654 
226034_at 1846 DUSP4 dual specificity phosphatase 4  6.838468179 
225314_at 132299 OCIAD2 OCIA domain containing 2  -8.275917817 
204990_s_at 3691 ITGB4 integrin, beta 4  -6.364422156 
203854_at 3426 CFI complement factor I  -6.363714998 
202310_s_at 1277 COL1A1 collagen, type I, alpha 1  -7.130038944 
1556499_s_at 1277 COL1A1 collagen, type I, alpha 1  -9.238542552 
213566_at 6039 RNASE6 ribonuclease, RNase A family, k6  -7.823580016 
204482_at 7122 CLDN5 claudin 5  -6.460963571 
221816_s_at 51131 PHF11 PHD finger protein 11  -6.825731298 
239132_at 4842 NOS1 nitric oxide synthase 1 (neuronal)  -6.386282534 
209395_at 1116 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39)  -10.14439331 
209396_s_at 1116 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39)  -9.362700349 
219719_at 51751 HIGD1B HIG1 hypoxia inducible domain family, member 1B  -6.669433848 
203540_at 2670 GFAP glial fibrillary acidic protein  -7.35128303 
201721_s_at 7805 LAPTM5 lysosomal protein transmembrane 5  -6.25877809 
232887_at 644139 PIRT phosphoinositide-interacting regulator of transient receptor potential 
channels  
-6.331567906 
204787_at 11326 VSIG4 V-set and immunoglobulin domain containing 4  -7.189520229 
208161_s_at 8714 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3  -6.929235405 
210055_at 7253 TSHR thyroid stimulating hormone receptor  -6.141153984 
202859_x_at 3576 IL8 interleukin 8  -8.035544596 
235417_at 90853 SPOCD1 SPOC domain containing 1  -6.444542888 
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203835_at 2615 LRRC32 leucine rich repeat containing 32  -6.267902391 
202238_s_at 4837 NNMT nicotinamide N-methyltransferase  -6.6617682 
202237_at 4837 NNMT nicotinamide N-methyltransferase  -7.208303354 
229391_s_at 441168 FAM26F family with sequence similarity 26, member F  -6.297620939 
223467_at 51655 RASD1 RAS, dexamethasone-induced 1  -8.103012345 
239461_at 117248 GALNTL2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 2  
-7.696742518 
228501_at 117248 GALNTL2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 2  
-6.995008809 
205786_s_at 3684 ITGAM integrin, alpha M (complement component 3 receptor 3 subunit)  -6.272756493 
208747_s_at 716 C1S complement component 1, s subcomponent  -8.132346089 
201859_at 5552 SRGN serglycin  -8.765885577 
201858_s_at 5552 SRGN serglycin  -8.111413158 
207397_s_at 3239 HOXD13 homeobox D13  6.35025642 
1568604_a_at 8618 CADPS Ca++-dependent secretion activator  -7.030383795 
231068_at 146802 SLC47A2 solute carrier family 47, member 2  -8.52812485 
215049_x_at 9332 CD163 CD163 molecule  -7.402833043 
218729_at 56925 LXN latexin  -6.457187984 
209875_s_at 6696 SPP1 secreted phosphoprotein 1  -7.285379742 
200986_at 710 SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1  -8.060359753 
225353_s_at 714 C1QC complement component 1, q subcomponent, C chain  -7.877615852 
202953_at 713 C1QB complement component 1, q subcomponent, B chain  -9.175565222 
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Supplementary Table S6. Results from Pathway Activation Score, Log Rank and Cox Regression analysis (NNI-8 GPC versus 
Primary Tumor gene signature). (+) represents patients with concordance to GPC signature; (-) represents patients with inverse gene 
expression relationship to GPC signature. 
 
 
Dataset Connectivity Maps Analysis Log Rank 
p-value 





(+) (-) total(+)(-) %(+)(-) Hazard Ratio p-
value 
Hazard Ratio p-value 
REMBRANDT 84 298 80 54 134 44.97 0.007 0.671 
(0.455 - 0.989) 
0.044 0.596 
(0.406 - 0.874) 
0.008 
Gravendeel 84 276 86 77 163 59.06 0.0007 0.691 
(0.488 - 0.977) 
0.036 0.567 
(0.407 - 0.791) 
0.0008 
 
Multivariate Cox Regression: 
REMBRANDT:  coxph(formula = Surv(survival, status) ~ age + grade + class, data = dat) 
Gravendeel:  coxph(formula = Surv(survival, status) ~ age + grade + class, data = dat) 
 
Univariate Cox Regression: 
REMBRANDT:  coxph(formula = Surv(survival, status) ~ class, data = dat) 
Gravendeel:  coxph(formula = Surv(survival, status) ~ class, data = dat) 
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Supplementary Table S7A. Activation scores, associated p-value and metadata of REMBRANDT samples identified as (+) or 






p-value Age Survival 
(mths) 
Status Histology Grade 
E08021 1.522597165 1 0 40 81.5 1 OLIGODENDROGLIOMA III 
E09448 1.422752629 0.934424851 0 60 229.1 1 OLIGODENDROGLIOMA III 
HF0891 1.303831733 0.856320873 0 35 28.8 1 GBM IV 
HF0142 1.288468221 0.84623054 0 25 0.3 1 GBM IV 
HF0066 1.216406036 0.798902076 0 50 9.1 1 GBM IV 
E10110 1.176753544 0.772859408 0 50 23.1 1 GBM IV 
HF0996 1.119487883 0.735248895 0 50 120.5 0 GBM IV 
E09804 1.103850023 0.724978378 0 70 42.4 0 OLIGODENDROGLIOMA II 
HF1136 1.084938272 0.712557659 0 35 45.3 1 ASTROCYTOMA III 
HF0108 1.077128487 0.707428407 0 35 132 0 ASTROCYTOMA III 
HF1227 1.074604481 0.705770709 0 50 251.7 0 OLIGODENDROGLIOMA II 
E10105 1.067544582 0.701133961 0 40 1.1 NA ASTROCYTOMA III 
E09278 1.050937357 0.690226792 0 40 36.6 0 GBM IV 
HF0920 1.049199817 0.689085624 0 40 1 1 OLIGODENDROGLIOMA II 
E09867 1.04340192 0.685277724 0 75 38.7 0 OLIGODENDROGLIOMA II 
E09690 1.029117513 0.675896118 0 75 62.3 0 GBM IV 
E09893 1.027983539 0.675151355 0 40 111.9 1 OLIGODENDROGLIOMA III 
E09394 1.019807956 0.669781857 0 30 51.7 1 MIXED III 
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HF1628 1.007590306 0.66175764 0 70 14.6 1 GBM IV 
E09802 0.99482396 0.653373054 0 80 32.2 1 GBM IV 
HF0184 0.987032465 0.648255814 0 65 12 1 OLIGODENDROGLIOMA III 
HF0975 0.978033836 0.642345762 0 60 36.5 1 ASTROCYTOMA III 
HF0251 0.974357567 0.63993129 0 65 22.7 1 OLIGODENDROGLIOMA III 
HF1382 0.962780064 0.632327503 0 35 48.3 1 GBM IV 
HF1511 0.960128029 0.63058572 0 25 56.6 1 ASTROCYTOMA II 
E09722 0.958006401 0.629192293 0 50 28.5 1 GBM IV 
HF1587 0.919524463 0.603918412 0 30 75.3 0 ASTROCYTOMA III 
HF0180 0.911165981 0.598428791 0.0105 35 0.3 1 GBM IV 
HF1677 0.903978052 0.593707957 0 50 63.5 0 ASTROCYTOMA II 
E09656 0.891229995 0.585335383 0 65 34.1 1 OLIGODENDROGLIOMA III 
HF1551 0.888523091 0.583557563 0 30 70.9 0 ASTROCYTOMA II 
E10299 0.878079561 0.576698539 0 40 44.6 0 ASTROCYTOMA II/III 
HF1613 0.870233196 0.571545262 0 35 66.8 1 ASTROCYTOMA III 
E10013 0.860045725 0.564854411 5.00E-04 55 4.9 1 GBM IV 
E09855 0.850022862 0.55827167 0.0247 25 38.4 0 ASTROCYTOMA III 
E10252B 0.846566072 0.556001345 0 55 53 1 GBM IV 
E09988 0.84526749 0.555148472 0 70 64.6 1 OLIGODENDROGLIOMA III 
HF0702 0.831184271 0.545899001 0.0011 50 8.5 1 ASTROCYTOMA III 
E09818 0.829263832 0.544637709 0 30 38.1 0 ASTROCYTOMA II/III 
E09997 0.827471422 0.543460504 0 35 46.9 0 ASTROCYTOMA II/III 
E09966 0.822496571 0.540193158 0.002 55 17.7 1 ASTROCYTOMA III 
HF1469 0.821326017 0.539424371 0 25 22.2 1 GBM IV 
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HF1640 0.81911294 0.537970882 0 50 5.5 1 GBM IV 
HF1295 0.80175583 0.526571209 0 55 19.1 1 ASTROCYTOMA III 
E09688 0.800877915 0.525994618 0 55 50.8 1 MIXED II 
E10267 0.789062643 0.518234672 0 75 12 1 GBM IV 
HF0408 0.770900777 0.506306458 0.0032 30 15.8 1 GBM IV 
E09454 0.760987654 0.499795791 0 55 18 1 GBM IV 
HF1344 0.758536808 0.498186143 0 60 9 1 ASTROCYTOMA II 
E10262 0.755884774 0.496444359 0.0074 50 18 1 GBM IV 
E09569 0.738052126 0.484732366 0 70 37.4 1 GBM IV 
E10211 0.736131687 0.483471074 0 85 28.4 1 GBM IV 
E09920 0.725761317 0.4766601 0.0074 25 59.4 1 ASTROCYTOMA III 
E10271 0.722981253 0.47483423 0.0044 30 12.5 1 GBM IV 
HF1191 0.715116598 0.469668941 6.00E-04 25 0.3 1 GBM IV 
E09959 0.713580247 0.468659908 0 50 46.4 1 ASTROCYTOMA III 
HF0966 0.709958848 0.466281472 2.00E-04 50 137.7 0 ASTROCYTOMA III 
E50123 0.674183813 0.442785412 0 30 17.5 1 GBM IV 
E10001 0.672610882 0.441752354 0 50 8.7 1 OLIGODENDROGLIOMA III 
HF0960 0.669666209 0.439818374 0 45 88.7 1 OLIGODENDROGLIOMA II 
E10252 0.666575217 0.437788295 0 55 53 1 GBM IV 
HF1490 0.665532693 0.437103594 0.0025 65 4 1 ASTROCYTOMA III 
HF0990 0.651906722 0.42815443 0 NA 88.3 1 GBM IV 
E09860 0.621490626 0.408177974 0 40 36.8 0 OLIGODENDROGLIOMA II 
HF1338 0.604572474 0.397066596 0 35 5.9 1 GBM IV 
E09956 0.604444444 0.39698251 0 70 21 1 GBM IV 
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HF0963 0.566035665 0.371756679 0.009 10 10.6 1 GBM IV 
E09610 0.565743027 0.371564482 0.0243 55 12.5 1 GBM IV 
HF1057 0.554513032 0.364188929 0.0021 55 24.5 1 OLIGODENDROGLIOMA III 
E09623 0.547379973 0.359504132 3.00E-04 50 20.7 1 GBM IV 
E10184 0.541033379 0.355335864 0 30 28.3 1 GBM IV 
HF1487 0.530132602 0.348176533 0 50 9.9 1 OLIGODENDROGLIOMA II 
E09921 0.511476909 0.335923986 0 40 36.4 0 ASTROCYTOMA II/III 
HF0442.5 0.509044353 0.33432635 0.0137 30 19.6 1 GBM IV 
HF0992 0.496607225 0.326157986 2.00E-04 30 20 1 GBM IV 
E10144 0.477750343 0.313773304 0.0012 50 25.9 1 GBM IV 
E10138 0.459789666 0.301977225 2.00E-04 25 46.9 0 ASTROCYTOMA II/III 
E09801 0.459021491 0.301472708 5.00E-04 30 42.5 1 ASTROCYTOMA III 
HF0654 0.387965249 0.25480492 0.0299 20 14.6 1 GBM IV 
HF1357 0.382094193 0.250948972 0.0141 40 30.8 1 OLIGODENDROGLIOMA III 
HF0816 -0.432245085 -0.40731102 0.0376 60 46.7 1 OLIGODENDROGLIOMA III 
E09471 -0.454631916 -0.428406467 0.0028 70 27.2 1 ASTROCYTOMA II 
HF1534 -0.478372199 -0.450777291 7.00E-04 20 7.8 1 GBM IV 
E10226 -0.53223594 -0.501533901 0.0285 65 18.7 1 GBM IV 
E10031 -0.545569273 -0.514098101 0.0032 55 27.5 1 GBM IV 
HF0316 -0.551641518 -0.519820068 0 40 73.4 1 ASTROCYTOMA II 
HF0954.2 -0.593379058 -0.559149978 0 70 11 1 ASTROCYTOMA III 
HF0606 -0.612821216 -0.577470615 0 30 76.8 1 ASTROCYTOMA II 
E09451 -0.636707819 -0.599979318 0 60 5.3 1 GBM IV 
HF0024 -0.649272977 -0.611819655 0 45 5.8 1 GBM IV 
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E09664 -0.661088249 -0.622953363 0.0094 40 27.1 1 OLIGODENDROGLIOMA II/III 
E09673 -0.665441244 -0.627055255 0 45 213.8 0 ASTROCYTOMA II 
E10158 -0.667142204 -0.628658095 0 70 40.6 0 GBM IV 
HF0844 -0.672281664 -0.633501086 0 30 63.8 1 ASTROCYTOMA II 
HF1538 -0.68349337 -0.644066044 0 55 3.2 1 GBM IV 
E10193 -0.687242798 -0.647599187 0 50 34.2 NA GBM IV 
HF1671 -0.689437586 -0.649667368 0 50 13.3 1 GBM IV 
E10284 -0.691687243 -0.651787253 0 55 4.8 1 GBM IV 
HF1077 -0.697960677 -0.657698804 0 45 73.4 1 GBM IV 
HF1137 -0.711074531 -0.670056186 0 35 18.3 1 GBM IV 
E09430 -0.715354367 -0.674089139 0 45 32 1 GBM IV 
HF0543 -0.715628715 -0.674347661 0 30 67.6 0 GBM IV 
E09483 -0.715829904 -0.674537244 0 65 10.3 1 GBM IV 
E10514 -0.716671239 -0.675330047 0 75 23.7 1 GBM IV 
HF0089 -0.72698674 -0.685050498 0 65 7.9 1 ASTROCYTOMA III 
E10551 -0.734192958 -0.691841026 0 65 12.3 1 GBM IV 
E09661 -0.739515318 -0.696856365 0 65 48.5 0 OLIGODENDROGLIOMA II 
E10488 -0.758774577 -0.715004653 0 55 21.9 1 GBM IV 
E10103 -0.764389575 -0.72029575 0 50 3.3 1 ASTROCYTOMA II/III 
E09930 -0.772565158 -0.727999724 0 50 5.1 1 GBM IV 
E09531 -0.773699131 -0.729068284 0 55 19.3 1 ASTROCYTOMA II/III 
HF1178 -0.788367627 -0.742890628 0 35 15.8 1 GBM IV 
HF0936 -0.797567444 -0.751559753 0 55 5.1 1 ASTROCYTOMA II 
E09649 -0.804773663 -0.758350281 0 70 9.7 1 GBM IV 
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HF0757 -0.813644262 -0.766709179 0 40 74.9 1 ASTROCYTOMA II 
HF0460 -0.816899863 -0.769776981 0 45 10.7 1 OLIGODENDROGLIOMA III 
HF1246 -0.829721079 -0.781858605 0 65 0.2 1 ASTROCYTOMA II 
E09602 -0.841481481 -0.792940609 0 60 4.1 1 GBM IV 
E10227 -0.845834476 -0.797042501 0 45 12.6 1 GBM IV 
E09239 -0.849419296 -0.80042053 0 30 63.3 1 ASTROCYTOMA III 
E09331 -0.864618198 -0.814742684 0 55 38.9 0 GBM IV 
E10290 -0.880951075 -0.830133398 0 30 6.9 1 GBM IV 
E10077 -0.88698674 -0.835820896 0 55 25.8 1 GBM IV 
E10300 -0.88870599 -0.837440971 0 60 9.4 1 GBM IV 
E09334 -0.89223594 -0.840767295 0 50 85.2 1 MIXED III 
E10305 -0.90434385 -0.852176761 0 40 10.1 1 GBM IV 
HF1585 -0.910068587 -0.857571266 0 25 19.9 1 GBM IV 
HF0953 -0.940283493 -0.886043225 0 35 44.6 1 ASTROCYTOMA II 
E09348 -0.942075903 -0.887732239 0 35 18.5 1 GBM IV 
E10002 -0.944691358 -0.890196822 0 55 8.4 1 GBM IV 
HF1356 -1.01733882 -0.958653614 0 50 13.5 1 GBM IV 
HF0608 -1.035354367 -0.975629933 0 50 10.6 1 ASTROCYTOMA II 
HF1220 -1.039433013 -0.979473303 0 35 10.4 1 GBM IV 
E09759 -1.061216278 -1 0 45 20.1 1 GBM IV 
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Supplementary Table S7B. Activation scores, associated p-value and metadata of Gravendeel samples identified as (+) or (-) based on 
the NNI-8 stemness signature. 
 






(yrs) Status Histology Grade CHR1p CHR19q IDH1 EGFR 
GSM405
467 




no LOH mutation wild type 
GSM405
476 















1.147946959 0.935575232 0 80.65 0.92 1 GBM IV no 
LOH 





1.13399177 0.924201771 0 38.53 10.28 1 OLIGODENDROGLI
OMA 
III LOH LOH mutation wild type 
GSM405
399 















1.126127115 0.917792088 0 32.59 6.31 1 GBM IV LOH LOH mutation NA 
GSM405
369 
1.106776406 0.902021286 0 50.34 4.13 1 GBM IV LOH LOH mutation wild type 
GSM405
201 
1.089437586 0.887890171 0 44.57 9.82 1 OLIGODENDROGLI
OMA 
III LOH LOH mutation NA 
GSM405
208 
1.088834019 0.887398265 0 51.4 3.04 1 OLIGODENDROGLI
OMA 
III LOH LOH mutation wild type 
GSM405
338 
1.064581619 0.867632591 0 50.23 7.96 1 OLIGODENDROGLI
OMA 




1.054485597 0.859404347 0 46.52 1.61 1 GBM IV no 
LOH 











1.003950617 0.818218406 0 53.65 5.62 1 OLIGODENDROGLI
OMA 
III LOH LOH mutation NA 
GSM405
257 
1.000164609 0.815132815 0 46.04 10.86 0 OLIGODENDROGLI
OMA 
III LOH LOH mutation wild type 
GSM405
437 
0.981545496 0.799958263 0 51.63 3.44 0 OLIGODENDROGLI
OMA 
II NA NA mutation NA 
GSM405
378 
0.975290352 0.794860329 0 57.22 0 1 OLIGODENDROGLI
OMA 





0.972491998 0.792579674 0 44.15 4.86 1 OLIGOASTROCYT
OMA 
III LOH LOH NA NA 
GSM405
227 
0.967773205 0.788733864 0 48.1 4.77 1 OLIGODENDROGLI
OMA 
III NA NA NA NA 
GSM405
449 
0.95820759 0.780937901 0 45.39 2.02 1 OLIGODENDROGLI
OMA 





0.941362597 0.767209254 0 39.36 1.59 1 GBM IV no 
LOH 









no LOH mutation wild type 
GSM405
327 
0.937796068 0.764302537 0 66.86 3.3 1 OLIGODENDROGLI
OMA 
III LOH LOH mutation wild type 
GSM405
329 
0.936406036 0.763169663 0 60.33 5.02 1 OLIGODENDROGLI
OMA 
III LOH LOH mutation NA 
GSM405
212 
0.936296296 0.763080225 0 23.33 17.49 1 OLIGODENDROGLI
OMA 





0.929382716 0.757445667 0 33.89 8.59 1 OLIGODENDROGLI
OMA 





0.896223137 0.730420654 0 38.07 4.07 1 OLIGOASTROCYT
OMA 




0.882725194 0.719419849 0 57.68 0.62 1 GBM IV NA NA NA NA 
GSM405
347 
0.875793324 0.713770384 0 43.11 0.19 1 OLIGOASTROCYT
OMA 




0.871568358 0.710327043 0 44.74 3.27 0 OLIGODENDROGLI
OMA 










41.98 0.6 1 OLIGODENDROGLI
OMA 





0.848870599 0.691828399 0 67.01 0.24 1 GBM IV NA NA NA NA 
GSM405
386 
0.84528578 0.688906776 0 53.85 3.76 1 OLIGODENDROGLI
OMA 
II LOH LOH mutation wild type 
GSM405
232 
0.844078647 0.687922965 0 35.7 0.98 1 GBM IV no 
LOH 
no LOH mutation wild type 
GSM405
223 






0.835976223 0.6813195 0 44.41 8.12 1 OLIGODENDROGLI
OMA 





0.833836305 0.67957547 0 75.13 2.21 1 OLIGODENDROGLI
OMA 
III LOH LOH mutation wild type 
GSM405
388 



























34.84 12.56 0 GBM IV no 
LOH 





0.794494742 0.647512149 0 33.12 0.71 1 GBM IV no 
LOH 




0.786465478 0.640968309 0 39.99 6.04 1 OLIGODENDROGLI
OMA 
III LOH LOH mutation wild type 
GSM405
289 






0.766620942 0.624795039 0.072 71.11 0.63 1 OLIGOASTROCYT
OMA 




0.742386831 0.605044272 0 40.06 10.34 1 OLIGOASTROCYT
OMA 














no LOH mutation NA 
GSM405
383 
0.711970736 0.580255195 0.029 37.6 1.32 1 ASTROCYTOMA II no 
LOH 







62.96 1.26 1 GBM IV no 
LOH 
no LOH NA NA 
GSM405
312 














77.31 0.02 1 GBM IV no 
LOH 
no LOH mutation NA 
GSM405
309 
0.682359396 0.556121993 0.004 54.6 0.26 1 GBM IV NA NA mutation NA 
GSM405
220 









no LOH NA wild type 
GSM405
249 
0.660027435 0.537921474 0 23.02 0.04 1 GBM IV NA NA mutation wild type 
GSM405
468 
0.65395519 0.532972602 0 33.48 7.04 0 PILOCYTIC 
ASTROCYTOMA 








51.44 2.3 1 GBM IV no 
LOH 











































48.35 0.47 1 GBM IV NA no LOH NA NA 
GSM405
284 















48.84 9.79 1 GBM IV no 
LOH 
no LOH mutation wild type 
GSM405
385 
0.602487426 0.491026444 0 34.78 1.26 0 GBM IV no 
LOH 





55.55 1.05 1 GBM IV no 
LOH 
no LOH NA NA 
GSM405
355 







54.06 1.3 1 GBM IV NA NA NA NA 
GSM405
372 
0.572748057 0.466788898 0 37.12 3.32 1 GBM IV LOH LOH NA NA 
GSM405
294 
















0.557274806 0.454178219 0.006 48.03 3.24 1 OLIGODENDROGLI
OMA 


























32.35 0.19 0 PILOCYTIC 
ASTROCYTOMA 







38.11 1.06 1 GBM IV no 
LOH 







70.67 0.91 1 GBM IV no 
LOH 







42.98 3.65 1 OLIGOASTROCYT
OMA 
III NA NA mutation wild type 
GSM405
203 
0.458655693 0.373803774 0 38.58 8.92 1 OLIGODENDROGLI
OMA 









































77.31 0.02 1 GBM IV no 
LOH 



























68.18 0.73 1 GBM IV NA no LOH mutation NA 
GSM405
470 



























52.88 5.56 0 GBM IV no 
LOH 

















36.66 13.3 0 OLIGOASTROCYT
OMA 










































41.09 0.29 1 GBM IV no 
LOH 



















-0.549516139 0 48.04 0.64 1 GBM IV no 
LOH 








-0.550471128 0 56.42 0.54 1 OLIGOASTROCYT
OMA 







-0.560339339 0 69.89 0.3 1 GBM IV NA NA NA NA 
GSM405
365 
-0.66085048 -0.575093907 0 64.29 2.66 1 GBM IV no 
LOH 









34.93 1.83 1 OLIGODENDROGLI
OMA 





-0.578054371 0 37.84 1.5 1 GBM IV no 
LOH 









11.72 0.03 0 PILOCYTIC 
ASTROCYTOMA 












-0.603345642 0 32.36 0.64 1 GBM IV no 
LOH 
























70.07 0.02 1 OLIGOASTROCYT
OMA 

























no LOH mutation NA 
GSM405
477 

























-0.650044566 0 37.61 9.85 1 OLIGODENDROGLI
OMA 







60.36 0.35 1 GBM IV no 
LOH 










33.09 6.62 0 GBM IV no 
LOH 





-0.680636022 0 59.03 2.79 1 GBM IV no 
LOH 





-0.683819316 0 65.35 0.3 1 GBM IV NA NA NA NA 
GSM405
233 
























-0.735293181 0 81.18 0.82 1 ASTROCYTOMA III no 
LOH 
































-0.759549882 0 38.4 6.08 0 ASTROCYTOMA III no 
LOH 

























































-0.811930986 0 67.48 0.5 1 GBM IV no 
LOH 


























































-0.916327115 0 61.1 0.35 1 GBM IV no 
LOH 














-0.95919017 0 64.28 1.14 1 GBM IV no 
LOH 













-1 0 69.88 0.53 1 GBM IV NA NA NA wild type 
 
 
 
 
 
 
 
 
 
